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Summary 
A central issue in cell biology is how a particular signaling pathway can specifically trigger 
distinct cellular outcomes. The phosphatidylinositol 3-kinase (PI3K)/Akt pathway mediates 
the effects of a variety of extracellular signals in a number of cellular processes including cell 
cycle progression, cell growth, differentiation and survival. To explore how dinstinct cell fate 
decisions are determined by PI3K/Akt signaling, a data-based mathematical model of 
erythropoietin (Epo)-induced PI3K/Akt signaling pathway in primary erythroid progenitor 
(colony-forming unit erythroid stage, CFU-E) and the factor-dependent murine BaF3-EpoR 
cell line was established. The mathematical model was constrained by experimental 
measured concentrations of signaling components and calibrated by various Akt dynamics 
under different conditions. With this modeling approach, the different stoichiometries of 
components were identified as the major cause for cell type-specific Akt activation. Model 
analyses delineated the differential role of negative regulators PTEN and SHIP1 as well as 
scaffold protein Gab isoforms in shaping Akt activation in different hematopoietic cell types. 
The quantitative link of the cellular Akt response to cell proliferation revealed that Akt 
activation is necessary but not sufficient to predict cell proliferation in both cell types.  
Further experiments revealed that Akt regulates cell growth and cell cycle progression in a 
context-dependent manner. Cell growth mediated by mTOR and GSK3 was Akt-dependent 
in CFU-E cells. However, in BaF3-EpoR cells the activation of mTOR pathway was only 
partially dependent on Akt while GSK3 phosphorylation was Akt-independent. Furthermore, 
the PI3K/Akt signaling pathway was identified as the major pathway regulating cell cycle 
progression in CFU-E cells, but not in BaF3-EpoR cells. In CFU-E cells, PTEN 
overexpression induced cell cycle arrest in the G1 phase, correlating with the increased 
mRNA levels of cell cycle inhibitors p27kip1 and cyclinG2. 
In conclusion, the dynamic modeling of PI3K/Akt pathway provided an insight of the 
quantitative mechanisms by which context-dependent PI3K/Akt signaling is linked to cell 
growth and cell cycle progression. The abundance of negative regulators PTEN and SHIP1 
together with the isoform-specific Gab-mediated PI3K activation led to cell type-specific Akt 
activation. The tumor suppressor PTEN strongly suppressed cell proliferation in primary 
CFU-E cells, coordinating cell growth and cell cycle progression. In contrast, in BaF3-EpoR 
cells there was only a moderate suppression of cell growth mediated by PTEN, while cell 
cycle progression was PTEN/Akt-independent. 
To date, a number of the components of the PI3K/Akt pathway have been found mutated 
or altered in abundance in a wide variety of human cancers highlighting the key role of this 
pathway in cellular transformation. This mathematical model will provide guidance for the 
rational design of effective therapeutic molecules and facilitate accurate predictions of the 
effect of existing drugs.  
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Zusammenfassung 
Eine zentrale Frage in der Zellbiologie ist, wie eine bestimmte Signalkaskade 
unterschiedliche zelluläre Effekte auslösen kann. Der Phosphatidylinositol 3-Kinase 
(PI3K)/Akt Signalweg vermittelt die Wirkung einer Vielzahl extrazellulärer Signale, die in 
verschiedenen zellulären Prozessen wie Zellzyklusprogression, Zellwachstum, 
Zelldifferenzierung und Zellüberleben eine Rolle spielen. Um zu untersuchen, wie die Akt-
Signalverarbeitung das Schicksal einer Zelle bestimmen kann, wurde ein datenbasiertes 
mathematisches Modell des Erythropoetin-induzierten PI3K/Akt Signalweges in primären 
erythroiden Vorläuferzellen (colony-forming unit erythroid stage, CFU-E) und in der murinen 
BaF3-EpoR Zelllinie etabliert. Die Modellparameter wurden durch experimentell gemessene 
Konzentrationen der Signalwegskomponenten festgelegt beziehungsweise mittels Daten 
über die Aktivierungsdynamik von Akt unter unterschiedlichen Bedingungen geschätzt. Mit 
Hilfe des mathematischen Modells wurde die Stöchiometrie der Signalwegskomponenten als 
die wesentliche Ursache für die Zelltyp-spezifische Aktivierung von Akt identifiziert. 
Modellanalysen machten deutlich, dass die negativen Regulatoren PTEN und SHIP1 sowie 
die Isoformen des Gerüstproteins Gab die Aktivierungskinetik von Akt in den untersuchten 
hematopoietischen Zelltypen unterschiedlich beeinflussen. Durch eine quantitative 
Verknüpfung des Akt-Signals mit der Zellvermehrung konnte gezeigt werden, dass Akt-
Aktivierung notwendig, aber nicht ausreichend ist, um die Zellvermehrung in den beiden 
Zelltypen vorherzusagen.  
Weitere Experimente verdeutlichten, dass Akt Zellwachstum und Zellzyklusprogression 
kontextspezifisch reguliert. In CFU-E-Zellen war das durch mTOR und GSK3 vermittelte 
Zellwachstum abhängig von Akt. In BaF3-EpoR-Zellen kontrollierte Akt die Aktivierung der 
mTOR-Kaskade jedoch nur teilweise, während die GSK3-Phosphorylierung unabhängig von 
Akt war. Zudem wurde der PI3K/Akt Signalweg als der Hauptweg für die 
Zellzyklusprogression in CFU-E-Zellen identifiziert, nicht jedoch in BaF3-EpoR-Zellen. In 
CFU-E-Zellen induzierte die Überexpression von PTEN einen Zellzyklus-Stopp in der G1-
Phase, was mit erhöhten mRNA-Mengen der Zellzyklusinhibitoren p27kip1 und CyclinG2 
korrelierte. 
Zusammenfassend ermöglichte die dynamische Modellierung des PI3K/Akt Signalweges 
einen Einblick in die quantitativen Mechanismen, durch welche die kontextabhängige Akt-
Signaltransduktion mit Zellwachstum und Zellzyklusprogression gekoppelt sind. Die Menge 
der negativen Regulatoren PTEN und SHIP1 sowie die spezifische PI3K Aktivierung über die 
Gab-Isoformen führte zu einer Zelltyp-spezifischen Akt-Phosphorylierung. In primären CFU-
E-Zellen unterdrückte der Tumorsupressor PTEN die Zellproliferation erheblich durch 
Koordination von Zellwachstum und Zellzyklus. In BaF3-EpoR-Zellen hingegen vermittelte 
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PTEN nur eine schwache Inhibition des Zellwachstums, während die Zellzyklusprogression 
sich PTEN/Akt-unabhängig zeigte. 
Viele der Komponenten des PI3K/Akt Signalweges wurden mittlerweile in einer Vielzahl 
von humanen Krebsarten als mutiert oder in ihrer Menge verändert identifiziert, was die 
Schlüsselrolle dieses Signalweges in der zellulären Transformation verdeutlicht. Dieses 
mathematische Modell könnte eine Orientierung zur zielgerichteten Entwicklung effektiver 
therapeutischer Substanzen geben und genaue Vorhersagen über die Wirkung existierender 
Medikamente ermöglichen. 
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1. Introduction 
1.1 The PI3K/Akt signaling pathway 
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway mediates the effects of a variety of 
extracellular signals in a number of cellular processes including cell growth, proliferation, and 
survival (Castaneda et al., 2010). Among several subtypes of PI3K, class I PI3Ks are best 
understood. Activation of Class I PI3Ks is facilitated by some receptors such as the 
erythropoietin receptor (EpoR), the platelet-derived growth factor (PDGF) through direct 
binding of PI3K to the tyrosin phosphorylated receptors (Damen et al., 1995; Rottapel et al., 
1994). However, scaffolding adaptor proteins such as insulin receptor substrate (IRS) 
(Richmond et al., 2005), GRB2-associated-binding protein (Gab) (Wickrema et al., 1999) 
have been reported to induce PI3K activation by bringing PI3K to cell membrane in close 
proximity to its phospholipid substrates. To ensure that the activation of PI3K signaling is 
appropriately suppressed or terminated, the phosphatases PTEN (Hlobilkova et al., 2003) 
and SHIP (Kalesnikoff et al., 2003) counteract PI3K by dephosphorylation of PIP3. PIP3 at 
the cell membrane recruits protein kinases Akt and its kinase PDK1. Activated Akt mediates 
a large spectrum of cellular functions, ranging from control of cell proliferation and survival to 
modulation of intermediary metabolism and angiogenesis (Bellacosa et al., 2005). 
 
1.1.1 Class IA PI3K 
There are three classes of PI3K (class I, class II and class III) based on structural features 
and lipid substrate preference (Figure 1.1). Mammals have three classe I PI3K isoforms: 
PI3K-C2 (PI3KC2A), PI3K-C2 (PI3KC2B) and PI3K-C2 (PI3KC2G). In vitro, they can 
convert phosphatidylinositols (PIs) and phosphatidylinositol-4-phosphate (PI4P) to the 
corresponding 3-phosphoinositide lipids (PI3P). The role of class II PI3Ks in mammals are 
still unknown (Vanhaesebroeck et al., 2010). Vacuolar protein sorting 34 (Vps34; known as 
PI3KC3) is the only class III PI3K. Vps34 has a lipid substrate specificity limited to PI, 
generating PI3P (Schu et al., 1993; Volinia et al., 1995). All known biological functions of 
Vps34 in mammals are related to the regulation of vesicle traffic, including autophagy, 
endocytosis and phagocytosis (Kihara et al., 2001). Class I PI3Ks are best understood. They 
are heterodimeric molecules composed of a regulatory and a catalytic subunit. 
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Figure 1.1 Classification of PI3K members and substrate preference. Adapted from (Bader et al., 
2005). 
 
Structure and function of PI3K regulatory subunit 
Class I PI3Ks were originally classed into those that bind the regulatory subunit p85 (class 
IA, p110andand those that bind to one of the two regulatory subunits p101 and p84 
(class IB, p110). Here, this study only focused on class IA PI3K mediated signaling. 
To date, five isoforms of p85 have been identified and are encoded by either PIK3R1 
(p85, p55, p50), PI3KR2 (p85) and PI3KR3 (p55). All p85 isoforms have two Src 
homology2 (SH2) domains, which specifically bind to phosphorylated YXXM motifs of 
activated receptors and engage class IA PI3Ks with Tyr kinase signaling pathways (Backer 
et al., 1992). Between two SH2 domains, there is the inter-SH2 (IS) domain, which is capable 
of binding to p110 catalytic subunit (Panayotou et al., 1992). At the N-SH2 domain, all p85 
isoforms have a proline-rich region, which may interact with the SH3 domain of the 
ubiquitous adaptor protein, such as Grb2 or Gab, facilitating the activation of PI3K (Wang et 
al., 1995). The isoforms p85 and p85 also contain an SH3 domain, a second proline-rich 
region and a BCA-homology GTPase activation domain (BH)-domain (Chamberlain et al., 
2008; Vanhaesebroeck et al., 2010). However, the roles of individual p85 subunits are 
unknown. In summary, regulatory subunits p85 provide at least three functions to p110 
proteins: (i) stabilization, (ii) blocking of their kinase activity in basal state and (iii) recruitment 
to pTyr residues in receptors and adaptor molecules (Vanhaesebroeck et al., 2010). 
Structure and function of PI3K catalytic subunits 
Mammals have three catalytic subunits of class IA PI3K, p110, - and, which exhibit 
distinct and specific functions. The and  isoforms have a broad tissue distribution; the 
expression of p110 is more restricted and predominantly detected in leukocytes (Chantry et 
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al., 1997; Vanhaesebroeck et al., 1997). All three isoforms share a basic domain structure 
containing an adaptor binding domain to p85 in the N-terminal portion of the protein, a 
phospholipids binding C2, a helical domain and a kinase domain at the C-terminal 
(Vanhaesebroeck et al., 1997; Wymann et al., 2003). Experiments using gene-targeted mice 
and p110 isoform selective inhibitors have uncovered nonredundant physiological functions 
of the p110 isoforms. p110 and p110 are the most prevalent catalytic subunits in non-
leukocytes and untransformed leukocytes, respectively (Bilancio et al., 2006; Geering et al., 
2007; Papakonstanti et al., 2008). However, p110 shares its role with p110 in immortalized 
and transformed leukocytes (Papakonstanti et al., 2008). Indeed, p110 isoforms interact non-
selectively with the different p85s, and have the same lipid substrate preference 
(Vanhaesebroeck et al., 1997). Using affinity and ion exchange chromatography and 
quantitative mass spectrometry, studies of Vanhaesebroeck’s group further demonstrated 
that the p85 regulatory and p110 subunits of class IA PI3Ks are present in equimolar amount 
in mammalian cell lines and tissues and are assembled in obligate heterodimers (Geering et 
al., 2007). Their data argue against the ‘‘free p85’’ model, by which the p85 can compete with 
heterodimeric p85/p110 complexes for pTyr binding sites, thereby decreasing PI3K signaling 
(Luo and Cantley, 2005; Ueki et al., 2003). Tumor-specific (somatic) mutations only present 
in PI3CA, the gene encoding p110 (Samuels et al., 2004), mostly induce gain-of-function of 
p110. The amplification of other PI3K isoforms in cancer is also documented (Kok et al., 
2009). 
Signal transmission from phosphoinositides 
Under normal conditions, the level of the phosphoinositides is tightly regulated by a set of 
specific kinases and phosphatases, as indicated in Figure1.2. 
 
Figure 1.2 The metabolism of 
phosphoinositides.  
PI3K: phosphatidylinositol 3-kinase, 
PI4K: phosphatidylinositol 4-kinase, 
PI5K: phosphatidylinositol 5-kinase, 
MTM: myotubularin,                   
PTEN: phosphatase and tensin 
homolog detected on chromosome 10,   
PLIP:  PTEN-like phosphatases, 
SHIP: SH2-containing inositol 
polyphosphate 5-phosphatase. 
Adapted from (Blero et al., 2007). 
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Class I PI3Ks phosphorylates the 3-inositol position of PI (PtdIns), PI4P (PtdIns(4)P) and 
PI(4,5)P2 to produce PI3P (PtdIns3P), PI(3,4)P2 (PtdIns(3,4)P2) and PI(3,4,5)P3 
(PtdIns(3,4,5)P3), which serve as membrane docking sites for multiple effector proteins 
containing phosphoinositide-binding domains, such as phox homology (PX) domain 
(Karathanassis et al., 2002), pleckstrin homology (PH) domains (Musacchio et al., 1993; 
Wang and Shaw, 1995) and cysteine-rich FYVE domains (Leevers et al., 1999). The 
preferred substrate of class IA PI3Ks is PI(4,5)P2. Its product PI(3,4,5)P3 regulates as an 
important second message the localization and function of Ser/Thr and Tyr protein kinases 
(such as Akt and BTK, respectively), adaptor proteins (such as Gab) and regulators of small 
GTPases (GAPs and GEFs) (Vanhaesebroeck et al., 2001). Inactivation of PI(3,4,5)P3 is 
quickly mediated by PI3- and PI5-phophatases, such as PTEN and SHIP. All PI3Ks are 
inhibited by the drugs wortmannin and LY294002. Furthermore, a number of pharmaceutical 
companies have been working on PI3K isoform specific inhibitors including the p110 
isoform specific inhibitors IC486068 and IC87114 (Lee et al., 2006). In addition to the lipid 
kinase activity, several PI3Ks also have protein kinase activity (Backer, 2005) but their 
physiological substrates remain unknown. 
 
1.1.2 Scaffold adaptor protein Gab 
The Grb2 associated binder (Gab) adaptor/scaffolding protein family comprises conserved 
proteins: mammalian Gab1, Gab2 and Gab3, Drosophila Dos and Caenorhabditis elegans 
Soc1 (Nishida and Hirano, 2003). Originally, Gab1 was identified as a binding protein for 
Grb2 (Holgado-Madruga et al., 1996). Both Gab1 and Gab2 are ubiquitously expressed, 
while Gab3 is highly expressed in lymphoid tissue (Gu et al., 1998; Nishida et al., 1999; Wolf 
et al., 2002). All three Gab proteins contain common domains: (i) a PH domain in the amino-
terminal region, (ii) tyrosine-based motifs mediating the binding of Grb2, Crk, p85, and SHP2, 
(iii) proline-rich sequences (PXXP) and (iv) the c-Met binding domain (MBD) in the C-terminal 
region (Nishida and Hirano, 2003) (Figure 1.3). In hematppoietic systems, Gab isoforms are 
differentially expressed in various cell lines, while only Gab1 is expressed in primary 
hematopoietic progenitors (Bouscary et al., 2001; Wickrema et al., 1999). Various studies 
have demonstrated that Gab1 and Gab2 are tyrosine phosphorylated and associate with 
several signaling molecules including Grb2, Shc, SHP2 and PI3K in response to various 
cytokines and growth factors, such as insulin, epidermal growth factor, thrombopoietin (Tpo) 
and Epo (Bouscary et al., 2001; Takahashi-Tezuka et al., 1998; Wickrema et al., 1999). 
Gab1 and Gab2 have 15 conserved tyrosines, distinct phosphorylation patterns of Gab 
isoforms evoked by different ligands and receptors might be the molecular basis for signaling 
selectivity (Brummer et al., 2008; Gual et al., 2000; Lehr et al., 1999). Studies of Gab1 and 
Gab2 knockout mice have clearly indicated an important role for Gab proteins in vivo. Gab1-
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deficient mice die as embryos with multiple defects in placental, heart, skin, and muscle 
development (Itoh et al., 2000). Gab2-deficient mice are viable, but have a defect in mast cell 
lineages and in allergic reactions (Nishida et al., 2002).  
 
 
Figure 1.3 Conserved structural features of Gab proteins. Adapted from (Wohrle et al., 2009).  
 
1.1.3 Phosphatases PTEN and SHIP1 
To ensure that the activation of PI3K signaling is appropriately suppressed or terminated, 
PTEN and SHIP counteract PI3K activity by hydrolyzing PI(3,4,5)P3 at the 3- or 5-position of 
the inositol ring, yielding PI(4,5)P2 and PI(3,4)P2, respectively. Mouse knockout studies have 
suggested that PTEN and SHIP have profound different biological functions. Homozygous 
PTEN knockout is early embryonic lethal while heterozygous mice survive, but die from 
multiple sporadic tumors. On the other hand, mice heterozygous for SHIP loss are virtually 
normal (Helgason et al., 1998; Liu et al., 1999). Also the homozygous SHIP-null mice do not 
have an increased susceptibility to cancer; however, they have a myeloproliferative disorder 
resulting in a decreased life span which may preclude complete assessment of susceptibility 
changes to cancer in these animals (Rohrschneider et al., 2000). 
PTEN 
The 403-amino-acide protein PTEN is a dual protein/lipid phosphatase, which comprises an 
N-terminal phosphatase domain and a C2 domain both required for the enzymatic activity 
(Figure 1.4). The Pten gene shows high identity between human and mouse (Steck et al., 
1997). In the majority of cell types PTEN is constitutively active thereby influence the basal 
PI(3,4,5)P3 level, maintaining it below the critical signaling threshold (Stambolic et al., 1998; 
Sun et al., 1999). Negative regulation of PTEN has been shown to occur via reactive oxygen 
species and Ser/Thr phosphorylation. PTEN undergoes reversible oxidation, forming a 
disulphide bond with a neighboring Cys in the catalytic active-site Cys residue. (Leslie et al., 
2003). Studies on the oxidative inactivation of PTEN show that this physiological regulation 
mechanism may have significant implications for the regulation of apoptosis in macrophages 
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and other oxidant producing leukocytes (Cho et al., 2004; Leslie et al., 2003). On the other 
hand, there is increasing evidence that indicates the importance of the Ser/Thr 
phosphorylation in the regulation of PTEN function. The dephosphorylation of the C-terminal 
tail results in an open conformation in basic regions that can interact with anionic lipids, thus 
enhancing its association with the plasma membrane and orientating the active site towards 
its lipid substrates (Das et al., 2003; Tolkacheva et al., 2001). The constitutively active 
Ser/Thr casein kinase 2 (CK2) (Li et al., 2002), and other kinases, such as Ser/Thr kinase 11 
(STK11/LKB1) (Mehenni et al., 2005), the microtubule associated kinase (MAST205) 
(Valiente et al., 2005) as well as GSK3 have been reported to phosphorylate PTEN at 
specific residues in vitro studies (Al-Khouri et al., 2005). 
In many primary and metastatic human cancers, mutations, deletions or promoter 
methylation lead to an inactive PTEN (Blanco-Aparicio et al., 2007; Parsons et al., 2005). 
Beyond PTEN mutations, deregulation of the PTEN network also occurs through crosstalk 
with other tumorigenic signaling pathways, such as those involving Ras, p53, TOR (Cully et 
al., 2006).  
 
Figure 1.4 PTEN C-terminal tail phosphorylation sites and their protein kinase partners. The 
403-amino-acid PTEN protein comprises an N-terminal phosphatase domain (amino acids 7–185) 
and a C2 domain (amino acids 186–351) that are both required for enzymatic activity. The catalytic 
cysteines Cys124 and Cys71 form a reversible disulphide bond upon oxidation. At the far end of the 
C-terminal tail a common protein-interaction PDZ binding sequence is present and within the C-
terminal tail exist two PEST sequences, which are rich in proline (P), glutamic acid (E), serine (S), 
and threonine (T). The phosphorylation sites spanning a highly acidic stretch of the C-terminal tail and 
their proposed protein kinase partners are highlighted. Adapted from (Downes et al., 2007) 
SHIP1  
SHIP1 and SHIP2 are the products of two different genes and belong to the family of the 
inositol polyphosphate 5-phosphatases. Ten mammalian inositol 5-phosphatase isoenzymes 
have been reported. However, SHIP1 and SHIP2 have a strongly conserved domain 
architecture. They contain an N-terminal SH2 domain, two NPXY motifs interacting with PTB 
domains and a C-terminal proline-rich region (PxxP motifs) with consensus sites for SH3 
domain interactions (Figure 1.5). The SH2 domain and NPXY sites mediate the binding of 
SHIP with a series of consensus motifs of adaptor proteins, such as Shc, Grb2, various Doks 
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and immunoreceptor signaling motifs (ITIM) (Pesesse et al., 2006). Knockout studies on 
SHIP1 and SHIP2 showed that these proteins are not redundant in function. SHIP2 is 
broadly expressed, while SHIP1 is specifically expressed in immune and hematopoietic cells. 
SHIP1 controls the levels of PI(3,4,5)P3 and is important in terminating signal transduction 
from cytokine-mediated signaling in hematopoietic systems. Recently, Mason et al. reported 
that SHIP1 binds to the EpoR in an SH2-dependent fashion through multiple pTyr residues, 
including Tyr401, Tyr429, and Tyr431, and that Epo stimulates the formation of a ternary 
complex consisting of SHIP1, Shc, and Grb2 (Mason et al., 2000). 
As antagonist of PI3K, PTEN hydrolyzes PIP3 to PI(4,5)P2, while SHIP1 removes the 
PIP3 5-phosphate, generating PI(3,4)P2. A high binding affinity of Akt to PI(3,4)P2 has been 
reported in vitro, but the activation of Akt by PI(3,4)P2 in vivo is still under debate. A 
constitutively active SHIP1 protein in Jurkat cells caused increased PI(3,4)P2 level. However, 
the Akt phosphorylation was reduced in these cells (Isakoff et al., 1998; Lemmon and 
Ferguson, 2001). PI(3,4)P2 can interact with an array of protein effectors. Proteins such as 
DAPP1 (dual adaptor of phosphotyrosine and 3-phosphoinositides 1) and TAPP (tandem PH 
domain-containing protein) can selectively interact with PI(3,4)P2 (Lemmon and Ferguson, 
2000). In addition, SHIP1 contains multiple structural domains, such as SH2-domains, C2 
domains and NPXY motifs that allow SHIP1 to function as a scaffolding protein for facilitating 
protein-protein interactions (Rohrschneider et al., 2000; Sly et al., 2007). Hence, SHIP1 may 
alter the activities of a subset of PIP3 effectors, potentially redirect signaling rather than stop 
it (Harris et al., 2008).   
 
Figure 1.5 The domain structure of SHIP. Two asterisks above the central enzymatic domain 
mark the locations of homology regions with all 5-phosphatases. The scale below the SHIP domain 
structure designates its length in amino acids. Adapted from (Rohrschneider et al., 2000) 
  
1.1.4 Akt 
The AGC kinases (related to AMP/GMP kinase and protein kinase C) includes the Akt1, 
Akt2, and Akt3 kinases. They consist of an N-terminal PH domain, followed by a kinase 
domain and a C-terminal regulatory hydrophobic motif (Knighton et al., 1991; Thomas et al., 
2002) (Figure 1.6). The specific or redundant functional roles of the three Akt isoforms are 
not clear. Activation of Akt involves its membrane translocation mediated by PIP3 and 
subsequently phosphorylation at both Ser473 and Thr308 sites (Vanhaesebroeck and Alessi, 
2000). At the membrane, phosphorylation at Thr308 in the activation T-loop is mediated by 
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the 3-phosphoinositide-dependent kinase 1 (PDK1) (Alessi et al., 1997). However, the 
identity of the kinase(s) responsible for Ser473 phosphorylation in hydrophobic motif is quite 
controversial. Candidates include the integrin-linked kinase (ILK), MAPK2, mTORC2 and Akt, 
PDK1 themselves (Bellacosa et al., 2005; Chan and Tsichlis, 2001).  
 
Figure 1.6 Pairwise % identity in Akt domains. Domain definitions using Akt1 residue numbers. 
PH: Pleckstrin Homology domain. LINK: Linker region, Akt 1(108–148), no significant homology to 
other proteins. CAT: Kinase Catalytic domain, homologous to all kinases, ~ 50% identical to the 
PKC, PKA, SGK and S6 families. EXT: C-terminal Extension, ~ 15% identical to the PKA family and 
~35–40% identical to the rest of AGC family members. Adapted from (Kumar and Madison, 2005). 
 
1.1.5 Akt mediated biological processes  
Activated Akt mediates a large spectrum of cellular functions, ranging from control of cell 
proliferation and survival to modulation of intermediary metabolism and angiogenesis (Figure 
1.7).  
Cell proliferation  
Phosphorylation of multiple substrates results in the proliferative effect of Akt: 
phosphorylation and consequent inhibition of GSK3  prevents degradation of cyclin D1 
(Diehl et al., 1998); translation of cyclin D1 and D3 transcripts is regulated by Akt/mTOR 
signaling (Muise-Helmericks et al., 1998); phosphorylation by Akt directly induces the 
cytoplasmic retention of cell cycle inhibitors, such as p21WAF1 and p27Kip1 (Testa and 
Bellacosa, 2001), the transcription of p27Kip1 can be further suppressed through Akt/FoxO 
axis (Medema et al., 2000). 
Cell survival  
Akt has an effect on both the caspase cascade and the transcriptional control to provide 
survival signals and prevent apoptosis (Kim et al., 2001; Testa and Bellacosa, 2001). Akt 
directly inhibits the caspase cascade by phosphorylating the pro-apoptotic factor BAD 
(Creagh and Martin, 2001), procaspase-9 and astrocytic phosphoprotein PED/PEA15 
(Trencia et al., 2003). In parallel, cytoplasmic retention of forkhead family factors prevents 
transcription of the pro-apoptotic genes Fas ligand, BIM, TRAIL, and TRADD (Basu et al., 
2003; Datta et al., 1999). On the contrary, Akt promotes nuclear translocation of the nuclear 
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factor NF-B, which transcribes the anti-apoptotic genes BFL1, cIAP1, and cIAP2 (Ouyang et 
al., 2006). 
Cell growth 
Akt also participates in the control of cell growth defined as an increase in cell size, not cell 
number, which is modulated by Akt/mTOR pathway. mTOR stimulates protein synthesis by 
phosphorylating two targets: ribosomal protein S6 kinase (p70 S6K) and eukaryotic initiation 
factor 4E binding protein 1, 2, and 3 (4E-BPs) (Gingras and Sonenberg, 1997; Kim and 
Sabatini, 2004).  
Figure 1.7 Downstream signaling: Akt substrates and their functions. Scheme depicting Akt 
substrates and associated cellular functions. Continuous lines imply direct phosphorylation by Akt, 
leading to activation (arrow end) or inhibition (blunt end). Broken lines indicate indirect or unknown 
mechanisms of activation/inhibition. Adapted from(Bellacosa et al., 2005). 
 
1.1.6 Alterations of PI3K/Akt signaling in human cancers 
Mounting evidence over the past dozen years indicates that PI3K/Akt alterations are 
common in many forms of human cancer. Hyperactivation of Akt is achieved in human 
cancer by an assortment of mechanisms, including amplification, overexpression, point 
mutation of the genes of Akt and of their upstream activators or by alteration of the 
downstream targets, and deletion or inactivation of pathway inhibitors (Bellacosa et al., 
2005).  
Upstream activators 
There are several mechanisms leading to the alteration of downstream Akt activation in 
human cancers. Overexpression of growth factor HER-2/neu in breast cancer (Zhou and 
Hung, 2003), overexpression of epidermal growth factor (EGF) receptor in glioblastoma 
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multiforme (Schlegel et al., 2002), mutation in the EpoR gene in primary familial congenital 
polycythemia (PFCP) (Rives et al., 2007), amplification/upregulation of the PIK3CA gene  
(Shayesteh et al., 1999) and mutation of PIK3CA or PIK3R1 (Philp et al., 2001; Samuels et 
al., 2004). 
Akt 
Akt2 is the predominant Akt family member broadly involved in cancers as shown in ovarian 
carcinoma (Cheng et al., 1992), primary pancreatic carcinomas and pancreatic cancer cell 
lines (Cheng et al., 1996; Miwa et al., 1996) as well as in hepatocellular carcinoma (Xu et al., 
2004). Increased Akt1 kinase activity was reported in about 40% of breast and ovarian 
cancers and in more than 50% of prostate carcinomas (Sun et al., 2001). Akt3 enzymatic 
activity was found in estrogen receptor-deficient breast cancer and androgen-insensitive 
prostate cancer cell lines (Nakatani et al., 1999). 
Deletion or inactivation of pathway inhibitors 
Like p53, PTEN was recognized as one of the most highly mutated tumor-suppressor genes. 
Somatic deletions or mutations of this gene have been identified in a large fraction of tumors, 
including glioblastomas and endometrial and advanced prostate cancers (Di Cristofano and 
Pandolfi, 2000; Sansal and Sellers, 2004). SHIP mutations have also been detected in acute 
myelogenous leukemia (AML) (Di Cristofano and Pandolfi, 2000). Evidence indicates that the 
loss of function of SHIP could be involved in leukemogenesis (Sattler et al., 1999). 
Downstream targets of Akt  
As downstream effector of mTOR, the translation initiation factor eIF4E has been shown to 
cooperate with c-Myc in B-cell lymphomagenesis (Ruggero et al., 2004; Wendel et al., 2004). 
Akt directly regulates the retention of FoxO transcription factor in the cytosol via 
phosphorylation. Studies with the dominant–negative FoxO or the inducible FoxO3aA3 
revealed the role of FoxO as putative tumor suppressor on Myc-driven lymphomagenesis 
(Bouchard et al., 2007).  
 
1.2 Epo induced PI3K/Akt pathway  
1.2.1 Erythropoiesis 
Erythropoiesis is the development of mature red blood cells (erythrocytes), which is regulated 
by various extracellular stimuli including a network of hematopoietic cytokines that exert their 
biologic effects through specific interactions with their cognate cell surface receptors 
(Arcasoy and Karayal, 2005; Krantz, 1991). The key regulator of the erythroid lineage is a 
30.4-kDa glycoprotein hormone named erythropoietin (Epo) (Papakonstanti et al.). Epo is the 
ligand for the erythropoietin receptor (EpoR) (Krantz and Goldwasser, 1984), a 
transmembrane cytokine receptor predominantly present on erythroid precursor cells. 
However, the expression of EpoR is not found on multipotential hematopoietic stem cells and 
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the early burst-forming units-erythroid (BFU-E). It begins to appear on the later BFU-E and is 
found in highest concentration on colony-forming units-erythroid (CFU-E), after which 
receptor numbers decline (Broudy et al., 1991). While BFU-Es are promoted by a large 
number of cytokines, such as stem cell factor (SCF), interleukin 3 (IL-3), interleukin 6 (IL-6) 
and transferrin, in addition to Epo, CFU-Es are highly dependent on Epo for proliferation and 
differentiation (Figure 1.8). Although the Epo–/– and EpoR–/– mice die at embryonic 12.5 
(E12.5) day owing to severe anemia, fetal livers of these mice contain normal numbers of 
committed erythroid CFU-E and BFU-E progenitors (Wu et al., 1995; Yoshimura et al., 1990). 
These studies suggested that Epo signaling is not required for lineage determination, but is 
required for proliferation of progenitors and their differentiation into mature red blood cells 
(Constantinescu et al., 1999).  
The studies of Jacobson et al. in 1957 established the kidney as the main source of 
circulating Epo in the adult (Jacobson et al., 1957). The other major site of Epo production in 
the adult is the liver, but hepatic production cannot compensate for loss of the kidneys in 
cases of chronic renal failure (Erslev et al., 1980). Besides, the expression of Epo has also 
been found in the brain (Masuda et al., 1994), the testis (Tan et al., 1992), and the placenta 
(Conrad et al., 1996). These studies also demonstrated that the local production of Epo could 
be required for a purpose other than erythropoiesis. 
Regulation of the Epo gene expression occurs mainly at the transcriptional level. There is 
no intracellular storage of the hormone (Moritz et al., 1997). Epo production is primarily 
regulated by the oxygen supply to a sensor in the kidney relative to its oxygen requirements 
(Bunn and Poyton, 1996). The Epo gene is activated by a hypoxia-inducible factor (HIF) 
(Huang et al., 1997; Wang and Semenza, 1993), which binds to the hypoxia-sensitive region 
of the Epo gene to activate it. Although the ratio of oxygen delivery to oxygen requirements is 
the primary physiologic regulator of Epo production, there are also other regulation 
mechanisms. For instance, androgenic steroids (Huang et al., 1997; Mirand et al., 1965), 
anabolic steroids (Doane et al., 1975), and cobaltous chloride (Goldwasser et al., 1957) 
stimulate Epo production by an unknown mechanism. 
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Figure 1.8 Schematic overview depicting the formation of erythrocytes from the Hematopoietic 
Stem Cell (HSC) during murine definitive erythropoiesis. The HSC gives rise to the multipotential 
progenitor cell CFU-GranulocyteErythrocyteMonocyteMegakaryocyte, which develops to the BFU-E 
after commitment to the erythroid lineage. Under the influence of SCF, IL-3, and Epo, the BFU-Es form 
burst-like colonies in vitro after 7-10 days. The CFU-E stage is strictly Epo-dependent and forms small 
colonies of about 8-64 cells after 2 days in vitro. The CFU-Es further develop into normoblasts under 
the tight control of Epo signaling. After ejection of the nucleus, the reticulocytes enter the blood stream 
and mature to erythrocytes. Adapted from (Becker, 2007). 
 
1.2.2 Signaling through the erythropoietin receptor 
In 1989 D'Andrea and coworkers successfully cloned the EpoR from murine erythroleukemia 
cells (D'Andrea et al., 1989). The EpoR is a member of the type I cytokine receptor family 
that includes receptors for various interleukins, granulocyte macrophage colony-stimulating 
factor (GM-CSF), granulocyte-colony stimulating factor (GCSF) and prolactin (Bazan, 1990; 
D'Andrea et al., 1990). The crystal structure analysis of EpoR revealed that the extracellular 
portion folds into two domains (D1 and D2), which form an L shape, with the long axis of 
each domain aligned at 90° to the other (Livnah et al., 1996). A common sequence motif, 
Trp-Ser-X-Trp-Ser (WSAWS), is highly conserved in the cytokine receptor superfamily. Most 
mutations in this motif abolish processing, ligand binding, and activation of the receptor 
(Yoshimura et al., 1992). EpoR exhibits no intrinsic tyrosine kinase enzymatic activity. 
Therefore, Epo/EpoR signaling is associated with the activation of the cytoplasmic Janus 
protein tyrosine kinase JAK2 (Witthuhn et al., 1993). The intracellular domain of EpoR 
contains two proline-rich motifs Box1 (residues 257–264) and Box2 (residues 303–313) and 
the region between Box1 and 2 (residues 265–302). These regions are implicated in the 
association of the EpoR with JAK2 (Huang et al., 2001; Miura et al., 1993) (Figure 1.9). 
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Figure 1.9 Schematic representation of 
conserved features and the domain structure 
of the EpoR. The cytokine receptor EpoR is a 
preformed homodimer consisting of an 
extracellular ligand-binding domain, a single 
transmembrane domain (indicated in red) as well 
as of a signal-transducing cytoplasmic domain. 
The extracellular domain displays two fibronectin 
type II domains (D1, D2), four characteristically 
spaced cysteine residues, as well as a 
membrane-proximal WSAWS motif (green bars). 
The cytoplasmic domain of the EpoR harbors two 
JAK2 binding sites, Box1 and Box2 (yellow bars) 
as well as eight Tyr residues that are 
phosphorylated by JAK2. Adapted from (Becker, 
2007). 
 
 
After ligand binding, EpoR undergoes a conformational change resulting in the rapid 
tyrosine phosphorylation of JAK2, which in turn phosphorylates the cytoplasmic Tyr residues 
of EpoR. The Tyr-phosphorylated EpoR then serves as a docking site for other Src 
Homology 2 (SH2) domains containing cellular proteins, initiating the subsequent signal 
transduction events including the phosphorylation and nuclear translocation of the signal 
transducer and activator of transcription 5 (STAT5), activation of phosphatidylinositol 3-
kinase (PI3K), and the mitogen-activated protein kinase (MAPK) signaling pathway (Figure 
1.10). 
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Figure 1.10 Signaling through the EpoR. The dimeric hematopoietic cytokine receptor EpoR with a 
single transmembrane domain is activated by Epo, which results in activation of the associated 
cytoplasmic tyrosine kinase JAK2. The latent transcription factor STAT5 is phosphorylated by JAK2 
and translocates to the nucleus. EpoR phosphorylation also activates the PI3K pathway, leading to 
phosphorylation of the Ser/Thr kinase Akt. Activation of the MAPK cascade, an array of three kinases, 
leads to dual phosphorylation of Erk (Wymann and Marone, 2005). 
 
JAK2 
The Janus family of tyrosine kinases (JAK) includes JAK1, JAK2, JAK3 and Tyk2. They 
belong to a family of protein tyrosine kinases that couple to cytokine receptors. Upon ligand 
binding to cytokine receptors, JAKs phosphorylate themselves and their associated 
receptors. JAK2 is rapidly phosphorylated in response to Epo stimulation. A variety of studies 
have led to a model in which binding of Epo induces a conformational change in the 
cytoplasmic domain of the receptor and allows the juxtaposition of JAK2 molecules in a 
manner that facilitates their transphosphorylation within the activation loop, resulting in the 
activation of the kinase (de la Chapelle et al., 1993; Watowich et al., 1994). Mutation of JAK2 
at Tyr1007 (Y1007F) can abolish the JAK2 activation (Feng et al., 1997). JAK2–/– mice die 
between day E13 and E15, with diminished number of fetal liver cells and erythroid 
progenitors. This suggested that JAK2 is required at an earlier stage of erythropoietic 
development compared to EpoR (Neubauer et al., 1998; Parganas et al., 1998). 
STAT5 
Studies of EpoR tyrosine-mutants concluded that either Tyr343 or Tyr401 is sufficient to 
mediate maximal activation of STAT5; Tyr 429 and Tyr 431 can partially activate STAT5 by 
association with its SH2 domain (Klingmuller et al., 1996). Ligand induced homodimerization 
of EpoR triggers the activation of JAK2. Following tyrosine phosphorylation by JAK2, STAT5 
isoforms a and b either homo- (STAT5a/STAT5a or STAT5b/STAT5b) or heterodimerizes 
(STAT5a/STAT5b) translocate to the nucleus. STAT5 dimers bind to specific DNA binding 
sites and activate transcription in the nucleus (Meyer and Vinkemeier, 2004; Zeng et al., 
2002). Some of the STAT5 targets identified are upregulated in several human cancers, 
suggesting that they might represent potential oncogenes in STAT5-associated malignancies 
(Chattopadhyay et al., 2007; Naka et al., 1997).  
MAPK 
Upon Epo binding, the growth factor receptor-bound protein 2 (GRB2) associated to the 
guanine nucleotide exchange factor (SOS) docks to the phosphorylated EpoR. Activated 
SOS switches the small GTPase protein Ras from the inactive (GDP-bound) to the active 
(GTP-bound) state (Zarich et al., 2006). Subsequently, Ras-activated factor (Raf) becomes 
activated when it binds to the active Ras. Raf activates the MAPK kinases (MEK)1/2, which 
in turn activate Erk 1/2 (Raman et al., 2007). Following the MAPK/Erk activation, a panoply of 
nuclear and cytoplasmic substrates becomes phosphorylated and activated, which are 
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involved in cell proliferation, survival, differentiation, motility and angiogenesis (Yoon and 
Seger, 2006). Hyperactivation of the MAPK pathway is frequently observed in human 
malignancies as a result of aberrant activation of receptor tyrosine kinases or gain-of-function 
mutations in Ras or Raf genes (Schubbert et al., 2007). Some studies have reported that the 
activation of PI3K by EpoR supports the activation of MAPK (Klingmuller et al., 1997). On the 
other hand, it has been reported that PI3K activity is not required for activation of MAPK by 
cytokines (Bouscary et al., 2003; Scheid and Duronio, 1996). 
PI3K  
Epo stimulation induces activation of PI3K through the direct association of PI3K with the last 
Tyr residue of the EpoR (Tyr479) (Damen et al., 1995; Gobert et al., 1995), or through 
recruitment with the Grb2-associated scaffold protein (Gab) via either Tyr343 or Tyr401 of 
the EpoR (Bouscary et al., 2003; Nishida et al., 1999). Some authors also reported the 
activation of the PI3K through the phosphorylation of the insulin receptor substrate 2 (IRS2) 
adaptor proteins (Bouscary et al., 2003). It has been previously proposed that IRS1 or IRS2 
may play an essential role in Epo-regulated erythropoiesis (Richmond et al., 2005). However, 
it has been reported that mice lacking both IRS1 and IRS2 do not show defect in 
erythropoiesis (Pelletier et al., 2006). Activated PI3K phosphorylates phosphatidylinositol 4,5-
bisphosphate (PI(4,5)P2) at the 3-position of the inositol ring, generating phosphatidylinositol 
3,4,5-trisphosphate (PIP3), which, in turn, initiates a vast array of signaling events (Figure 
1.11). Components of the PI3K pathway, including thymoma viral proto-oncogene (Akt), 
mammalian target of rapamycin (mTOR), glycogen synthase kinase 3 (GSK3) and the O 
subclass of the forkhead family of transcription factors (FoxO), are critical regulators of cell 
proliferation, survival, and motility (Bader et al., 2005; Cantley, 2002; Katso et al., 2001; 
Vivanco and Sawyers, 2002). 
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Figure 1.11 Graphical representation of the dynamic pathway model of Epo-induced PI3K 
pathway. In the hematopoietic system the PI3K can be activated through direct binding with the 
phosphorylated EpoR (pEpoR) at position Y479 or indirectly activated through the adaptor protein 
Gab1/2. Activated PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) at the 3-
position of the inositol ring, generating phosphatidylinositol 3,4,5-trisphosphate (PIP3). PTEN and 
SHIP counteract PI3K activity by hydrolyzing PI(3,4,5)P3 at the 3- or 5-position of the inositol ring, 
yielding PI(4,5)P2 and PI(3,4)P2, respectively. PIP3 at the cell membrane recruits protein kinases Akt 
and its kinase PDK1. Akt is subsequently phosphorylated at both Ser473 and Thr308 sites and 
activated. Activated Akt mediates a large spectrum of cellular functions, ranging from control of cell 
proliferation and survival to modulation of intermediary metabolism and angiogenesis (Castaneda et 
al., 2010). 
 
Termination of EpoR signal  
The amplitude and duration of EpoR signaling are modulated by negative regulators. The 
cytokine-inducible SH2-containing protein (CIS) and the suppressor of cytokine signaling 3 
(SOCS3) are members of the suppressors of cytokine signaling family binding EpoR, 
specifically on Tyr401 (Ketteler et al., 2003) and interfering with the receptor binding with 
STAT5. Additionally, CIS also mediates the ubiquitination and degradation of activated EpoR 
(Ungureanu et al., 2002). Phosphorylation of Tyr429 in the EpoR recruits the tyrosine 
phosphatase SHP1, which dephosphorylates and inactivates JAK2. Moreover, Epo binding 
promotes also endocytosis and degradation of the EpoR (Sawyer and Hankins, 1993; 
Walrafen et al., 2005). 
 
1.3 Systems biology approach 
"Systems biology...is about putting together rather than taking apart, integration rather than 
reduction. It requires that we develop ways of thinking about integration that are as rigorous 
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as our reductionist programmes, but different....It means changing our philosophy, in the full 
sense of the term" (Noble, 2006). 
Systems biology integrates computational and theoretical methods with experimental 
efforts, to gain insight into the mechanisms and dynamics of biological systems on a system 
level (Friboulet and Thomas, 2005; Kitano, 2002). On one hand, the breakthrough in 
technical innovations in single-molecule measurements, nanotechnology and high-
throughput measurements in molecular biology enable scientists to collect comprehensive 
data on system performance. On the other hand, a system with numerous components and 
interconnections or interactions gives rise to emergent properties that are not found in the 
individual components. In contrast to the traditional reductionistic approach, systems biology 
no longer focuses on the analysis of individual, isolated reactions, but on integrated 
networks. Therefore, with a systems biology approach it is possible to gain a deep insight 
into the complexity, robustness, modularity, feedback regulation and fragility of the complete 
system (Csete and Doyle, 2002). Moreover, a multi-scale systems-biology approach can 
span a wide range of spatial and temporal scales to understand, predict and control the 
properties of biological systems such as cells, organ, organism and ecosystem 
(Laubenbacher et al., 2009).  
Mathematical modeling is an iterative process depicted in Figure 1.12 (Kitano, 2002; 
Kolch et al., 2005). A hypothesis-driven mathematical model is defined based on the 
established biological knowledge and available qualitative and quantitative experimental 
information. Of course, the decision which type of the model to choose and how detailed it 
should be depends on the biological question the model is supposed to answer. Models used 
for signaling pathway can be classified into different categories (Klipp and Liebermeister, 
2006): (i) A deterministic process with defined future states is the counterpart to a stochastic 
process described through probability distribution. (ii) Continues models relied on finer timing 
and exact molecular concentrations are the counterpart to discrete models for representing 
data with a sequence of quantities. (iii) Models that may or may not describe the processes 
in space. Deterministic and continuous models are the common type of biological models 
and are represented by ordinary differential equations (ODE). ODE networks describe 
kinetics in a mass action approximation. Rates of a reaction i.e., d[Xi]/dt are proportional to 
the concentrations of the reacting species. When model structure and parameter values have 
been adjusted by implementing experimental data, further mathematical exploration and 
analysis can reveal underlying mechanisms beyond observations and examine complex 
biological interactions (Andrews and Arkin, 2006; Maiwald et al., 2007). Moreover, model 
simulation is powerful tool to guide new experiments, which in turn, can further improve the 
model (Becker, 2008).  
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Figure 1.12 Iterative cycle between experiments and modeling in systems biology. In close 
collaboration between experimentalists and theoreticians, open biological questions are addressed 
in an iterative cycle approach of quantitative data generation, mathematical modeling, in silico 
predictions, experimental validation and design of new experiments. Adapted from (Kitano, 2002) 
      
One of the particularly challenging tasks of systems biology is to understand the 
underlying structure of signaling networks and how changes in these networks can affect the 
transmission of information. In this respect, mathematical models representing the kinetic 
properties of a system have already proven to be predictive and useful tools in a number of 
cases. Examples of these are NGFR signaling (Qiu et al., 2004; Sasagawa et al., 2005), 
EGFR signaling (Schoeberl et al., 2002; Wiley et al., 2003), MAPK cascades (Kolch et al., 
2005; Schilling et al., 2009), JAK-STAT signal transduction (Swameye et al., 2003; Yamada 
et al., 2003; Zi et al., 2005) and calcium signaling (Kummer et al., 2000). Recently, several 
integrative models have been used to examine the cross-talk of PI3K/Akt pathway and 
MAPK pathway by C. et. al. (C et al., 2008) and Wang et.al. (Wang et al., 2009). However, it 
is still required to develop computational models for a detailed description of the PI3K/Akt 
pathway structure and its dynamic in specific cell systems. 
 
1.4 Objective 
A central issue in cell biology is how a particular signaling pathway can specifically trigger 
distinct cellular outcomes. The specificity of response to one signaling cascade depends on 
diverse factors including the timing and strength of extracellular signals, the nature of protein 
isoforms, subcellular localization of signaling proteins, synergy and feedback controls, and 
quantitative differences in the expression of pathway constituents. How these regulating 
factors are integrated to determine the signaling output and what are their particular effects 
on fine-tuning the signal transduction still remain to be clarified. Moreover, how does the 
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pathway specify different biological output, leading to cell type-specific responses? It is a big 
challenge here for mathematical modeling. 
In erythrogenesis, Epo induced PI3K/Akt pathway mediates a large spectrum of cellular 
functions of erythroid progenitor cells, ranging from control of cell survival, proliferation and 
differentiation. In order to closely representing PI3K/Akt signaling in an in vivo situation, 
primary erythroid progenitor cells at the CFU-E stage (CFU-E) were chosen as a cellular 
model system for our study. In addition, the factor-dependent murine pro-B cell line BaF3 
exogenously expressing the murine EpoR is a well established system to study Epo-
dependent signaling.  
The goal of this work was to first establish an ODE model, representing the topology and 
dynamics of PI3K/Akt pathway in both systems based on stoichiometric analysis of the 
pathway components. The model was further calibrated by quantitative, time-resolved kinetic 
properties of the pathway. By applying mathematical approach, it was aimed to identify the 
crucial regulatory mechanisms, which determine the cell type-specific PI3K/Akt signaling in 
CFU-E and BaF3-EpoR cells, in particular, the PTEN and SHIP1 mediated negative 
regulations. Furthermore, the quantitative link of Akt activation to its downstream signaling as 
well as cellular decisions can help to understand how the PI3K/Akt pathway specifies 
different biological output, leading to context-dependent responses in different hematopoietic 
cells. 
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2. Results 
2.1 Cell type-specific activation profile of Epo-induced PI3K/Akt signaling  
2.1.1 Generation of time-course data in CFU-E and BaF3-EpoR cells 
To explore the dynamic response of the pathway upon Epo stimulation, time courses of 
EpoR and Akt phosphorylation were performed by quantitative immunoblotting in CFU-E and 
BaF3-EpoR cells. A standardized protocol was established that optimizes the preparation, 
cultivation and stimulation of cells and ensures the reproducibility and comparability of 
experimental data. Preliminary tests and dose-response experiments revealed that a growth 
factor depletion time of 5 hours in BaF3-EpoR and 2 hours in CFU-E cells as well as a dose 
of 5 and 2.5 U/ml Epo, respectively, are appropriate for maximal signal activation within the 
linear range. Hence, these conditions were used in all time-course experiments. The 
experimental data demonstrated that in both cell types the initial phosphorylation of EpoR 
and Akt increased rapidly upon Epo stimulation, but their deactivation kinetics differed 
fundamentally (Figure 2.1 A, C). In CFU-E cells the phosphorylation of EpoR revealed a 
transient maximum approximately 10 min after Epo addition followed by a sharp decline, 
while the pAkt signal remained at a constant high level for at least 40 min. Interestingly, in 
contrast to the dynamics observed in primary cells, Akt phosphorylation in BaF3-EpoR cells 
returned to basal level after 30 min despite sustained pEpoR level over a one-hour 
observation period. Remarkably, it was found that not only the duration but also the 
magnitude of EpoR and Akt phosphorylation exhibited significant differences between these 
two cell types. Although the maximal amount of pEpoR measured in BaF3-EpoR cells was 
approximately 10-fold higher compared to CFU-E cells, the phosphorylation of Akt was 
considerably stronger (approximately 3-fold) in CFU-E cells (Figure 2.1 B, C). 
Taken together, the observations reveal that Akt activation is more sustained and stronger 
in CFU-E cells than in BaF3-EpoR cells despite shorter and weaker EpoR activation (Figure 
2.1.C). These striking discrepancies in the dynamic behavior of EpoR/PI3K/Akt signaling 
between CFU-E and BaF3-EpoR cells suggest that there are differences in the regulation of 
Akt activation and emphasized the importance of studies that compare the stoichiometry of 
pathway components and dissect potential positive and negative regulatory mechanisms of 
PI3K/Akt signaling in primary cells versus the cell line. 
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Figure 2.1 Cell type-specific EpoR/PI3K/Akt signaling. Growth factor-depleted CFU-E cells 
(2x107 cells/ml) and BaF3-EpoR cells (4x107 cells/ml) were stimulated for the indicated times with 
2.5 or 5 U/ml Epo, respectively. (A) Time courses of EpoR and Akt phosphorylation for 1h. EpoR 
was immunoprecipitated (IP) from total cytoplasmic lysates (TCL). Levels of phosphorylated and 
total EpoR as well as the calibrator GST-EpoR used for normalization of the IP were determined by 
subsequent quantitative immunoblotting (IB). TCL (100g) were analyzed by immunoblotting with 
anti-phospho-Akt Ser473 (-pAkt Ser473) and anti-Akt (-Akt) antibodies. The endogenous level of 
PDI from TCL was quantified to normalize the phospho-Akt (pAkt) and total-Akt (tAkt) signals. (B) 
The magnitude of EpoR and Akt phosphorylation in CFU-E and BaF3-EpoR cells was compared by 
analyzing the samples on the same immunoblot. Bars represent the relative magnitudes of pEpoR 
and pAkt compared to each other in CFU-E and BaF3-EpoR cells after 10 min Epo stimulation. (C) 
To visualize the dynamics of experimentally measured EpoR and Akt phosphorylation in (A, B), 
smoothing splines (dashed lines) were calculated using the GelInspector software. Experimental 
data are depicted as solid circles (quantified data shown in Table 6.1, 6.2). Dashed lines represent 
the smooth splines. The experiment was repeated at least three times with similar results and 
representative blots are shown. 
 
2.1.2 Quantification of PI3K/Akt pathway components 
To quantify endogenous levels of pathway components, recombinant proteins were used in 
combination with quantitative immunoblotting. Recombinant proteins (calibrators) consisting 
of either the full-length protein of interest or a truncated version harboring the relevant 
epitopes for antibody binding were tagged with glutathione S-transferase (GST) or 
streptavidin binding-peptide (SBP) for purification and expressed in E.coli. The absolute 
concentrations of the calibrators were determined by means of a known BSA standard. To 
quantify endogenous protein levels, the respective calibrators were spiked into either cellular 
lysates or lysis buffer without cellular material in a dilution series prior to 
immunoprecipitation. After quantification of immunoblotting signals, endogenous protein 
concentrations could be estimated in absolute molecule numbers per cell based on the 
calculated calibration curves. The ratios of signaling components between CFU-E and BaF3-
EpoR cells were further confirmed by directly comparing the immunoblotting signals of 
samples loaded on the same blot.  
First, the endogenous levels of the negative regulators PTEN and SHIP1 were analyzed 
applying the calibrators SBP-PTEN and GST-SHIP1, respectively. Impressively, both PTEN 
and SHIP1 were found to be expressed almost 35-fold and 20-fold higher in BaF3-EpoR cells 
compared to their levels in CFU-E cells (Figure 2.2 A, B, F and Figure 2.3). 
Next, other intracellular key components of PI3K/Akt signaling, PI3K, Akt as well as PDK1 
were analyzed. The concentration of PI3K in cells was determined by detecting the protein 
level of p85 applying the calibrator SBP-p85. The endogenous levels of p85 were observed 
to be in the range of approximately 10,500 molecules per cell in BaF3-EpoR cells and 3,000 
molecules per cell in CFU-E cells (Figure 2.2. C, F and Figure 2.3). The endogenous 
concentration of Akt in BaF3-EpoR cells was estimated to be in the range of 430,000 
molecules per cell (Figure 2.2 E, F and Figure 2.3). By loading the samples on the same gel, 
the endogenous protein level of Akt in CFU-E cells was directly compared to its level in 
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BaF3-EpoR cells and determined to be in the range of 100,000 molecules per cell (Figure 2.2 
F). For PDK1, we estimated a ratio of approximately 3:1 between BaF3-EpoR and CFU-E 
cells by directly comparing the immunoblotting signals of samples loaded on the same blot 
(Figure 2.2 F). 
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Figure 2.2 Quantification of molecule numbers per cell of PI3K/Akt pathway components. 
Endogenous protein levels of (A) PTEN, (B) SHIP1, (C) p85, (D) Akt and (E) Gab1 were estimated 
in cellular lysates of BaF3-EpoR and CFU-E cells using corresponding recombinant calibrator 
proteins. Non-stimulated 1×107 BaF3-EpoR cells or 5×106 CFU-E cells were lysed and proteins of 
interest including recombinant standards were immunoprecipitated and subsequently analyzed by 
quantitative immunoblotting. Dilution series of recombinant proteins were plotted with linear 
regression functions (solid lines), and 95% confidence intervals were defined (dashed lines). The 
levels of endogenous proteins are indicated by dashed drop lines. In (F), the ratios of PTEN, SHIP1, 
Akt, p85 and PDK1 between both cells were further confirmed by directly comparing the 
immunoblotting signals of samples loaded on the same blot. 
 
The adaptor protein Gab that ispresent in different isoforms, i.e. Gab1 and Gab2, 
coordinates the assembly of the PI3K complex and thereby recruits and enhances the 
enzymatic activity of PI3K. In primary erythroid progenitors, EpoR utilizes Gab1, whereas 
Gab2 is dominantly present in BaF3-EpoR cells (Edmead et al., 2006; Miyakawa et al., 
2001). In our study, we detected tyrosine phosphorylation of Gab1 and Gab2 in CFU-E and 
BaF3-EpoR cells respectively following exposure to Epo, see Figure 2.5. Furthermore, the 
endogenous level of Gab1 was determined in the range of 5,000 molecules per cell in CFU-E 
cells applying calibrator GST-Gab1 (Figure 2.2 E, F and Figure 2.3).  
To consider the difference in cell size, the average cytoplasmic volumes of both cells were 
determined by confocal microscopy (experiment by Andrea C. Pfeifer, DKFZ Heidelberg). 
The quantification revealed that BaF3 cells have a cytoplasmic volume of 1400 µm3, which is 
approximately 3 times larger compared to the cytoplasmic volume of CFU-E determined as 
399 µm3. This information was used to convert molecules/cell into concentration in nM. The 
number of EpoR on the cell surface of BaF3-EpoR cells was determined as 15,700 
molecules per cell by a saturation-binding assay with [125I]-labeled Epo (Becker et al., 2010). 
Molecules per cell for EpoR on the surface of CFU-E cells was reported as 1,000 previously 
(D'Andrea and Zon, 1990). For an overview of the stoichiometry of pathway components see 
Figure 2.3. 
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Figure 2.3 Stoichiometric analysis of PI3K pathway components. See main text for detailed 
explanation of the quantification. ‘-‘ indicates the absence and ‘+’ indicates the presence of protein in 
cells, for which quantitative information is not available. 
  
In summary, the concentrations of pathway components Akt, PI3K and PDK1 were 
detected to be within the same range in both cell types. However, the density of EpoR on the 
cell surface and the endogenous levels of PTEN and SHIP1 were found to be profoundly 
higher in BaF3-EpoR cells. This is consistent with the kinetics of EpoR and Akt (Figure 2.1). 
Additionally, the expression of distinct Gab isoforms was observed in these two cell types. To 
address if the stoichiometry of different protein species participates in modulating the cell 
type-specific PI3K/Akt signaling in CFU-E and BaF3-EpoR cells, a mathematical modeling 
approach was applied, which can help to understand complex and highly dynamic 
interactions of PI3K/Akt pathway components beyond experimental observations. 
 
2.2 Data-based mathematical model of EpoR/PI3K/Akt signaling 
A mathematical modeling approach provides a useful tool to independently assess the effect 
of each core component during the complex and dynamic interactions in PI3K/Akt signaling. 
In essence, modeling analysis allows for examining various aspects associated with the 
dynamics of pathway components, yielding detailed information on reaction rates and fluxes, 
which are difficult to be investigated experimentally. 
In collaboration with Sandip Kar, Lu Wang and Thomas Höfer (DKFZ, Heidelberg), an 
ODE-based mathematical model was developed for the Epo-induced EpoR/PI3K/Akt signal 
transduction in both CFU-E and BaF3-EpoR cell systems. The mathematical model 
incorporated protein-protein and protein-lipid interactions as well as enzymatic reactions 
without considering transient complex formation. As there is no feedback regulation from 
downstream components reaching the receptor, the receptor activation model could be 
separated from the core model of PI3K/Akt activation. In order to take into account the effect 
of the relative subcellular distribution of proteins on the reaction rates, cellular membrane 
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and cytoplasm were defined as distinct compartments. Based on the experimental 
measurements as well as on literature data, the concentrations of key reaction species in this 
pathway were fixed and rescaled to densities on the cellular membrane or to cytoplasmic 
concentrations (Table 6.10). 
 
2.2.1 The receptor activation model  
The receptor activation model was developed to capture signal initiation at the plasma 
membrane. Therefore, trafficking and multisite phosphorylation of EpoR were not considered 
and receptor down-regulation mechanisms such as receptor endocytosis as well as 
dephosphorylation were summarized in two negative feedback loops: (i) dephosphorylation 
of the receptor by phosphatase SHP1 (Klingmuller et al., 1995; Sharlow et al., 1997) and (ii) 
the signal suppression mediated by cytokine-inducible signaling suppressors, such as 
SOCS3, which inhibits the activity of upstream receptor kinase JAK2 (Marine et al., 1999). In 
addition, the depletion of extracellular ligand mediated by receptor endocytosis during the 
time of observation was detected by directly immunoprecipitating Epo from the medium. 
Experimental data showed that for BaF3-EpoR cells stimulated with 5 U/ml Epo, ligand 
depletion in the medium was rapid and could be described by an exponential decay function 
y=5e-0.01732t (Becker et al., 2010). Epo depletion in the medium of BaF3-EpoR cells was 
observed to be much slower at higher Epo concentrations due to the saturation of ligand-
receptor binding (Becker, unpublished data). Moreover, data from that study allowed 
assuming a nearly constant ligand concentration for CFU-E cells stimulated with 2.5 U/ml 
Epo within one hour observation, which could be explained by an approximately 10-fold 
lower EpoR cell surface expression in primary cells compared to BaF3-EpoR cells. The 
established receptor activation model is schematically depicted in Figure 2.4, describing 
different Epo input functions in CFU-E and BaF3-EpoR cells, activation of EpoR upon Epo 
binding to the receptor and subsequent activation of two negative feedback loops. 
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Figure 2.4 The receptor activation model. The receptor activation model includes different Epo 
input functions in CFU-E and BaF3-EpoR cells, activation of EpoR upon Epo binding to the receptor 
and subsequent activation of two negative feedback loops. The reaction steps of the model are 
numbered from 1 to 6 (red).The individual reactions and their parameters are listed in detail in 
Appendix 6.3. 
 
2.2.2 The core model of PI3K/Akt activation 
The core model is divided into three interconnected submodules describing PI3K activation, 
PIP3 regulation and Akt activation.  
PI3K activation: was modeled through direct binding to phosphorylated EpoR (Miura et al., 
1994) or via the scaffold protein Gab1/2 (Bouscary et al., 2003; Wojchowski et al., 1999). 
Although Gab1 and Gab2 seem to mediate overlapping biological signals in many cells, they 
may exert their functions by distinct mechanisms (Gu et al., 2000; Gu and Neel, 2003; 
Rodrigues et al., 2000). Results of a preliminary experiment using the PI3K inhibitor 
LY240002 show that Gab1 and Gab2 exhibited distinct activation kinetics: Gab1 
phosphorylation was clearly reduced in the presence of LY240002 suggesting a PIP3-
mediated positive feedback on Gab1 activation (Eulenfeld and Schaper, 2009; Itoh et al., 
2000), whereas Gab2 phosphorylation was unaffected (Figure 2.5). Gab1, Gab2, and Gab3 
were expressed in BaF3 cells, but the dominant isoform is Gab2 (Miyakawa et al., 2001). 
Therefore, isoform-specific parameters were assumed for the indirect PI3K activation 
mediated by Gab1 and Gab2 in CFU-E and BaF3-EpoR cells, respectively. Besides PI3K 
activation upon Epo stimulation, a cytosolic constitutive active PI3K was assumed in the 
model (Batty and Downes, 1996; Jia et al., 2008), which possesses a different catalytic 
activity than the complexes pEpoR-PI3K and pEpoR-Gab1/2-PI3K.  
Results  39 
 
Figure 2.5 Distinct activation kinetics of Gab1 and Gab2. In a preliminary experiment, growth 
factor-depleted (A) CFU-E cells (2x107 cells/ml) or (B) BaF3-EpoR cells (4x107 cells/ml) were pre-
incubated with 10  µM LY294002 for 30 min and then stimulated with 2.5 U/ml or 5 U/ml Epo 
respectively for the indicated times. As control, cells were treated with the same amount of DMSO 
and Epo. EpoR and Gab1/2 were immunoprecipitated from cellular lysates; phospho-EpoR (pEpoR) 
and phospho-Gab1/2 (pGab1/2) were detected by subsequent immunoblotting. pAkt Ser473 signals 
were detected from TCL. Pre-incubation with LY294002 for 30 min did not affect Epo-induced EpoR 
phosphorylation, but almost completely abolished Akt activation in both cell types. However, the 
phosphorylation of Gab1 in CFU-E cells was clearly reduced, whereas Gab2 phosphorylation was 
unaffected in BaF3-EpoR cells. 
 
PIP3 regulation: Active PI3K phosphorylates PI(4,5)P2 generating PIP3 in the plasma 
membrane. It is well known that PTEN and SHIP1 share the property of negatively regulating 
PIP3 levels by hydrolyzing PI(3,4,5)P3. However, the mechanisms for their regulation remain 
elusive. Previous studies have indicated that in the majority of cell types PTEN is 
constitutively active, thereby influencing basal PI(3,4,5)P3 levels, maintaining it below a 
critical signaling threshold (Stambolic et al., 1998; Sun et al., 1999). In contrast, SHIP1 gets 
activated upon membrane recruitment mediated by its binding to the phosphorylated EpoR 
(Mason et al., 2000). These different activation mechanisms were implemented in the model, 
describing the regulation of PIP3 levels by PTEN and SHIP1.  
Akt activation: PIP3, generated upon activation of PI3K, recruits Akt and its kinase PDK1 to 
the plasma membrane via their PH domain, facilitating PDK1 to phosphorylate Akt at Thr308 
(Stokoe et al., 1997). Akt is also phosphorylated at Ser473 by other kinases to achieve its full 
activation (Shiota et al., 2006). A synchronized activation at both Thr308 and Ser473 of Akt 
in CFU-E cells was measured (Figure 2.6), while the phosphorylation at Thr308 was 
undetectable in BaF3-EpoR cells. Therefore, Akt double phosphorylation is summarized to 
one reaction catalyzed by membrane-recruited PDK1in the model. Activated Akt rapidly 
dissociates from the membrane and is dephosphorylated in the cytoplasm. 
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Figure 2.6 Synchronized activation of Akt at Ser473 and Thr308 in CFU-E cells. (A) Lysates of 
CFU-E cells treated with 2.5 U/ml Epo were collected at the time indicated and analyzed by 
immunoblotting with specific antibodies for pAkt Ser473, pAkt Thr308 and an antibody against total 
Akt. The endogenous level of PDI from TCL was quantified as normalizer. (B) Time courses of Akt 
phosphorylation at Ser473 and Thr308. Experimental data are depicted as dots. Dashed lines 
represent the smooth splines. The experiment was repeated at least three times with similar results 
and representative blots are shown.  
 
To reduce model complexity, we condensed some sequential multi-step processes to a 
simplified one-step description without changing the network topology (Borisov et al., 2009). 
For instance, Gab cannot bind directly to Epo receptor. The activation of Gab requires an 
additional adaptor protein, Grb2, which mediates the recruitment of Gab to the pEpoR. 
Subsequently Gab is phosphorylated at multiple tyrosine residues (Borisov et al., 2009). 
Likewise, SHIP1 has been described to directly associate with EpoR in a SH2-dependent 
manner through multiple phosphotyrosine residues, including Tyr401, Tyr429, and Tyr431 
(Mason et al, 2000) or to form a complex with Grb2 and Shc (Damen et al, 1996; Lioubin et 
al, 1996). As in those cases the key process is the membrane recruitment of Gab and 
SHIP1, all these simultaneously or sequential binding events should have a small effect on 
downstream signaling and can be described as one-step process. 
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Figure 2.7 The core model of PI3K/Akt activation. The core-model of PI3K/Akt activation consists 
of three submodules: activation of PI3K (blue), regulation of PIP3 level at the plasma membrane (red), 
and activation of Akt (green). See text for a detailed explanation about the model modules. The 
reaction steps of the model are numbered from 1 to 21 (red). The individual reactions and their 
parameters are listed in detail in Appendix 6.3. 
 
2.3 Model calibration using muti-experiment fitting  
To determine the parameters of the EpoR/PI3K/Akt pathway model, time-resolved 
quantitative data of pathway activation were required to calibrate the models. The data sets 
were generated in CFU-E and BaF3-EpoR cells monitoring the kinetics of EpoR and Akt 
simultaneously by quantitative immunoblotting. 
 
2.3.1 Epo ligand-receptor dynamics 
To monitor ligand-receptor dynamics, EpoR phosphorylation in CFU-E and BaF3-EpoR cells 
was determined in a time-resolved manner in response to different doses of Epo within a 
range from 0.1 to 10 U/ml in CFU-E and 0.5 to 50 U/ml in BaF3-EpoR cells (Figure 2.8 A, B). 
In general, the receptor activation in primary cells was much weaker and more transient 
compared to BaF3-EpoR cells (see Figure 2.1 B). In both cells, a high dose of Epo prolonged 
the activation of receptor and shifted the activation peak to earlier time. Additionally, to 
accurately represent the dynamic behavior, time courses with more dense sampling were 
performed with an Epo stimulation of 2.5 U/ml in CFU-E cells and of 5 U/ml in BaF3-EpoR 
cells (see Figure 2.1).   
For a quantitative modeling approach, information about the absolute concentration is 
particularly required for reliable parameter estimates. The relative signal intensities of 
Results  42 
receptor phosphorylation between different doses of Epo as well as between CFU-E and 
BaF3-EpoR cells were experimentally determined. Quantification of the absolute amount of 
the phosphorylated receptor, however, is technically difficult. To define the absolute receptor 
phosphorylation level, it was assumed that the receptors on the CFU-E cell surface are 
maximally 75% phosphorylated (Figure 2.8 C, at 5 min stimulated with 10 U/ml Epo). In 
addition, a receptor phosphorylation level of 50% or 90% was also tested in silico, but this 
had no significant influence on the model behavior. Based on this assumption, experimental 
data were transformed into absolute concentrations in nM. 
The receptor activation models were separately calculated to experimental data acquired 
in CFU-E and BaF3-EpoR cells, performing 1000 fits with random initial parameter guesses. 
The models were sufficient in representing both the dose response and particularly the 
densely sampled time course data in both cell types (Figure 2.8 C). The distribution of the 
calibrated parameter values of 10% of the best 1000 fits is plotted in Figure 2.9 A. Out of 7 
parameters, only two were non-identifiable. These parameters were related to 
phosphokinase inhibitor and correlated with each other (Figure 2.9 B). The fixation of one of 
the two parameters led to the identification of all the parameters. 
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Figure 2.8 Epo ligand-receptor dynamics. Immunoblotting analysis of EpoR phosphorylation in 
response to different Epo concentrations in (A) CFU-E and (B) BaF3-EpoR cells. T indicates 
samples generated in CFU-E cells transduced with the empty pMOWSnr vector as control for 
another independent experiment and those were excluded from the fitting. Model trajectories of the 
best fit are indicated by solid lines and experimental data are represented by circles with standard 
error for EpoR dose response (left) (quantified data shown in Table 6.3) and the densely sampled 
time courses (right) in (C) CFU-E and (D) BaF3-EpoR cells. Standard deviations of the measured 
data were estimated with a standard error model, considering contribution of relative errors Erel (10% 
relative to measured value (Y)) and absolute errors Eabs (5% relative to max(Y) over all Y). The 
experiment was repeated two times with similar results and representative blots are shown.  
 
 
Figure 2.9 Parameter distribution analysis of the receptor activation model in CFU-E and 
BaF3-EpoR cells. (A) The distribution of the calibrated parameter values of 10% of the best 1000 
fits, highlighting the non-identifiable parameters (blue boxes). Ji: EpoR occupying half of the binding 
sites, n: Hill coefficient, Ki: inhibition of EpoR activation by kinase inhibitor. (B) Dependency of the 
two non-identifiable phosphokinase inhibitor-associated parameters was identified with the mean 
optimal transformation approach (MOTA) (Hengl et al., 2007).  
 
2.3.2 Core model calibration by muti-experiment fitting  
Akt phosphorylation was measured as system’s output signal in a time-resolved manner in 
both cells by quantitative immunoblotting (see Figure 2.1). To dissect the specific role of 
PTEN and SHIP1 in negative regulation, we overexpressed the two proteins individually in 
CFU-E cells and observed Akt activation as the response of the perturbed system. In order to 
perform time-course experiments in PTEN or SHIP1-overexpressing CFU-E cells, freshly 
isolated primary cells were retrovirally transduced. The transduction efficiency reached 10-
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20%. Magnetic-activated cell sorting (MACS) with the low-affinity nerve growth factor 
receptor (LNGFR) surface marker enabled an efficient positive selection of transduced cells 
after 11-14 h transduction (see Materials and methods 4.2.5). PTEN was overexpressed on 
average 12-fold, while 11-fold increase on SHIP1 protein level was achieved (Figure 2.10 A, 
B). Overexpression of PTEN in CFU-E cells strongly abolished Akt phosphorylation, reducing 
the peak amplitude around 60%. SHIP1 overexpression only led to a reduction in pAkt signal 
duration. At 10 min, a reduction of 25 % was detected, while at 60 min a reduction of 60% 
was detected in SHIP1-overexpressing cells compared to control cells (Figure 2.10 A, C). 
Additionally, to accurately represent the pAkt dynamic, time course experiments with dense 
sampling were performed with an Epo stimulation of 2.5 U/ml in PTEN or SHIP1-
overexpressing CFU-E cells (Figure 2.10 D).  
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Figure 2.10 Overexpression of PTEN and SHIP1 in CFU-E cells. CFU-E cells retrovirally 
transduced with PTEN, SHIP1 or vector control were stimulated with 2.5 U/ml Epo for the indicated 
times and subjected to quantitative immunoblotting. (A) Immunoblotting data of TCL to determine the 
effects of PTEN and SHIP1 overexpression on Akt phosphorylation and the overexpression levels of 
PTEN and SHIP1. (B) The expression levels of PTEN and SHIP1. (C) The fold change of pAkt 
amplitude at 10 min and 60 min. (D) Time courses of pAkt Ser473 and Thr308 in PTEN or SHIP1-
overexpressing CFU-E cells (quantified data shown in Table 6.5). (*) indicates a non-transduced 
sample as negative control and (**) indicates a PTEN-transduced sample from another independent 
experiment as positive control for transduction. The experiment was repeated at least three times 
with similar results and representative blots are shown.  
 
Total protein levels remained constant during the time investigated, thus justifying 
application of mass conservation in the model. To define the absolute amount of 
phosphorylated Akt, a quantitative protein array was applied that combines in-spot 
normalization and binding model-based calibration. The maximal phosphorylation degree of 
Akt was determined to be 54% in CFU-E cells stimulated with 2.5 U/ml Epo at 10 min. Based 
on this information, all pAkt data in Figure 2.1 and Figure 2.10 were scaled to absolute 
concentrations in nM. 
For the PI3K/Akt core model, the trajectory of receptor activation in each cell type based 
on the best parameter estimation served as input. The PI3K/Akt core model was 
simultaneously calibrated to multiple time-course data of Akt phosphorylation recorded in 
wild type CFU-E and BaF3-EpoR cells as well as in PTEN- or SHIP1-overexpressing CFU-E 
cells, performing 5000 fits with random initial parameter guesses. Standard deviations of the 
measured data were estimated with an error model, considering contribution of relative errors 
Erel (10% relative to Y) and absolute errors Eabs (5% relative to max(Y) over all Y). For the 
best fit (Figure 2.11), the total 2 = 42.56, which is defined as the model deviation from the 
data normalized with the measurement error, indicates an accurate description of the data in 
respect to the total number of N = 58 data points. 
 
Figure 2.11 Muti-experiment fitting for the PI3K/Akt core model calibration. Trajectories of the 
best fit of the PI3K/Akt core model are indicated by solid lines and experimental data are 
represented by circles. Standard deviations of the measured data were estimated with the standard 
error model. Parameter estimation was performed to simultaneously fit the model to four different 
data sets (4 data sets) generated in wild type CFU-E (blue) and BaF3-EpoR (black) cells (data refer 
to Figure 2.1) as well as SHIP1 (green) and PTEN (red)-overexpressing CFU-E cells (data refer to 
Figure 2.10). 2-values comparable to N indicate accurate description of the data. 
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2.4 Model validation and control analysis of the PI3K/Akt pathway 
2.4.1 Constrained model prediction of PTEN or SHIP1 overexpression in BaF3-EpoR 
cells 
Having estimated the parameter sets of the kinetic model, the model quality was evaluated 
by deriving predictions from the model, which could then be tested experimentally. For a 
good accuracy of model simulations, the estimated parameters are required to be identifiable 
and display small confidence intervals. Thus, the calibrated core model parameter values of 
1% of the best 5000 fits was plotted in Figure 2.12 A. Most of the parameters exhibited a 
large distribution of values indicating a non-identifiability. However, the rate constants of 
PIP3 turnover by PTEN (vPI45P2) and by SHIP1 (vPI34P2) as well as the two parameters 
directly related to Akt activation, namely the rate constants of Akt phosphorylation (vpAkt) 
and dephosphorylation (dpAkt), were well identified in a narrower relative distribution within 
20% standard deviation. The response equation of pAkt that describes the phosphorylation 
level of Akt in steady state condition was solved as a function of PIP3 level (Figure 2.12 B). 
Since total levels of Akt and PDK1 are constant, the ability to predict Akt phosphorylation 
relies on the determination of PIP3 levels and the relevant correlations of dpAkt/vpAkt, 
lpAkt/kpAkt (dissociation / association rate constants of Akt to PIP3), IPDK1/kPDK1 
(dissociation / association rate constants of PDK1 to PIP3) and dpAkt/kAkt. When PIP3 goes 
to infinity, pAkt only depends on dpAkt/vpAkt, indicating its decisive role in determining the 
Akt dynamics. The turnover of PIP3 level is strictly controlled by PTEN and SHIP1 activities, 
with the rate constants vPI45P2 and vPI34P2, respectively. A linear correlation between 
these two parameters was also identified.  
Since each data set used for fitting contains information relevant for different parameters, 
the identifiability of the relevant parameter correlations was improved by fitting the core 
model to different data sets: these were two wild type BaF3-EpoR and CFU-E data sets (2 x 
WT) and three data sets including two wild type data and the overexpression of SHIP1 or 
PTEN in CFU-E cells (2 x WT + oe SHIP1 or 2 x WT + oe PTEN) and all data sets (4 data 
sets). The results show that the fitting to 4 data sets with the maximum amount of information 
constrains all the correlations in the best way (Figure 2.12 C). Remarkably, the high 
correlation between dpAkt and vpAkt was identified in all the cases, while the correlation 
between vPI45P2 and vPI34P2 was progressively increased by using the overexpression 
data in CFU-E cells, with PTEN having stronger effect in line with its more significant effects 
on Akt activation.   
To examine the predictive power of the model for the effects of PTEN and SHIP1 
overexpression on Akt activation in BaF3-EpoR cells, we first overexpressed PTEN or SHIP1 
in BaF3-EpoR cells. The overexpression level of PTEN was 3-fold while a 4-fold increase 
was measured for SHIP1 compared to their endogenous protein levels by immunoblotting 
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(Figure 2.13 B). Overexpression of PTEN or SHIP1 reduced Akt phosphorylation in BaF3-
EpoR cells, with PTEN having a stonger effect (Figure 2.13 B). As expected, the EpoR 
phosphorylation was not affected by overexpression (Figure 2.13 A). In line with the 
unchanged receptor levels, the activation of Erk1/2, the components of Epo-induced MAPK 
cascade, remained comparable between control cells and the cells-overexpressing PTEN or 
SHIP1. 
Next, the model was employed to predict Akt phosphorylation in BaF3-EpoR with elevated 
PTEN or SHIP1 concentration, which was experimentally determined, as described above. 
Again, the model predictions were examined from the determined models fitted to different 
data sets. To verify the robustness of the predictions, the simulations were repeated with 
parameter sets obtained for 1% of the best 5000 fits of each determined model (Figure 2.13 
C). Trajectories of pAkt in wild type BaF3-EpoR (black lines) and in PTEN (green lines) or 
SHIP1 (red lines)-overexpressing cells are converged tightly, which largely relies on the high 
correlation between dpAkt and vpAkt. The 2-values were calculated to determine the 
agreement between the overexpression data and the model predictions. The results show 
that the predictions derived from the models calibrated to PTEN data (2 x WT + oe PTEN 
and 4 data sets) were comparable and in good agreement with the experimental data, 
whereas the model calibrated to wild type data and SHIP1 data resulted in a much higher 2-
value (Figure 2.14 B). 
With this modeling approach, the correlation between dpAkt and vpAkt was identified as 
decisive factor to constrain the predicted pAkt behavior, while the correlation between 
vPI45P2 and vPI34P2 determined the differential effects of PTEN and SHIP1 on Akt 
activation. In the end, the best parameter set allowed to accurately predict pAkt dynamics 
after perturbation of PTEN and SHIP1 concentrations in BaF3-EpoR cells. 
 
  
 
 
 . 
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Figure 2.12 Parameter distribution analysis of the PI3K/Akt core model and data improved 
identifiability of the parameter correlations. (A) The distribution of the calibrated parameter values 
of 1% of the best 5000 fits, highlighting the non-identifiable parameters (blue boxes). The core model 
was calibrated to 4 data sets, refer to Figure 2.11. (B) Response equation of pAkt at steady state. (C) 
The relevant parameter correlations identified by fitting the core model to two wild type BaF3-EpoR 
and CFU-E data sets (2 x WT) to three data sets including two wild types and overexpression of 
SHIP1 or PTEN in CFU-E cells (2 x WT+ oe SHIP1 or 2 x WT + oe PTEN) and to 4 data sets. 
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Figure 2.13 Experimental validation of model predictions: PTEN or SHIP1 overexpression in 
BaF3-EpoR cells. BaF3-EpoR cells retrovirally transduced with PTEN, SHIP1 or vector control were 
stimulated with 5 U/ml Epo for the indicated times and subjected to quantitative immunoblotting. (A) 
Comparable EpoR phosphorylation levels between PTEN or SHIP1-overexpressing and control BaF3-
EpoR cells. Immunoprecipitations were performed with anti-EpoR together with anti-PTEN or anti-
SHIP1. (B) Immunoblotting data of TCL to determine the effects of PTEN or SHIP1 overexpression on 
Akt and Erk phosphorylation. Expression levels of PTEN and SHIP1 were depicted as bar charts. (C) 
Simulation of the effects of PTEN (green lines) or SHIP1 (red lines) overexpression on Akt 
phosphorylation in BaF3-EpoR cells. Black lines represent the model trajectory of Akt phosphorylation 
in wild type cells. Red and green lines represent simulations of pAkt in PTEN or SHIP1-
overexpressing cells, respectively, based on the best 1% of 5000 fits. Circles represent the 
experimental data with error bar based on biological replicates (quantified data shown in Table 6.6). 
The experiment was repeated at least three times with similar results and representative blots are 
shown. 
 
2.4.2 Fine-tuned control of Akt activation by PTEN and SHIP1  
A major focus of this study was to dissect the role of PTEN and SHIP1 in the regulation of 
Akt activation. The experimental model validation confirmed the initial assumption that PTEN 
is constitutively active while SHIP1 becomes activated upon binding to pEpoR. Next, to 
analyse the effects on pAkt dynamics, the calculated model was applied to simulate pAkt 
dynamics for different initial concentrations of PTEN or SHIP1 in CFU-E and BaF3-EpoR 
cells. In line with their activation mechanisms, in CFU-E cells PTEN strongly controled the 
initial level and amplitude (maximum activation) of pAkt, while SHIP1 had a major effect on 
the signal duration (time until signal drops down to 10% of its maximum activation) (Figure 
2.14 A). In contrast, in BaF3-EpoR cells, the effects on pAkt were enhanced (Figure 2.14B), 
indicating that this cell type is more sensitive to changes in PTEN and SHIP1 levels. 
Particularly, SHIP1 strongly affected the amplitude of pAkt. Additionaly, it was explored how 
PTEN and SHIP1 affect the integral of pAkt activation (60 min) for different Epo 
concentrations ranging from 0.001 to 50 U/ml in both cell types (Figure 2.14 C, D). The 
results showed that constitutive active PTEN mainly contributed to regulate the PIP3 level at 
low levels of Epo. With increasing stimulus doses, more EpoR on the cell surface were 
getting phosphorylated, subsequently activating more SHIP1. Hence, in contrast to PTEN, 
SHIP1 played a crucial role in controlling the PIP3 levels at high levels of Epo.  
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Figure 2.14 Fine-tuned control of Akt activation by PTEN and SHIP1. The calculated model was 
applied to simulate Akt dynamics for different initial concentrations of PTEN or SHIP1. Effect of relative 
changes in PTEN or SHIP1 concentration compared to the initial concentrations (dashed lines) on Akt 
dynamics in (A) CFU-E cells and (B) BaF3-EpoR cells and on the integral Akt activation (60 min) for 
different Epo concentrations in (C) CFU-E cells and (D) BaF3-EpoR cells. 
  
2.4.3 Isoform-specific role of Gab1/2 on controlling PI3K/Akt signaling 
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Upon Epo stimulation, both Gab1 and Gab2 are phosphorylated at their tyrosine residues 
and associate with the Tyr-phosphorylated EpoR (pEpoR-pGab1/2 complex formation). The 
tyrosine motifs of Gab1/2 then mediate the engagement and activation of PI3K (pEpoR-
pGab1/2-PI3K complex formation) (Wickrema et al., 1999). To dissect the dynamics of the 
Gab-mediated two-step activation of PI3K, the complex formations of pEpoR-pGab1/2 and 
pEpoR-pGab1/2-PI3K were stimulated (Figure 2.15 A, B). According to the model 
predictions, the activation of both pEpoR-pGab1/2 and pEpoR-pGab1/2-PI3K complexes 
would rapidly follow the EpoR phosphorylation, showing transient and sustained dynamics in 
CFU-E and BaF3-EpoR cells, respectively. Importantly, the ratio between the amplitude of 
pEpoR-pGab1/2-PI3K and pEpoR-pGab1/2 activation (indicated by arrows in Figure 2.15) 
indicates the activation efficiency of PI3K by pEpoR-pGab1/2. The model prediction: 
pGab2)-(pEpoR Amplitude
 PI3K)-pGab2-(pEpoR Amplitude
pGab1)-(pEpoR Amplitude
 PI3K)-pGab1-(pEpoR Amplitude   
indicates that pEpoR-pGab1 would activate PI3K with greater efficiency than pEpoR-Gab2, 
suggesting an isoform-specific role of Gab1/2 on Akt activation. Quantitative data on Gab1/2 
phosphorylation was not used for model training and was now acquired experimentally to test 
the model predictions. The experimentally detectable total Gab1/2 phosphorylation 
constitutes the sum of the pEpoR-pGab1/2 and pEpoR-pGab1/2-PI3K fractions. Remarkably, 
the overlay of experimental data with the simulated total Gab1/2 phosphorylation dynamics 
were in good agreement (Figure 2.15), suggesting that our model can accurately describe 
the different kinetics of Gab1 in CFU-E cells and Gab2 in BaF3-EpoR cells. 
To examine whether both Gab1 and Gab2 have decisive role on Akt activation, we 
reduced the core PI3K/Akt model by setting all Gab1 or Gab2 related parameters to 0 and 
calibrated them individually to 4 data sets, performing 5000 fits with random initial parameter 
guesses. The model without Gab1 failed to describe the data, in particular, the 
overexpression data in CFU-E cells, while the model without Gab2 was still sufficient in 
describing all the data, having a comparable 2-value to the core model (Figure 2.16 A). In 
addition, the model without Gab2 can also give correct predictions about the pAkt behavior in 
PTEN or SHIP1-overexpressing BaF3-EpoR cells. The likelihood-ratio test (LRT) further 
confirmed that only the model without Gab1 is not compliant with the data (goodness-of-fit: p 
< 0.01) (Maiwald and Timmer, 2008) (Figure 2.16 B). This model reduction approach reveals 
a vital role for Gab1 in CFU-E cells but a negligible role for Gab2 in BaF3-EpoR cells. 
Consistent with the approach above, the results demonstrate that besides the abundance of 
negative regulators, Gab-mediated isoform-specific PI3K activation is also important in 
determining the PI3K/Akt signaling in hematopoietic cells. 
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Figure 2.15 Experimental testing of the model predictions for Gab activation. Trajectories 
(solid lines) represent model predictions for EpoR phosphorylation and the complex formations of 
pEpoR-pGab1/2 and pEpoR-pGab1/2-PI3K. Experimental data are represented by circles with 
standard deviation in (A) CFU-E and (B) BaF3-EpoR cells. The amplitudes of pEpoR-pGab1/2 and 
pEpoR-pGab1/2-PI3K are indicated by dashed drop lines and arrows. The total phosphorylation 
levels of Gab1/2 (pGab1/2total) are predicted by the model as the sum of the activation of pEpoR-
pGab1/2 and pEpoR-pGab1/2-PI3K. Gab1 and Gab2 were immunoprecipitated with anti-Gab1 and 
anti-Gab2, respectively. Their total phosphorylation levels were determined by subsequent 
quantitative immunoblotting. Experimental data were scaled to the model predictions by matching 
the relative phosphorylation level of Akt at 10 min with the prediction curves (indicated by dashed 
lines). Standard deviations of the measured data were estimated with the standard error model. The 
experiment was repeated twice with similar results and representative blots are shown. 
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Figure 2.16 Muti-experiment fitting for model reduction and the likelihood-ratio test (LRT). The 
core PI3K/Akt model was reduced by setting all Gab1 or Gab2 related parameters to 0 and calibrated 
individually to 4 data sets, performing 5000 fits with random initial parameter guesses. (A) 
Trajectories of the model without Gab1 or without Gab2 are indicated by solid lines and experimental 
data are represented by circles with the standard error estimation. The model simulations of pAkt in 
PTEN or SHIP1-overexpressing BaF3-EpoR cells are indicated by dashed lines. Overexpression 
data in BaF3-EpoR cells is depicted as triangles with experimental error (data refer to Figure 2.13). 
(B) The likelihood-ratio test (LRT). LRT evaluates nested models 1  2 with numPars1 < numPars2 
and determines the probability that the smaller model is sufficient to describe the measurements 
(Maiwald and Timmer, 2008). 
 
2.5 Distinct cell fate decisions triggered by PI3K/Akt signaling  
Akt regulates many processes including cell proliferation and survival, cell growth, glucose 
metabolism, cell motility and angiogenesis (Bellacosa et al., 2005). This study addressed the 
following questions: how cellular behavior specifically and quantitatively depends on the 
signal strength of PI3K/Akt signaling and how distinct cell fate decisions are triggered by 
PI3K/Akt signaling in different cell types. 
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2.5.1 Correlation between Akt phosphorylation and cell proliferation  
To target Akt-mediated cellular processes, previous studies typically have utilized the 
PI3K inhibitors LY294002 and wortmannin. However, these inhibitors are not entirely specific 
for PI3K (Davies et al., 2000; Rajkumar et al., 2005). In this study, the suppression of Akt 
activation by PTEN and SHIP1 enabled us to specifically assess and target PI3K/Akt-
mediated cellular processes. To monitor cell proliferation, DNA content was measured by 3H-
Thymidine incorporation assay in CFU-E and BaF3-EpoR cells transduced either with PTEN, 
SHIP1 or empty vector and stimulated with different doses of Epo from 0.001 to 50 U/ml, 
which represents the normal Epo concentration range in plasma of healthy persons 
(Jelkmann, 2004) (Figure 2.17 A). Thymidine incorporation was determined after 14 hours 
Epo stimulation in CFU-E cells and after 38 hours Epo stimulation in BaF3-EpoR cells. The 
experimental data showed that PTEN and SHIP1 overexpression in both cell types 
suppressed cell proliferation in a dose dependent manner, with PTEN having a stronger 
effect. The dose-response curves exhibited the typical signmoid curve and reach a maximum 
after 10 U/ml Epo in both cell types. Remarkably, in CFU-E cells both PTEN and SHIP1 
overexpression reduced basal proliferation rates at low-dose Epo. However, a reduced pAkt 
basal level was only observed under PTEN overexpression. 
Next, the correlation between the extent of Akt activation and cell proliferation was 
explored. The extent of signal was determined by the integrated area below the activation 
curve, which has been linked to DNA synthesis (Asthagiri et al., 2000) and cell proliferation 
(Schilling et al., 2009). With the established EpoR/PI3K/Akt model, the integral pAkt 
responses were calculated for elevated concentration of PTEN or SHIP1 and for different 
doses of Epo in a range from 0.001 to 50 U/ml. For the PI3K/Akt core model calibration, Epo 
concentrations of 2.5 U/ml in CFU-E cells and 5 U/ml in BaF3-EpoR cells were used. To 
predict the integrated pAkt signal, the calibrated model was applied to simulate the dose–
response curve for the amplitude of Akt phosphorylation (Figure 2.17 B). Model predictions 
showed good agreement with experiment data, indicating a high accuracy of the model 
prediction. The 2-values were calculated to determine the agreement between measured 
proliferation data and the integral of pAkt (see Material and methods 4.5.4). The different 
integration times were examined and the best time window with the lowest 2-value was 
identified at 12 min in CFU-E cells and 16 min in BaF3-EpoR cells. The correlation between 
the integral of pAkt and cell proliferation was stronger in CFU-E cells than in BaF3-EpoR 
cells (Figure 2.17 C). Although a correlation was found between the calculated integral of 
pAkt and the proliferation of wild type and PTEN-overexpressing CFU-E cells, the model 
failed to describe the reduced basal proliferation of SHIP1-overexpressing CFU-E cells. In 
BaF3-EpoR cells, the suppression of cell proliferation by PTEN and SHIP1 was less 
profound than the reduction of pAkt levels.  
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Taken together, experimental data revealed that PTEN and SHIP1 suppress Akt-mediated 
cell proliferation in both CFU-E and BaF3-EpoR cells and further indicated that the signal 
propagation in PI3K/Akt downstream could be different and cell type-specific. The results 
demonstrate that Akt activation is necessary but not sufficient to predict cell proliferation in 
both cells. To explore possible mechanisms underlying the PTEN and SHIP1 triggered 
suppression of cell proliferation, more detailed analyses of the dynamics of Akt downstream 
targets were performed. 
 
Figure 2.17 Correlation of integrated pAkt signal and cell proliferation. (A) Retrovirally 
transduced CFU-E and BaF3-EpoR cells were incubated with increasing Epo concentrations for 14 h 
or 38 h, respectively, and DNA content was measured by [3H]-Thymidine incorporation. Experimental 
data are depicted as dots. Lines represent sigmoidal regression curves. (B) Model predicted and 
experimentally mesured maximum phosphorylation levels of Akt in CFU-E and BaF3-EpoR cells. 
Standard deviations of the measured data were estimated with the standard error model. (C) For 
different Epo concentrations, integrated responses of pAkt were calculated with the original models 
and the models with elevated PTEN or SHIP1 levels in CFU-E and BaF3-EpoR cells. 
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2.5.2 Context-dependent information processing through the Akt/GSK3 and Akt/mTOR 
pathways 
Cell growth and cell cycle progression are generally tightly coupled, allowing cells to 
proliferate continuously while maintaining their size. As well-known Akt downstream targets, 
GSK3 and mTOR, which regulate cell survival, protein synthesis and cell cycle progression 
(Fingar et al., 2004; Liu et al., 2008), were further investigated in CFU-E and BaF3-EpoR 
cells.  
To assess GSK3and mTOR activities, the phosphorylation levels of GSK3 and S6, a 
downstream target of mTOR, were analyzed in PTEN-overexpressing cells compared to 
control CFU-E and BaF3-EpoR cells, respectively. Findings form these experiments can be 
summarized as: in CFU-E cells (Figure 2.18), (i) the phosphorylation of GSK3 strictly 
followed Akt phosphorylation, showing a linear response between Akt and its direct target. (ii) 
In contrast, the phosphorylation of S6 was gradually accumulating over time and reached a 
plateau from 60 min to the end of the observation period (180 min). (iii) PTEN mediated 
reduction of pAkt was sufficient to lower the phosphorylation of GSK3 and S6, indicating an 
absolute control of their activities by pAkt in CFU-E cells. In BaF3-EpoR cells (Figure 2.19), 
(iv) GSK3 was phosphorylated in response to Epo stimulation but its phosphorylation level 
was surprisingly not affected by PTEN overexpression, indicating a decoupling of signal 
transduction from pAkt to pGSK3 in BaF3-EpoR cells. (v) In contrast to the accumulating 
response in CFU-E cells, the phosphorylation of S6 showed a different kinetic in BaF3-EpoR 
cells, which decayed over time, but not as rapidly as the pAkt signal. Moreover, PTEN 
overexpression in BaF3-EpoR cells reduced the peak amplitude of pAkt around 70%, but the 
peak amplitude of pS6 in PTEN-overexpressing cells was only 30% lower than in control 
cells. As expected, SHIP1 overexpression exhibited a consistent but relative moderate 
effects on the reduction of Akt, GSK3 and S6 phosphorylation compared to PTEN 
overexpression. 
To further dissect the underlying mechanism of the decoupling of signal transduction from 
Akt to GSK3 in BaF3-EpoR cells, the ratio of total and phosphorylated Akt and GSK3 
between CFU-E and BaF3-EpoR cells was determined (Figure 2.20). As described before, 
Akt phosphorylation in BaF3-EpoR cells is much weaker than in CFU-E cells. However, a 
comparable phosphorylation level of GSK3 was detected in both cell types. By applying the 
PI3K inhibitor LY294002, Akt phosphorylation was abolished in BaF3-EpoR cells (Figure 
2.21 A). The results showed that the exposure to 10M LY294002 completely blocked Akt 
phosphorylation, while the phosphorylation level of GSK3 was only slightly reduced. In a 
preliminary experiment, Akt overexpression dramatically increased the pAkt level around 10-
fold after 10 min Epo stimulation, while the pGSK3 level was only slightly elevated (Figure 
2.21 B). These findings suggested that the low activation level of Akt may below a threshold 
Results  59 
required to activate GSK3 efficiently and instead of Akt, another Epo-induced kinase may 
phosphorylate GSK3 in BaF3-EpoR cells. 
Taken together, the observations revealed that in primary CFU-E cells, Akt 
phosphorylation is the key player in regulating GSK3andS6 phosphorylation, while in BaF3-
EpoR cells, Akt phosphorylation leads to an inefficient phosphorylation of GSK3 and only 
partially actives S6, demonstrating a context-dependent Akt downstream signal propagation 
in different hematopoietic cell types. 
 
 
Figure 2.18 Analysis of the dynamics of Akt downstream targets by quantitative 
immunoblotting. (A) CFU-E and BaF3-EpoR cells retrovirally transduced with PTEN or vector 
control were stimulated with 2.5 U/ml or 5 U/ml Epo, respectively, for the indicated times and 
subjected to quantitative immunoblotting. Total PTEN, pAkt Ser473, pGSK3 (the sum of pGSK3 
Ser21 and pGSK3 Ser9) and pS6 Ser235/236 levels in (B) CFU-E and (C) BaF3-EpoR cells were 
quantified. For phosphorylation signals, each time course was normalized setting the maximum 
signal in control cells to 1. Standard deviations of the measured data were estimated with the 
standard error model. The sold line represents the smooth spline. PTEN Overexpression in CFU-E 
cells was repeated two times, while PTEN overexpression in BaF3-EpoR cells was repeated three 
times with similar results and representative blots are shown. 
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Figure 2.19 Analysis of the dynamics of Akt downstream targets by quantitative 
immunoblotting. (A) CFU-E and BaF3-EpoR cells retrovirally transduced with SHIP1 or vector 
control were stimulated with 2.5 U/ml or 5 U/ml Epo, respectively, for the indicated times and 
subjected to quantitative immunoblotting. Total SHIP1, pAkt Ser473, pGSK3 and pS6 Ser235/236 
levels in (B) CFU-E and (C) BaF3-EpoR cells were quantified. For phosphorylation signals, each 
time-course was normalized setting the maximum signal in control cells to 1. Standard deviations of 
the measured data were estimated with the standard error model. The sold line represents the 
smooth spline. SHIP1 Overexpression in CFU-E cells was a preliminary experiment, while SHIP1 
overexpression in BaF3-EpoR cells was repeated two times with similar results and representative 
blots are shown. 
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Figure 2.20 Comparison of total and phosphorylated Akt and GSK3 levels between CFU-E and 
BaF3-EpoR cells. Growth factor-depleted CFU-E cells (2x107 cells/ml) and BaF3-EpoR cells (4x107 
cells/ml) were stimulated for 10 min with 2.5 or 5 U/ml Epo, respectively. (A) TCL (20 l) were loaded 
and analyzed by immunoblotting. Blots are part of the same gel, allowing a direct comparison of 
signals between samples. (B)The ratio of total and phosphorylated Akt, GSK3 were depicted as bar 
charts with standard deviation.  
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Figure 2.21 Effect of LY294002 and Akt overexpression on the phosphorylation of Akt and 
GSK3 in BaF3-EpoR cells. (A) Effect of LY294002 on the phosphorylation pattern of Akt and GSK3. 
BaF3-EpoR cells were pre-incubated with 10 µM LY294002 or DMSO as control for 30 min and then 
stimulated with 5 U/ml Epo for the indicated times. pAkt Ser473 and pGSK3 signals were detected by 
immunoblotting of the TCL. Experimental data are represented by circles and the smooth splines are 
indicated by solid lines. (B) Effect of Akt overexpression on Akt and GSK3 phosphorylation. Akt was 
retrovirally transduced in BaF3-EpoR cells. pAkt Ser473, pGSK3, pErk1/2, tAkt and PDI signals were 
detected in Akt-overexpressing cells compared to control BaF3-EpoR cells. The fold changes of tAkt, 
pAkt and pGSK3 after 10 min Epo stimulation were depicted as bar charts. 
 
2.5.3 Cell-cycle arrest induced by PTEN overexpression only in CFU-E cells  
To provide insight into the roles of Epo and Akt as modulators of cell cycle, genome-wide 
expression profiling was performed in collaboration with Maria Saile (University Hospital of 
Heidelberg at Mannheim) and Jie Bao (University of Freiburg). Time-resolved genome wide 
expression profiling was performed in both CFU-E and BaF3-EpoR cells. CFU-E cells 
isolated from murine fetal livers were stimulated with 0.5 U/ml Epo and total RNA was 
extracted at time points 0, 1, 2, 3, 4, 5, 6, 7, 8, 14, 19, 24 h (performed by Julie Bachmann). 
Control cells were left unstimulated and RNA was isolated every hour between 0 and 7 h. 
Beyond 7 h without Epo stimulation CFU-E cells undergo apoptosis. Next, to directly target 
the transcriptional regulation mediated by the PI3K/Akt signaling, Akt activation was 
specifically suppressed by PTEN overexpression in BaF3-EpoR cells. BaF3-EpoR cells were 
retroviral transduced either with PTEN or empty vector as control and pre-incubated with 0.5 
U/ml Epo for 16 h. Subsequently, transduced cells were selected by MACS and seeded in 
fresh serum-free medium in a concentration of 20 x 104 cells/ml. After 5 h starvation, cells 
were stimulated with 1 U/ml Epo and total RNA was extracted at time points 0, 1, 2, 3, 4, 5, 
7, 18.5 h. For hybridization, the GeneChip Mouse Genome 430 2.0 Array (Affymetrix) was 
used that comprises 45,100 probe sets representing 20,700 genes. Data analysis was 
performed by calculating the logarithmic fold change with respect to gene expression at 0 h. 
To get a systematic overview of cell cycle regulation, the gene expression profile of all the 
cyclins (Ccn), cyclin-dependent kinases (Cdk) and Cdk inhibitors (Cdkn) was analyzed. The 
fold expressions (log2) was plotted as a heat map over time. The profile of CFU-E cells 
showed that the withdrawal of Epo (Figure 2.22, left) induced a significant decrease of 
cyclins, such as Ccnd1, Ccnd2, Ccng1, Ccnh, Ccnl2, while an increase of Ccng2, which is 
up-regulated as cells undergo cell cycle arrest. Epo withdrawal also strongly increased the 
expression of Cdk inhibitors, such as Cdkn1a, Cdkn1b, Cdkn2aip, Cdkn2C and moderately 
affected Cdks. Compared to Epo withdrawal, during the first 8 h, Epo efficiently suppressed 
the decrease of cyclins, such as Ccnd2, Ccng1, Ccnl2 and also the increase of Ccng2 and 
Cdk inhibitors, such as Cdkn1b, Cdkn2aip, Cdkn2C. However, during 14 h to 24 h 
observation period, the cells with Epo showed a similar gene expression profile than the cells 
without Epo during the first 7 h Epo (Figure 2.22, right). This might imply that Epo induces an 
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early transient proliferation phase within a time window of roughly 8 h and afterwards drives 
cell differentiation by promoting cell cycle exit. In line with the previous study of Fang et al., 
they showed that Epo promoted the proliferation of erythroblaste at early stage than at later 
stage (Fang et al., 2007). In BaF3-EpoR cells (Figure 2.23), Epo promoted sustainable up-
regulation of Ccnbilp, Ccnd2 and down-regulation of Ccng2, Cdkn1b. Several additional 
genes were also transiently modulated by Epo, including Cdk18, Cdk5r1, Cdk7, Cdkn1a, and 
Cdkn3. Surprisingly, their expression profile was not affected by PTEN overexpression, 
suggesting an Akt-independent cell cycle regulation in BaF3-EpoR cells. 
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Figure 2.22 Analysis of the expression profile of cell-cycle regulated genes in CFU-E cells. 
Time-resolved expression profiling was performed in CFU-E cells with or without Epo stimulation. The 
fold expressions (log2) of all the Ccn (cyclin), Cdk (cyclin-dependent kinase) and Cdkn (Cdk inhibitor) 
were plotted as a heat map over time. 
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Figure 2.23 Analysis of the expression profile of cell-cycle regulated genes in BaF3-EpoR 
cells. Time-resolved expression profiling was performed in BaF3-EpoR control and PTEN-
overexpressing cells stimulated with 1 U/ml Epo. The fold expressions (log2) of all the Ccn (cyclin), 
Cdk (cyclin-dependent kinase) and Cdkn (Cdk inhibitor) were plotted as a heat map over time. 
 
PTEN-induced G1-phase cell cycle arrest has been reported in various tumor cells, by 
which PTEN could manifest its tumor suppressor activity (Radu et al., 2003; Zhu et al., 
2001). In concordance with the gene profiling analysis shown above, the mechanism was 
associated with the reduced levels of cyclin D2 (Huang et al., 2007) and the increased levels 
of p27KIP1 (Seminario et al., 2003) and cyclin G2 expression (Martinez-Gac et al., 2004). 
Therefore, the expression kinetics of Ccnd2, Cdkn1b and Ccng2 were validated by 
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quantitative RT-PCR in control cells and PTEN-overexpressing CFU-E and BaF3-EpoR cells. 
Additionally, it was examined whether PTEN-mediated cell cycle arrest can be mimicked by 
the PI3K inhibitor LY294002.  The quantitative RT-PCR data in Figure 2.24 A showed that in 
CFU-E cells, Epo addition maintained the mRNA levels of Cdkn1b and Ccng2 at constant 
initial levels. Overexpression of PTEN (20-fold increased on mRNA level) significantly 
elevated the basal levels of Cdkn1b and Ccng2 (approximately 2-fold). Consistently, the 
exposure to 10M LY294002 also increased the transcription levels of Cdkn1b and Ccng2 
and maintained them at high levels. Unexpectedly, the Ccnd2 level was increased in 
LY294002 treated CFU-E cells, but not in PTEN-overexpressing cells. The results were 
confirmed by independent measurements (Figure 2.24 B).  
In BaF3-EpoR cells, the application of LY294002 efficiently inhibited the decreases of 
Cdkn1b and Ccng2 induced by Epo, while it only slightly reduced the overall level of Ccnd2 
without changing its dynamic. Surprisingly, the mRNA levels of all three genes were 
comparable between control and PTEN-overexpressing cells during the 7h observation 
period (Figure 2.24 A). The results were confirmed by independent measurements (Figure 
2.24 B).  
Next, cell-cycle distribution of control cells and PTEN-overexpressing CFU-E and BaF3-
EpoR cells were analyzed using propidium iodide (PI) staining by flow cytometry. Growth 
factor-depletion cells were cultured in the presence of Epo at 1 U/ml. The bar charts showing 
percentage (%) distribution of cells in SubG1 (or < 2N), G0/G1, S or G2/M phases of the cell 
cycle are depicted in Figure 2.24 C. In CFU-E cells, Epo addition interestingly decreased S 
phase fractions after 10 h Epo treatment. This finding is consistent with the Epo-promoted 
cell cycle exit at late stages indicated by the microarray analysis. Importantly, it was 
observed that almost 10% more PTEN-overexpressing cells were arrested in G0/G1phase at 
0h and 12% more after 10h Epo addition compared to control CFU-E cells. This shows in a 
good alignment with the gene-expression data that PTEN significantly elevated the mRNA 
levels of the cell cycle inhibitors p27kip1 and cyclinG2, which induced cell cycle arrest at 
G0/G1 in PTEN expressing CFU-E cells. Additionally, Epo promoted cells into G2/M phase 
(from 15% to 21%) in control CFU-E cells, which may be blocked by PTEN overexpression 
(remained at 17%). In line with the gene-expression analysis, the cell cycle distribution of 
BaF3-EpoR cells did not appreciably differ between control and PTEN-overexpressing cells 
at 0h, 16h and 40h (Figure 2.22 C). 
Collectively, the results showed that cell cycle progression was mainly regulated by 
PI3K/Akt signaling in CFU-E cells, but not in BaF3-EpoR cells and that PTEN overexpression 
blocks CFU-E cell cycle progression in the G1 phase, correlating with a significant increase 
of the mRNA levels of cell cycle inhibitors p27kip1 and cyclinG2. Gene expression analysis in 
SHIP1-overexpressing cells further confirmed the Akt-mediated cell type-specific cell cycle 
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regulation in CFU-E and BaF3-EpoR cells (Figure 6. 1-3). Additionally, increased basal 
mRNA levels of p27kip1 and cyclinG2 were also observed in SHIP1-overexpressing CFU-E 
cells. This is again in line with the reduced basal proliferation of SHIP1-overexpressing CFU-
E cells, which could not be explained by the change on Akt phosphorylation as well as its 
downstream proteins in these cells. Discrepancies regarding cell cycle regulation between 
PTEN-overexpressing and LY294002 treated BaF3-EpoR cells revealed a non-specific, 
indiscriminate inhibition of the PI3K pathway in this cell type by LY294002. 
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Figure 2. 24 PTEN induced G1 cell cycle arrest only in CFU-E cells. (A) CFU-E and BaF3-EpoR 
cells retrovirally transduced with PTEN or vector control were stimulated with 1 U/ml Epo for the 
indicated times and subjected to quantitative RT-PCR. Error bars represent standard deviations of 
technical duplicates. (B) PTEN-overexpressing and control CFU-E and BaF3-EpoR cells were 
stimulated with 1 U/ml Epo for 2 h or left untreated and subjected to quantitative RT-PCR. Error bars 
represent standard deviations of two to three biological replicates. (C) Cell cycle distribution of CFU-E 
and BaF3-EpoR cells transduced with PTEN or vector control. Cells were stimulated with 1 U/ml Epo 
or left untreated for the indicated times, stained with propidium iodide, and then subjected to cell cycle 
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analysis by fluorescence-activated cell sorting (refer to Figure 6.5-7). Percentages of cells in different 
cell cycle phases are shown. The experiment was repeated three times with similar results and 
representative data are shown. (D) SHIP1-overexpressing and control CFU-E and BaF3-EpoR cells 
were stimulated with 1 U/ml Epo for 2 h or left untreated and subjected to quantitative RT-PCR. Error 
bars represent standard deviations of two to three biological replicates. 
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3 Discussion 
3.1 Signal initiation: cell type-specific receptor activation 
Primary CFU-E cells endogenously express Epo receptors on their surface and are the most 
Epo-sensitive cells. BaF3-EpoR cells that exogenously express the EpoR are a well 
established system to study Epo-dependent signaling. However, by systematically comparing 
Epo-induced signal initiation through EpoR in primary CFU-E and the cell line BaF3-EpoR, a 
number of striking differences were observed. Previously, an approximately 10-fold higher 
EpoR cell surface expression in BaF3-EpoR cells was determined (Becker et al., 2010) 
compared to primary cells (D'Andrea and Zon, 1990). Additionally, Epo depletion in the 
medium of BaF3-EpoR cells mediated by receptor endocytosis is more efficient than in CFU-
E cells due to the high density of receptors on the cell surface (Becker et al., 2010). In line 
with this study, here a quantitative analysis of the receptor activation revealed that the 
maximal activation of pEpoR measured in BaF3-EpoR cells was approximately 10-fold higher 
compared to in CFU-E cells. Moreover, the duration of receptor activation was more 
sustained in BaF3-EpoR cells. The mathematical modeling approach helped to elucidate 
further discrepancies regarding the attenuation of EpoR signaling between these two cell 
types. As mechanisms for attenuating EpoR signaling, ligand degradation, activation of the 
phosphatase SHP1 and the Epo-inducible kinase inhibitor SOCS3 were incorporated in the 
receptor models, which demonstrated good accuracy on describing the experimental data in 
both CFU-E and BaF3-EpoR cells. However, initially tested model versions, lacking the Epo-
inducible kinase inhibitor SOCS3, were already sufficient to capture the receptor activation 
dynamic in CFU-E cells but poorly reflected the experimental data in BaF3-EpoR cells. 
Hence, in BaF3-EpoR cells, besides activation of the phosphatase SHP1, rapid Epo 
degradation in the medium and activation of the additional ligand-inducible signaling 
suppressor SOCS is essential to attenuate EpoR signaling, whereas in CFU-E cells, these 
mechanisms are not necessary . 
 
3.2 Epo-induced signal transduction via the PI3K/Akt pathway 
3.2.1 Stoichiometry is the major cause for cell type-specific Akt activation 
Time-resolved dynamic data of EpoR and Akt activation revealed that despite weaker and 
shorter EpoR activation, Akt activation is stronger and more sustained in CFU-E cells than in 
BaF3-EpoR cells. The apparent discrepancies on Akt kinetics in these two cell types 
provided an efficient model to study the regulatory mechanisms that determine cell type-
specific PI3K/Akt signal transduction in response to Epo. To consider the cell context-
dependent concentrations of pathway components, the absolute amount of important 
pathway components were determined based on serial dilutions of recombinant calibrator 
proteins. This revealed strong alterations in the stoichiometries between primary CFU-E and 
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BaF3-EpoR cells. In particular, both PTEN and SHIP1 as essential negative regulators of the 
PI3K/Akt pathway were detected with much higher concentrations in BaF3-EpoR cells than in 
CFU-E cells. In addition, Gab1 was expressed and phosphorylated in response to Epo in 
primary CFU-E cells, while Gab2 was the dominant isoform expressed in BaF3-EpoR cells. 
Other pathway components including PI3K, Akt and PDK1 were detected to be present in 
comparable concentrations in CFU-E and BaF3-EpoR cells. 
The mathematical model was constrained by the initial concentrations of signaling 
components and calibrated by various Akt dynamics under different conditions. With this 
modeling approach, the different stoichiometries of components were identified as the major 
cause for cell type-specific Akt activation. In CFU-E cells, the low levels of PTEN and SHIP1 
together with the highly efficient activation of PI3K by Gab1 lead to strong and sustained Akt 
activation. In contrast, despite high activation level of the receptor, Akt activation was weak 
and transient in BaF3-EpoR cells due to the high levels of PTEN and SHIP1 and the 
dominant isoform Gab2, which is inefficient in activation of PI3K. 
 
3.2.2 Role of the specific Gab1/2 isoforms in PI3K/Akt signaling 
Epo stimulation induces activation of PI3K through the direct PI3K-binding to the EpoR 
(Damen et al., 1995) or through the recruitment by Gab isoforms (Bouscary et al., 2003). The 
adaptor protein Gab coordinates the assembly of the PI3K complex and thereby recruits and 
enhances the enzymatic activity of PI3K. Gab1 and Gab2 are differentially expressed in 
various cell lines, but in primary hematopoietic progenitors only Gab1 is expressed 
(Bouscary et al., 2001; Wickrema et al., 1999). Here, upon Epo stimulation Gab1 and Gab2 
were phosphorylated and associated with EpoR, SHP2, p85 and Grb2 while Gab2 in primary 
CFU-E cells and BaF3-EpoR cells, respectively (Figure 6.12). It would be important to 
determine whether the PI3K activation mediated by distinct Gab isoforms is redundant and 
contributes to cell type-specific Akt signaling in these two cell types. To address this point, 
first, the PI3K/Akt core model was established with isoform-specific parameters for Gab1 and 
Gab2. The model was sufficient in describing wild type and PTEN- and SHIP1-
overexpression data in both cell types. Furthermore, a model reduction was performed by 
setting all Gab1 or Gab2. This approach related parameters to 0 and revealed a vital role for 
Gab1 in CFU-E cells but a negligible role for Gab2 in BaF3-EpoR cells. Thus, these findings 
indicated that in CFU-E cells both Gab-dependent and Gab-independent pathways contribute 
to PI3K activation. In contrast, in BaF3-EpoR cells PI3K is activated mainly through the Gab-
independent direct binding to EpoR. 
Both Gab1 and Gab2 were phosphorylated in response to Epo stimulation. However, the 
Gab-mediated PI3K activation is a two-step activation including the phosphorylation and 
association of Gab with the receptor and the activation of PI3K by the pGab-pEpoR complex. 
Discussion  72 
Therefore, the phosphorylation status of Gab isoforms may not directly indicate the Gab-
mediated PI3K activation. Further model analysis explored the dynamics of the two-step 
PI3K activation mediated by distinct Gab isoforms, which are beyond experimental 
observations. The model analysis showed that in the first step, the phosphorylation of Gab1 
and Gab2 followed the receptor activation in both cell types. In the second step, PI3K could 
be activated by pGab1-pEpoR complex with greater efficiency than by pGab2-pEpoR, 
indicating an isoform-specific activation of PI3K. Recent studies shed light on the underlying 
mechanisms of the non-redundant Gab1 and Gab2 functions. The recruitment of Gab1 to 
PIP3 by its PH domain is regarded as a positive feedback loop for activation of Gab1 
(Rodrigues et al., 2000), whereas Gab2, but not Gab1 has been shown to be negatively 
regulated by serine phosphorylation by Akt (Cronshaw et al., 2004). Moreover, in BaF3-c-Kit 
cells the activation of PI3K by c-Kit has been shown to be both Gab2-dependent and Gab2-
independent (Sun et al., 2008). However, since Gab1 and Gab2 have 15 conserved 
tyrosines, distinct phosphorylation patterns of Gab isoforms evoked by different ligands and 
receptors might be the molecular basis for signaling selectivity (Brummer et al., 2008; Gual et 
al., 2000; Lehr et al., 1999). 
  
3.2.3 Overlapping but non-redundant roles of PTEN and SHIP1 in PI3K/Akt signaling 
In the hematopoietic system, the termination of PI3K signaling by dephosporylation of 
PI(3,4,5)P3 involves PTEN, which transforms PI(3,4,5)P3 to PI(4,5)P2, and SHIP1, which 
generates PI(3,4)P2 from PI(3,4,5)P3 (Vivanco and Sawyers, 2002). Knock out mutations in 
Pten (Alimov et al., 1999, Celebi et al., 2000), but not Ship1 (Helgason et al., 2000), give a 
strong cancer phenotype in mice, suggesting their different biological functions. PTEN and 
SHIP1 appear to be not redundant probably due to distinct products and different activation 
dynamics. A high binding affinity of Akt to PI(3,4)P2 has been reported in vitro, but the 
activation of Akt by PI(3,4)P2 in vivo is still under debate (Isakoff et al., 1998; Lemmon and 
Ferguson, 2001). Previous studies have indicated that in the majority of cell types PTEN is 
constitutively active, thereby influencing basal PI(3,4,5)P3 levels, maintaining it below a 
critical signaling threshold (Stambolic et al., 1998; Sun et al., 1999). In contrast, SHIP1 gets 
activated upon membrane recruitment mediated by binding to the phosphorylated EpoR 
(Mason et al., 2000). Here, in our model Akt was solely activated by PIP(3,4,5)P3. The model 
focused on the investigation of the kinetic properties of PTEN and SHIP1 as well as their 
roles in regulating Akt activation. Overexpression of either of the phosphatases in CFU-E and 
BaF3-EpoR cells provided a tool for exploring their molecular regulatory mechanisms. 
Optimal parameter estimation by multi-experiment fitting and experimental model validation 
confirmed the initial model assumptions. The results revealed that constitutively active PTEN 
strongly controls both pAkt amplitude and duration, while SHIP1 has an effect only on the 
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signal duration, due to its pEpoR dependent activation. Model analysis on how PTEN and 
SHIP1 affect the integral Akt activation suggested that PTEN maintains basal/low receptor-
stimulated levels of PIP3, whereas SHIP1 primarily controls receptor-activated levels of 
PIP3. This finding is consistent with previous studies that demonstrated that PTEN acts as a 
‘sentinel’ while SHIP1 as a ‘gatekeeper’, of the Akt signaling cascade (Harris et al., 2008). 
Importantly, this cooperative action of PTEN and SHIP1 could be of physiological 
significance as Epo plasma levels can vary between 1.5 x 10-3 to 10 U/ml in healthy persons 
(Jelkmann, 2004), thereby ensuring appropriate cellular responses over a broad range of 
stimuli in the hematopoietic system.  
PTEN acts as a tumor suppressor by negatively regulating PI3K/Akt signaling pathway 
and has been shown to play a pivotal role in cell apoptosis and cell cycle arrest, preventing 
cells from growing and dividing too rapidly (Ward, 2004). In certain cells, SHIP1 can also 
downregulate Akt activation (Kulp et al., 2004) and thereby suppress cell proliferation and 
survival (Curnock et al., 2004). Here, the 3H-thymidine incorporation assay further 
demonstrated the proliferation-suppressive effects of PTEN and SHIP1 in line with their 
crucial role as tumor suppressors. In contrast to PTEN, which strongly suppressed cell 
proliferation, SHIP1 exhibited a moderate effect on regulating PIP3 levels and Akt-mediated 
cellular processes. The underlying mechanisms of the PTEN and SHIP1 suppressed cell 
proliferation in CFU-E and BaF3-EpoR cells were further investigated (see 3.3).   
PTEN acts as an antagonist of PI3K. SHIP1 generates PI(3,4)P2, which can interact with 
an array of protein effectors, as an second messenger (Lemmon and Ferguson, 2000). In 
addition, SHIP1 contains multiple structural domains, such as SH2-domains, C2 domains 
and NPXY motifs that allow SHIP1 to function as a scaffolding protein facilitating protein-
protein interactions (Rohrschneider et al., 2000; Sly et al., 2007). Hence, SHIP1 may alter 
the activities of a subset of PIP3 effectors, potentially redirect signaling rather than stop it 
(Harris et al., 2008).   
  
3.3 Distinct cell fate decisions triggered by cell type-specific PI3K/Akt signaling 
3.3.1 Akt activation is not indicative for cell proliferation 
A potential correlation between Akt activation and cell proliferation was examined. Cell 
proliferation was measured in both CFU-E and BaF3-EpoR cells with elevated PTEN or 
SHIP1 concentration. Then, the correlation between the integral of pAkt signal and the 
proliferation data was evaluated. The experimental data showed that PTEN and SHIP1 
overexpression in both cell types suppressed cell proliferation in a dose dependent manner. 
In CFU-E cells, a high correlation was found between the integral of pAkt and the 
proliferation of wild type and PTEN-overexpressing cells. However, the integral of pAkt failed 
to describe the reduced basal proliferation of SHIP1-overexpressing cells. This indicated that 
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in this cell type cell proliferation is more sensitive to SHIP1 overexpression than Akt 
phosphorylation. In BaF3-EpoR cells, the suppression of cell proliferation by PTEN and 
SHIP1 was less profound than the reduction of pAkt. No effect was detected on survival in 
response to PTEN and SHIP1 overexpression in both cell types (Figure 6.9, 6.10). In CFU-E 
and BaF3-EpoR cells, Epo triggers, besides Akt pathway, other pathways such as the JAK2-
STAT5 and Ras/Erk pathways. These pathways also influence cell survival, apoptosis and 
cell proliferation. While activation of JAK2-STAT5 signaling has been primarily associated 
with survival signaling (Yoon and Watowich, 2003), an essential role of PI3K/Akt and MARK 
pathway for differentiation and proliferation responses has been shown (Ghaffari et al., 2006; 
Zhang and Lodish, 2007). Indeed, the proliferation of CFU-E cells has been shown to 
correlate with overexpression of ERK1 and ERK2 in a dose dependent manner (Schilling et 
al., 2009). However, in our study, PTEN and SHIP1 mediated inhibition of Akt 
phosphorylation led to suppression of cell proliferation in CFU-E and BaF3-EpoR cells. The 
correlation between the integral of pAkt and cell proliferation was stronger in CFU-E cells 
than in BaF3-EpoR cells. It speculated that the signal propagation in PI3K/Akt downstream 
could be different and cell type-specific. The quantitative link of the cellular Akt response to 
cell proliferation revealed that Akt activation is necessary but not sufficient to predict cell 
proliferation in both cells. 
 
3.3.2 Akt/GSK3 and Akt/mTOR, context-dependent activation 
GSK3 and mTOR pathways have been intensively studied in the context of cell growth and 
proliferation (Fingar et al., 2004; Hahn-Windgassen et al., 2005; Liu et al., 2008). In this 
study, context-dependent information processing through the Akt/GSK3 and Akt/mTOR 
pathways was detected in CFU-E and BaF3-EpoR cells. The observations revealed that Akt 
is the key player in regulating GSK3andS6 phosphorylation in primary CFU-E cells, while 
S6 phosphorylation is only partially Akt-dependent and GSK3 phosphorylation is Akt-
independent in BaF3-EpoR cells. Further experimental analysis indicated that the low 
activation level of Akt may be below the threshold required to activate GSK3 efficiently. 
Instead of Akt, another Epo-induced kinase may phosphorylate GSK3 and partially regulate 
S6 in BaF3-EpoR cells. A functional overlap has been reported for the serine-threonine 
kinases Pim and Akt in control of hematopoietic cell growth and survival (Hammerman et al., 
2005). In parental BaF3 cells, Pim-1 mRNA expression has been reported to be strictly 
dependent on IL-3 (Adam et al., 2006). Consistent with this study, an Epo-induced Pim-1 
mRNA expression was detected in BaF3-EpoR cells and with relative lower level in CFU-E 
cells (Figure 6.4).  
In line with the proliferation data, PTEN- and SHIP1- mediated signal attenuation was 
damped in BaF3-EpoR cells due to the decoupling of signal transduction from pAkt to 
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pGSK3. A model extension is required for studying the mechanisms by which pAkt regulates 
GSK3 and mTOR in a context-dependent manner. Applying this extended mathematical 
model, it is possible to quantitatively correlate GSK3 and mTOR activation with the cell 
proliferation, and to find adequate indicators for distinct cellular outcomes triggered by 
PI3K/Akt signaling.  
 
3.3.3 Cell cycle regulation is Akt-dependent in CFU-E while Akt-independent in BaF3-
EpoR cells  
PI3K/Akt signaling promotes cell cycle progression by regulating synthesis, stability or 
subcellular localization of the transcription factor FoxO and cell cycle regulators cyclinD, 
p21CIP1, cyclinG2, p27KIP1 (Chang et al., 2003; Radu et al., 2003; Zhu et al., 2001). PTEN-
induced G1 phase cell cycle arrest has been reported in various tumor cells (Radu et al., 
2003; Zhu et al., 2001). Our observations showed that cell cycle progression is mainly 
regulated by the PI3K/Akt signaling in CFU-E cells. PTEN overexpression induced CFU-E 
cell cycle arrest in the G1 phase, correlating with the increasd basal mRNA levels of cell 
cycle inhibitors p27kip1 and cyclinG2. Moreover, the increased basal mRNA levels of p27kip1 
and cyclinG2 were also detected in SHIP1-overexpressing CFU-E cells. This is again in line 
with the reduced basal proliferation of SHIP1-overexpressing CFU-E cells, which could not 
be explained by the phosphorylation level of Akt as well as its downstream proteins. In 
contrast to CFU-E cells, cell cycle regulation is Akt-independent in BaF3-EpoR cells. 
Overexpression of PTEN had no effect either on the gene expression profile of cell cycle 
regulators, or on cell cycle distribution. 
During the preincubation period, in the presence of Epo, SHIP1 similar to PTEN efficiently 
reduced the pAkt level in CFU-E cells and resulted in increased mRNA levels of cell cycle 
inhibitors. Subsequently, during the experimental period, Epo addition maintained the mRNA 
levels of cell cycle regulators at constant initial levels in CFU-E cells. Cellular transformation 
events, such as cell cycle arrest (Ferrell and Machleder, 1998), initiation of programmed cell 
death (Eissing et al., 2004) and cellular proliferation (Chickarmane et al., 2009) have 
previously been modeled with a bistable switch character. Our findings suggested that the 
long-term preincubation rather than transient Epo stimulation is sufficient to induce changes 
in the switch’s state for cell cycle progression in CFU-E cells and that the basal levels of cell 
cycle inhibitor p27kip1 and cyclinG2 could function as indicator for cell cycle arrest in CFU-E 
cells. 
In contrast to CFU-E cells, Epo significantly upregulated the cell cycle activator cyclinD2 
and downregulated the cell cycle inhibitors p27kip1 and cyclinG2. Transcription factors FoxO 
played a central role in regulating cell cycle genes, such as cyclinD2 (Glauser and Schlegel, 
2009), p27kip1 (Dehan and Pagano, 2005) and cyclinG2 (Martinez-Gac et al., 2004). 
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Phosphorylation by Akt inhibits FoxO activity by promoting its nuclear export and 
proteasome-mediated degradation (Burgering and Kops, 2002). Our study showed that cell 
cycle progression in BaF3-EpoR cells is Epo-dependent, but Akt-independent. Consistent 
with the observation on GSK3 and S6 activation, the findings indicated that another 
serine/threonine kinase may share the common substrates with Akt in regulating overlapping 
cellular responses in BaF3-EpoR cells. 
 
3.4 Conclusion and future perspectives 
By a data-based mathematical modeling approach, the stoichiometry of molecular 
components was identified as a major cause for the cell type-specific behaviors of Akt in 
CFU-E and BaF3-EpoR cells. Particularly, model analyses delineated the differential role of 
negative regulators PTEN and SHIP1 as well as distinct isoforms of the scaffold protein Gab 
in shaping the Akt signal. Next, further exploration of the correlation between PI3K/Akt 
signaling and cell proliferation revealed how disntinct cell fate decisions are triggered by cell 
context-dependent signaling in different cell systems.  
 
Figure 3.1 Dinstinct cell fate decisions triggered by cell type-specific PI3K/Akt signaling in 
CFU-E and BaF3-EpoR cells. In CFU-E cells, the low level of PTEN and SHIP1 together with the 
additional Gab1-mediated PI3K activation leads to strong and sustained Akt activation, which strongly 
promotes cell proliferation, coordinating cell growth and cell cycle progression. In contrast, in BaF3-
EpoR cells, despite high activation of the receptor, Akt activation is weak and transient due to the high 
levels of PTEN and SHIP1. In BaF3-EpoR cells, only mTOR mediated cell growth is partially regulated 
by Akt, while the regulation of GSK3 and cell cycle progression is Akt-independent.   
As illustrated in Figure 3.1, the abundance of negative regulators PTEN and SHIP1 
together with the isoform-specific Gab-mediated PI3K activation led to cell type-specific Akt 
activation in CFU-E and BaF3-EpoR cells. In CFU-E cells, strong and sustained Akt 
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activation strongly promoted cell proliferation, coordinating cell growth and cell cycle 
progression. In contrast, in BaF3-EpoR cells, only cell growth is partially regulated by Akt, 
while cell cycle progression was Akt-independent. Further model extensions are required to 
integrate these three pathways and quantitatively correlate the context-dependent PI3K/Akt 
signaling with cell proliferation. It aims to find adequate indicators for distinct cellular 
outcomes triggered by PI3K/Akt signaling. 
The established mathematical models provide important tools to quantitatively predict the 
behaviors of pathway components upon alteration of one or more compoents. As a future 
perspective, sensitivity analysis will be applied to identify the crucial mechanisms that control 
PI3K/Akt pathway activation and determine cell type-specific signaling in the cell line and 
primary cells.  
To date, a number of the components of the PI3K/Akt pathway have been found mutated 
or altered in abundance in a wide variety of human cancers highlighting the key role of this 
pathway in cellular transformation. This mathematical model will provide guidance for the 
rational design of effective therapeutic molecules and facilitate accurate predictions of the 
effect of existing drugs.  
 
 
Materials and methods  78 
4. Materials and methods 
If not stated otherwise, chemicals were purchased from Sigma and mammalian cell 
culture media and supplements were obtained from Gibco. 
 
4.1 Molecular biology techniques 
4.1.1 Preparation of competent E. coli cells 
For high-efficiency transformation of plasmid DNA, the E. coli strain DH5 dam+ 
(Stratagene) was used. To prepare chemically competent bacteria, DH5 cells were 
cultured in a volume of 500 ml LB medium up to an optical density of 0.6-0.8 as 
measured at 600 nm. After incubation on ice for 10 min, cells were sedimented with 
4,100 g for 5 min at 4°C and resuspended in 150 ml TFBI (100 mM RbCl, 50 mM MnCl2, 
10 mM CaCl2, 30 mM potassium acetate, 15% glycerol, pH 5.3). Following 20 min of 
incubation on ice, cells were centrifuged for 5 min at 1,400 g and 4°C, resuspended in 
10-15 ml TFBII (10 mM RbCl, 75 mM CaCl2, 10 mM MOPS pH 7.0, 15% glycerol), and 
aliquots were stored at -80°C. 
 
4.1.2 Purification of plasmid DNA 
Plasmid DNA was amplified in E. coli cultures either in small analytic or large preparative 
scale. To isolate plasmid DNA in small scale, E. coli cells were cultured o/n at 37°C in 
1ml LB medium supplemented with 100 g/ml ampicillin. After sedimentation, cells were 
resuspended in 100 l of remaining medium and lysed by alkaline lysis in 300 l TENS 
buffer (10 mM Tris pH 8.0, 1 mM EDTA pH 8.0, 100 mM NaOH, 0.5% SDS). Proteins 
were precipitated by adding 150 l sodium acetate (3 M, pH 5.2). After centrifugation for 
2 min at 15,700 g, the supernatant was transferred to a new tube and DNA was 
precipitated using two volumes of ice-cold ethanol. The DNA was washed with 70% 
ethanol and resuspended in 50 l TE (10 mM Tris pH 8.0, 1 mM EDTA pH 8.0) 
supplemented with 40 g/ml RNaseA (Roche Diagnostics). For sequencing grade, the 
QIAprep Spin Miniprep Kit (Qiagen) was used according to the manufacturer’s 
instructions. 
To prepare plasmid DNA in large scale, a single colony or 50 l of an E. coli culture 
were cultured in 100 or 200ml LB medium supplemented with ampicillin for 16-18 h at 
37°C. For purification, the JETSTAR 2.0 Maxi Kit (Genomed) was used according to the 
manufacturer’s instructions. 
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4.1.3 Quantification of plasmid DNA 
The concentration of DNA was determined by measuring the absorbance of diluted 1:50 
in ddH2O at 260 nm (Ultrospec 3100 pro, GE Healthcare). 
All DNA sequences were verified by sequencing service of MWG Biotech AG, 
Martinsried, Germany. 1 g of DNA of plasmid preparations were provide for 
sequencing. 
 
4.1.4 Molecular cloning of DNA fragments 
To generate specific DNA sequences, plasmid DNA was digested using a 3-5 fold 
excess of the corresponding restriction enzyme (New England Biolabs). For sequential 
digestion, DNA fragments were purified with the QIAquick PCR Purification Kit 
(Qiagen). The resulting DNA fragments were separated on a 1-2% agarose gel 
(Invitrogen) supplemented with 100 ng/ml ethidiumbromide and excised from the gel 
using a scalpel. After elution and purification of the DNA fragments with the QIAEXII 
Gel Extraction Kit (Qiagen), vector and an excess of insert DNA were ligated for 10-20 
min at RT using 1 l of Quick T4 DNA Ligase (New England Biolabs) and subsequently 
transformed into competent E. coli DH5 cells. For transformation, 40 l competent 
DH5 dam+ cells were thawed on ice and mixed with 0.5 g of plasmid and 5 l of 
ligation reaction. After incubation on ice for 20 min, cells were subjected to a heat shock 
for 5 min at 37°C under shaking (270 rpm) followed by incubation for 10 min on ice. 
Subsequently, cells were diluted in 1 ml LB medium and incubated at 37°C under 
shaking for 30min. For transformation of plasmid, 100 l of cells suspension were plated 
on LB agar plates supplemented with 100 g/ml ampicillin. For transformation of ligation 
reaction, total cells were plate in a volume of 100 l on TB agar plates (Fluka). The 
plates were incubated at 37°C o/n and single colonies were picked for further cultivation 
in LB medium supplemented with 100 g/ml ampicillin.  
 
4.1.5 Amplification of DNA fragments 
To manipulate DNA by site-directed mutagenesis or by introducing restriction sites or 
linker sequences, DNA was amplified by PCR in a PTC-200 Thermo Cycler (MJ 
Research). The number and duration of cycles as well as the annealing temperatures 
were optimized for the expected product length and the corresponding primers. The 
annealing temperature of the PCR was generally chosen to be 4-8°C lower than the 
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melting temperature TM of the primers calculated by the formula TM in °C =  (2x(A+T) + 
4x(G+C)). In general, PCR amplification was performed in a 50 l reaction volume 
containing 50 ng plasmid template DNA, 100 M of each dNTP, 1 M of forward and 
reverse primer, 10% of DMSO, 2.5 U Cloned Pfu DNA Polymerase (Stratagene) and 
buffer according to the manufacturer’s manual. 
 
4.1.6 Generation of plasmids 
Retroviral expression vectors were pMOWS-puro-MCS/M2 (pMOWS). For stable 
transfection of BaF3 with EpoR, pMOWS-Kz-HA-EpoR was generated in our laboratory 
by Verena Becker (Becker et al., 2008). The murine SHIP1 and human PTEN cDNAs 
were cloned into pMOWS (by Christian Schröter) and its derivative pMOWSnr-MCS/M2, 
in which the puromycin resistance gene was replaced by the LNGFR cDNA (Miltenyi 
Biotech) that allows magnetic bead selection of transduced cells (Ketteler et al., 2002). 
The murine Gab1 cDNA were amplified by PCR using pCMV-SPORT6-GAB1 as 
template, introducing restriction sites Pac1 at 5’, BamH1 at 3’ and cloned into 
pMOWSnr-M2 (Table 4.1). 
Mutagenesis of PTEN and SHIP1 were performed by overlap extension polymerase 
chain reaction (or OE-PCR) using pMOWS-PTEN and pMOWS-(KZ)HA-SHIP1 as 
templates, respectively (Figure 4.1). The mutation G to R at the 129-residue of PTEN 
(PTEN-G129R) abrogates both lipid and protein phosphatase activities, while PTEN-
G129E lacks lipid phosphatase activity yet retains protein phosphatase activity (Sharrard 
and Maitland, 2000). IP-SHIP1 is a 5’-phosphatase-defective SHIP1 (Sasaoka et al., 
2004). 
Recombinant protein expression plasmids: The pGEX2T system (GE Healthcare) 
was used to generate N-terminally GST-tagged constructs and the derived pSBPEX 
system (Keefe et al., 2001) to generate N-terminally SBP-tagged constructs. SBP-PTEN 
is full length recombinant protein, while GST-Gab1, GST-p110 and GST-SHIP1 are 
truncated proteins (Table 4.2). The PCR primers using for the fragments generation are 
listed in Table 4.3.  
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Vector Insert Fragment (Original Vector) Target Vector 
Name Name Restriction sties (5’, 3’) Name Restriction sties (5’, 3’) 
pMOWSnr-(KZ)HA-SHIP1 pMOWS-(KZ)HA-SHIP1 Bgl II, EcoR1 pMOWSnr-MCS BamH1, EcoR1 
pMOWSnr-PTEN pMOWS-PTEN EcoR1, BamH1 pMOWSnr-M2 EcoR1, BamH1 
pMOWSnr-Gab1 PCR* Pac1, BamH1 pMOWSnr-M2 EcoR1, BamH1 
pMOWS-(KZ)HA-IP-SHIP1 OE-PCR** Mfel, Ndel pMOWS-(KZ)HA-SHIP1 Mfel, Ndel 
pMOWS-PTEN-G129R OE-PCR** EcoR1, BamH1 pMOWS-PTEN EcoR1, BamH1 
pMOWS -PTEN-G129E OE-PCR** EcoR1, BamH1 pMOWS-PTEN EcoR1, BamH1 
pMOWS-(KZ)HA-EpoR-F7-479Y pBa-EpoR-F7-479Y PmI1, EcoR1 pMOWS-(KZ)HA-EpoR PmI1, EcoR1 
Table 4.1 Retroviral expression vectors. *The oligonucleotides used for construction of pMOWSnr-Gab1 were listed in Table. ** The 
oligonucleotides used in overlap extension PCR were listed in Figure B 
 
 
Vector 
 
Insert Fragment (Original Vector) 
 
Target Vector 
Name (kD)  Name Restriction sties (5’, 3’) Name Restriction sties (5’, 3’) 
pSBP-PTEN (64) pMOWS-PTEN EcoR1, BamH1 pSBPEX EcoR1, BamH1 
pGST-Gab1 (110) PCR* BamH1, EcoR1l pGEX2T BamH1, EcoR1 
pGST-p110(100) PCR* BglII, Xmal pGEX2T BamH1, EcoR1 
pGST-SHIP1 (120) PCR* BglII, EcoR1 pGEX2T BamH1, EcoR1 
Table 4. 2 Recombinant protein expression plasmids. *The oligonucleotides used for construction of recombinant proteins were listed in Table 
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Table 4.3 Oligonucleotides. The oligonucleotides were used for construction of retroviral expression 
vectors (Ret), calibrator proteins (Cal). The using restriction enzymes are given in the primer names 
and their matching oligonucleotides are capitalized. 
 
 
Name Use Sequence (restriction site) 
Gab1-EcoR1-for Ret cgccgcGAATTCtcacttcacattcttggtgggtgtctcggactc 
Gab1-BamH1-rev Ret cgccgcGGATCCatgagcggcggcgaagtggtttgctcg 
p110-Pac1-for Ret cgccgcTTAATTAAactactgtcggttatccttggacacattgtgcgc 
p110-Bglll-rev Ret cgccgcAGATCTatgccccctggggtggactgccccatg 
Gab1-EcoR1-for Cal cgccgcGAATTCtcacttcacattcttggtgggtgtctcggactc 
Gab1-BamH1-rev1724 Cal cgccgcGGATCCgaagatcctgtgaagccgctgactggctcc 
p110-Xmal-for2151 Cal cgccgcCCCCGGGaacatatgcatcatctccttggtttgggg 
p110-Bglll-rev Cal cgccgcAGATCTatgccccctggggtggactgccccatg 
SHIP1-BglII-for Cal cgcAGATCTccagagcctgacatgatcacc 
SHIP1-EcoR1-rev3060  Cal gacGAATTCcttagggaaggaactcacggatcc  
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Figure 4.1 Site-directed mutagenesis of PTEN and SHIP1 by OE-PCR. (A) Site-directed 
mutagenesis of PTEN and SHIP1. Letters in red indicate the positions of mutagenesis. (B) Primers for 
OE-PCR. Italic capital letters represent the sequences of the induced restriction enzymes; the black 
highlights indicate the overlapping sequences containing the site-directed mutations. (C) Principle of 
OE-PCR. Site-directed mutagenesis is accomplished by using mutagenic primers (b and c) and 
flanking primers (a and d) to generate intermediate PCR products AB and CD that are overlapping 
fragments of the entire product AD. Products AB and CD are denatured when used as template DNA 
for the second PCR; strands of each product hybridize at their overlapping, complementary regions 
that also contain the desired mutation (indicated by the cross). Amplification of product AD in PCR #2 
is driven by primers a and d. Final product AD can be inserted into an expression vector (gray circle) 
to generate larger quantities of DNA, which should also be sequenced to ensure the presence of the 
desired mutation. (adapted from (Heckman and Pease, 2007) 
 
4.2 Cell culture techniques  
4.2.1 Cultivation of mammalian cell lines 
The packaging cell line Phoenix eco was cultured in DMEM medium supplemented with 
10% FCS and 1% antibiotics (10,000 U/ml penicillin and 10,000 g/ml streptomycin sulfate). 
For selection of Phoenix eco cells stably expressing Gag-Pol-Env, cells were treated with 2 
g/ml Diphtheria toxin (Calbiochem) and 200 g/ml Hygromycin B (Roche Diagnostics). 
Phoenix eco cells were subcultured by treatment with 0.5 mg/ml Trypsin and 0.2 mg/ml 
EDTA and never cultured for longer than 2 weeks prior to transfection. 
The IL-3 dependent murine pro B cell line BaF3 was cultured in RPMI 1640 medium 
including 10% WEHI as a source of IL-3 and supplemented with 10% FCS and 1% 
antibiotics. Cells were subcultured after reaching a density of 5-8 x 105 cells/ml. 
The murine fibroblast cell line NIH3T3 was cultured in DMEM medium supplemented with 
10% calf serum and 1% antibiotics. Cells were grown to 85% confluency and subcultured by 
treatment with 0.5 mg/ml Trypsin and 0.2 mg/ml EDTA. 
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In general, cells were stored in liquid nitrogen in 90% serum and 10% DMSO at a density 
of 5 x 106 for Phoenix eco and BaF3 cells or 1 x 106 for NIH3T3 cells. 
 
4.2.2 Preparation of WEHI-conditioned medium 
To prepare IL-3 containing medium, WEHI-3B cells were cultured in RPMI 1640(Ralph and 
Nakoinz, 1977; Warner et al., 1969) supplemented with 10% FCS and antibiotics until 
confluency. After expansion of the cells in a total volume of 50 ml, WEHI-conditioned medium 
was harvested every 5 days by centrifugation and subsequent filtration through a 0.2 m filter 
in order to remove cell debris. The remaining adherent cells as well as the sedimented cells 
were further supplied with 50 ml of fresh medium and adherent cells were subcultured after 
4-6 weeks. 
 
4.2.3 Preparation of murine fetal liver cells  
Fetal liver cells (FLC) of Balb/c mice were isolated at d13.5 from the uterus of sacrificed 
female. Fetal livers of embryos were dissected and resuspended in 500µl ice-cold PBS 
supplemented with 0.3% BSA. After passing through a 40 m cell strainer (BD Biosciences), 
cells were treated with 9 ml Red Blood Cell Lysing Buffer (Sigma-Aldrich) to remove 
erythrocytes. For negative depletion, FLC of 40 livers were incubated with 10 µl rat 
antibodies against the following surface markers: GR1, CD41, CD11b, CD14, CD45, 
CD45R/B220, CD4, CD8, Ter119 (30µl) (all purchased from BD Pharmingen), and with the 
rat monoclonal antibody YBM/42 (gift from Suzanne M. Watt, University of Oxford, Oxford, 
UK) for 30 min at 4°C. Cells were washed 3 times in PBS/ 0.3%BSA and were incubated for 
30 min at 4°C with anti-rat antibody-coupled magnetic beads and negative sorted with MACS 
columns according to the manufacturer's instructions (Miltenyi Biotech). Sorted CFU-E cells 
were cultivated for 14 h in Pancerin 401 (PAN Biotech) and 50 µM -mercaptoethanol 
supplemented with 0.5 U/ml Epo (Cilag-Jansen).   
 
4.2.4 Transient transfection of Phoenix eco cells 
Transient transfection of Phoenix eco cells was performed by calcium-phosphate 
precipitation either in small scale (6-well plate) or large scale (25 cm2 dish).  
For small scale transfection, cells were seeded at a density of 8 x 105 cells in 6-well plates 
16-18 h prior to transfection. A mix of 10 g of plasmid DNA and 12.5 l CaCl2 (2.5 M) was 
precipitated together with 125 l of 2x HBS (280 mM NaCl, 50 mM HEPES, 1.5 mM 
Na2HPO4, pH 7.05). For large scale transfection cell were seeded at a density of 12x106 in 
25 cm2 dishes and 1875 l of 2x HBS was dropwise added to a mixture of 150 g plasmid 
DNA and 187.5 l CaCl2 (2.5 M) while vortexing. The suspension was dropwise transferred 
to the cells. To ensure an efficient uptake of DNA, cells were incubated for 6-8 h in DMEM 
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medium supplemented with 25 M chloroquine. Subsequently, the medium was replaced by 
IMDM supplemented with 30% FCS, 1% antibiotics, and 50 M -mercaptoethanol. The 
retrovirus-containing supernatant was harvested after 16-18 h of incubation and filtered 
through a 0.45 m filter (Millipore). Supernatants were either directly used or stored at -80°C 
for up to 3 months. Transfection efficiency was determined by measuring GFP expression in 
the FL-1 channel of a FACSCalibur (Becton Dickinson), in general yielding a GFP-positive 
population of 75-90%. 
 
4.2.5 Retroviral transduction of cells 
To stably transduced BaF3 cells, 250 l retroviral supernatants of pMOWS-Kz-HA-EpoR 
generated with Phoenix eco cells were adjusted to 8 g/ml polybrene, mixed with 1 x 105 
BaF3 cells and centrifuged for 2 h at 340 g and 37°C in a round bottom 2-ml microcentrifuge 
tubes. After centrifugation, cells were cultured for 48 h in standard medium, subsequently 
selected and further cultured with 1.5 g/ml puromycin. Transduction efficiency was 
determined by measuring GFP expression in the FL-1 channel of a FACSCalibur (Becton 
Dickinson), in general yielding a GFP-positive population of 35-45%.  
To transduce BaF3-EpoR and CFU-E cells in large scale, 4.5 ml retroviral supernatants 
supplemented with 8 g/ml polybrene were mixed with 5 x 106 cells in a 6-well plate and 
centrifuged at 37 °C for 3h in a Heraeus centrifuge 2200 or 2500 r.p.m., respectively. 
Following spin-infection cells were cultivated for 12-14 h in the standard mediums.  
Successfully transduced cells were isolated using the MACSelect LNGFR selection kit 
(Miltenyi Biotech) according to the manufacturer's instructions. Briefly, 6x107 washed cells 
were resuspended in 1ml PBS/ 0.3% BSA and incubated with 150 µl MACS beads on ice for 
15 min to magnetically label positively transduced cells. LS columns were placed in the 
magnetic field of a MACS Separator and rinsed with 1 ml PBS/ 0.3% BSA. Cells were 
applied onto the column in 8 ml PBS/ 0.3% BSA and the flow through was collected as 
negative unlabeled cell fraction. The column was washed four times with 3 ml PBS/ 0.3% 
BSA. To elute the positive fraction, the column was removed from the magnetic field and 
transduced cells were flushed out with 5 ml PBS/ 0.3% BSA by firmly applying the plunger. 
Standardized procedures for PTEN or SHIP1 overexpression in CFU-E and BaF3-EpoR 
cells are depicted in Figure 4.2. 
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Figure 4.2 Standardized procedures for overexpression PTEN or SHIP1 in CFU-E and BaF3-
EpoR cells.  
 
4.2.6 TUNEL assay 
For detection and quantification of apoptosis at single cell level, the In Situ Cell Death 
Detection Kit (Roche Diagnostics, Mannheim) was used. The TUNEL (Terminal 
deoxynucleotidyl Transferase-mediated dUTP nick end labelling) assay relies on the 
detection of single- and double-stranded DNA breaks that occur during the early stages of 
apoptosis. Apoptotic cells are identified by using TdT to transfer fluorescein-dUTP to these 
strand breaks of cleaved DNA. Briefly, 2 x 106 cells were fixed in freshly prepared 2% 
paraformaldehyde and permeabilised with 0.1% Triton X-100, 0.1% sodium citrate for 2 min. 
The positive control was treated with digestion buffer (DNaseI recombinant, DNaseI buffer, 
Roche Diagnostics, Mannheim) for 10 min. After washing with PBS/ 0.3% BSA, cells were 
resuspended in TUNEL reaction mixture (TdT, fluorescein-dUTP, reaction buffer) to label 
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free 3’-OH groups of single- and double-stranded DNA. Fluorescein-dUTP incorporated in 
nucleotide polymers is detected and quantified by flow cytometry using the FL-2 channel of a 
FACSCalibur (Becton Dickinson). For statistical evaluation a two-sided, unpaired Student’s t-
test was performed with P<0.05 considered significant. 
 
4.2.7 Cell cycle distribution (PI staining)  
For detection and quantification of cell cycle distribution at single cell level, Propidium Iodide 
staining for DNA content was performed. Propidium iodide (PI) binds to DNA by intercalating 
between the bases with little or no sequence preference. The intensity of the PI signal, then, 
is directly proportional to DNA content. Briefly, 2x106 cells were added into 1 ml 'fridge cold' 
70% ethanol while vortexing. After at least 30 min incubation at 4 °C, samples may be kept at 
-20°C for up to 2 weeks. For FACS analysis, cells were washed with PBS/0.3% BSA and 
incubated with ribonuclease reaction mixture at room temperature for 5 min. After washing 
with PBS/0.3% BSA, cells were resuspended in propidium iodide solution to label the DNA. 
The fluorescence emission is detected and quantified by flow cytometry using the FL-2 
channel of a FACSCalibur (Becton Dickinson). The histograms were plotted by the 
MultiCycle (Phoenix Flow Systems) program and the program provided the estimate of 
percentage of cells in major phases of the cell cycle with fractional DNA content. 
 
4.2.8 Proliferation assay 
For proliferation assay, Coulter Counter and 3H-Thymidine incorporation assay were 
performed to determine the number of cells that were growing in the absence or presence of 
Epo.  
Coulter Counter assay:  BaF3-EpoR cells wild type and-overexpressing PTEN or SHIP1 
were washing three times with RPML 1640 and plate at densities of 5 x 104 cells/ well in 24-
well plates in the absence or presence of Epo (Janssen-Cliag) concentrations range from 
0.01 to 5 U/ml in RPMI 1640. After 4 days, cells numbers were determined using a Coulter 
Counter Z2 (Beckman, particle size 4.00-17.35 m) and expressed as the percentage of 
growth obtained in a parallel well containing 5% WEHI-conditioned medium as a source for 
IL-3. 
[3H] -Thymidine incorporation assay: To obtain pure population of CFU-E cells for [3H]-
Thymidine incorporation, BFU-E and CFU-E cells were isolated from fetal liver cells (FLC) by 
negative depletion with MACS as described above without antibody against CD41. 
Subsequently, retroviral transduction was performed as described above. Transduced cells 
were seeded in IMDM/sct, which was prepared by supplementing IMDM (Invitrogen) with 
15% fetal calf serum, 1% BSA (Sigma-Aldrich), 200 mg/ml hHolo-Transferrin, 10 mg/ml 
insulin, 50 ng/ml rmSCF, 10 ng/ml rmIL-3, 10 ng/ml rhIL-6 (all from R&D), and 10 U/ml Epo 
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(Cilag-Jansen). After 14h cultivation, CFU-E cells were sorted by MACS negative selection 
again. Transduced BaF3-EpoR cells were prepared as describe above. To measure cellular 
proliferation, [3H]-Thymidine incorporation assay was performed to determine the DNA 
content of cells that were growing in the absence or presence of Epo. After washing with 
serum free medium, BaF3-EpoR cells were plated at densities of 10 x 104 cells / well in 96-
well plates in the absence or presence of Epo (Janssen-Cliag) concentrations range from 
0.001 to 10 U/ml in RPMI 1640, while CFU-E cells were plated at densities of 20 x 104cells / 
well in 96-well plates in the absent or present of Epo in Pancerin 401. After 4h incubation, 1 
µCi/well 3H-Thymidine was added and cells were cultivated for 38h for BaF3-EpoR cells and 
14 h for CFU-E cells. Cells were collected and the incorporated radioactivity was measured 
using a scintillation counter. To quantify the proliferation assay, regression lines are 
calculated with a four-parameter Hill regression (y=y0+(axb/cb+xb)). As the logarithmic 
transformation is a monotonic transformation, the sigmoidality of the curve is also true for a 
linear axis (Schilling et al., 2009). 
 
4.3 Biochemical and immunological protein analysis 
4.3.1 Time-course experiments in BaF3-EpoR and CFU-E cells 
BaF3-EpoR cells were washed three times with RPMI 1640 and starved for 4-5 h at 37°C in 
RPMI 1640 supplemented with 1 mg/ml BSA. CFU-E cells were washed three times and 
starved in Panserin 401 supplemented with 50 µM -mercaptoethanol for 1-2h. For time-
course experiments 4 x 107 BaF3-EpoR or 2 x 107 CFU-E cells/ml were pre-incubated for 5 
min at 37°C and subsequently stimulated with 0.5-50 U/ml Epo (Janssen-Cilag) at 37°C. For 
each time point, 1 x 107 BaF3-EpoR or 0.5 x 107 CFU-E cells were taken from the pool of 
cells and lysed by adding 2 x Nonidet P-40 (NP40) lysis buffer, thereby terminating the 
reaction. 
 
4.3.2 Preparation of cellular lysates 
Detergent lysates of cells were prepared with 2 x 1% NP40 buffer (1 x buffer: 1% NP40, 150 
mM NaCl, 20 mM Tris pH 7.4, 10 mM NaF, 1 mM EDTA pH 8.0, 1 mM ZnCl2 pH 4.0, 1 mM 
MgCl2, 1 mM Na3VO4, 10% Glycerol) supplemented with 2 µg/ml aprotinin and 200 µg/ml 
AEBSF. After 30 min of incubation at 4°C with overhead rotation, the lysate was centrifuged 
for 10 min at 20,000 g and 4°C. The supernatant was either used directly, processed further 
by immunoprecipitation or total cellular lysates were stored at -80°C. 
 
4.3.3 Immunoprecipitation 
Immunoprecipitation was performed with an equivalent of 1 x 107 BaF3-EpoR or 0.5 x 107 
CFU-E cells by adding the target-specific antibody and 25 µl of Protein A/G sepharose (GE 
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Healthcare) to the lysate for 2-8 h or o/n at 4°C. The immunoprecipitates were washed twice 
with 1 x 1% NP40 lysis buffer and once with TNE buffer (10 mM Tris pH 7.4, 100 mM NaCl, 1 
mM EDTA, pH 8.0, 100 µM Na3VO4) and were resuspended in 25 µl 2 x SDS sample buffer 
(1 x buffer: 2% SDS, 50 mM Tris pH 7.4, 10% glycerol, 5% -mercaptoethanol, 100 mM DTT, 
0.01% bromphenolblue). Immunoprecipitates were immediately subjected to protein gel 
electrophoresis or stored at -20°C. 
Samples for time-course analysis of EpoR, JAK2, p85, SHIP1 or Gab1 were prepared 
prior to immunoprecipitation by adding adequate mount of calibrator protein to the lysates. 
 
4.3.4 SDS-PAGE and immunoblot analysis 
Proteins were separated according to their electrophoretic mobility in a denaturing SDS-
PAGE (Laemmli, 1970). Protein samples were boiled at 95 °C for 2 min in SDS sample 
buffer. Protein samples were separated by 10% or 15% SDS-PAGE with low bis-acrylamide 
(GE Healthcare) (Table 4.4) and separated in an electric field in running buffer (192 mM 
glycine, 25 mM Tris, 0.1% SDS). Immunoprecipitates were centrifuged for 2 min at 15,700 g 
before loading. For total cellular lysates, an amount of 50-100 µg protein resuspended in 2 / 
4 x SDS sample buffer were separated by SDS-PAGE. Sample loading on SDS-PAGE was 
randomized to avoid correlated blotting errors (Schilling et al., 2005b) 
 
 Stacking gel 
 
(10 ml) 
Separating gel 
10% 
(20 ml) 
Separating gel 
15% 
(20 ml) 
40% acrylamide 1 ml 5 ml 7.5 ml 
2% w/v methylenebisacrylamide 0.5 ml 1.3 ml 0.88 ml 
1M Tris-HCl, pH 6.8 1.25 ml - - 
1.5M Tris-HCl, pH 8.8 - 5 ml 5 ml 
10% SDS 0.1 ml 0.2 ml 0.2 ml 
ddH2O 7.15 ml 8.5 ml 6.42 ml 
APS (10 %) 100 µl 200 µl 200 µl 
Temed 10 µl 20 µl 20 µl 
Table 4.4. SDS-Page for 10% and 15% polyacrylamide gels. 
Immunoblotting was performed in semi-dry chambers (GE Healthcare) on nitrocellulose 
membranes with a pore size of 0.2 µm (What man) or PVDF membrane (Millipore)  
Blotting was performed in transfer buffer (192 mM glycine, 25 mM Tris, 0.075% SDS, 0.5 
mM Na3VO4, 15% methanol) for 1 h at approximately 1.3 mA/cm2. Proteins were reversibly 
stained immobilized with Ponceau Red. After blocking unspecific antibody binding with 2-5% 
BSA diluted in TBS-T (10 mM Tris pH 7.4, 150 mM NaCl, 0.2% Tween-20), membranes were 
incubated with the appropriate first and secondary antibodies and proteins were visualized 
with the ECL or ECL Advance Western Blotting Detection Reagents (GE Healthcare) and 
subsequently detected on a Lumi-Imager F1TM (Roche Diagnostics, Mannheim). 
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Quantification was performed using the LumiAnalyst 3.1 software (Roche Diagnostics, 
Mannheim). To evaluate total protein levels, membranes were incubated in stripping buffer 
(62.5 mM Tris pH 6.8, 2% SDS, 100 mM -mercaptoethanol) for 20-25 min at 65°C, blocked 
with 2-5 % BSA diluted in TBS-T, and reprobed with the appropriate first and secondary 
antibody. 
 
4.3.5 Coomassie staining 
For Coomassie staining, gels were incubated in Staining Solution (0.25% Coomassie Brilliant 
Blue, 50% methanol, 12.5% acetic acid) for 10 min at room temperature. Subsequently, gels 
were incubated in Destaining Solution 1 (45% methanol, 10% acetic acid) for 10 min and in 
Destaining Solution 2 (5% methanol, 5% acetic acid) o/n at room temperature. 
 
4.3.6 Expression and purification of recombinant proteins in E.coli 
For high-efficiency expression of calibrator constructs, expression plasmids were 
transformed into competent E. coli BL21 (DE3) CodonPlusRIL cells (Stratagene) as 
described for DH5 cells. A single positive colony was cultured in 25 ml LB medium 
supplemented with 100 g/ml ampicillin and 50 g chloramphenicol at 37°C o/n. This o/n 
culture was then added to 225 ml fresh LB medium supplemented with ampicillin and 
chloramphenicol and cultured at 37°C for 90 min. After IPTG was added at a final 
concentration of 0.2 mM to induce protein expression, cells were cultured for another 3 h at 
37°C. Cells were sedimented, washed with cold PBS and stored at -20°C o/n. 
Upon thawing the cell pellet was resuspended in 15 ml bacterial lysis buffer (10 mM Tris 
pH 8.0, 100 mM NaCl, 1 mM EDTA) supplemented with 70 l lysozyme solution (50 mg/ml) 
and 75 l 1 M DTT, and lysed on ice for 20 min. After adding 2.25 ml 10% N-lauroylsarcosine 
the suspension was vortexed for 1 min and sonicated (Sonopuls, Bandelin) three times for 1 
min on ice. The bacterial lysate was then centrifuged at 15,000 g for 15 min at 4°C to remove 
cell debris. The supernatant was carefully transferred to a fresh tube and 350 l Triton X-100 
were added. To bind GST- or SBP-tagged recombinant proteins, the supernatant was 
incubated with 500 l glutathione sepharose beads or 500 l streptavidin sepharose beads, 
respectively, and rotated for 1 h at 4°C. Subsequently, beads were washed four times with 
cold 9% PBS, 1% NP40 supplemented with 5 mM DTT and once with cold PBS 
supplemented with 5 mM DTT. Beads were subsequently transferred to a 0,45 µm filter unit 
(Millipore) and recombinant proteins were eluted in fractions of 500 l elution buffer (75 mM 
Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 5 mM DTT) supplemented with 20 mM reduced 
glutathione or 2 mM biotin for GST- or SBP-tagged proteins, respectively. Protein aliquots 
were stored at -80°C. 
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4.3.7 Quantification of proteins 
To determine protein concentrations of cellular lysates the BCA Protein Assay Kit (Pierce) 
was used according to the manufacturer’s instructions. 
For quantification of recombinant calibrator proteins, a dilution series of the respective 
recombinant calibrator protein and a BSA standard series were separated by SDS-PAGE. 
The gel was Coomassie stained and band intensities were quantified using a Lumi-Imager 
F1 (Roche Diagnostics, Mannheim) and the LumiAnalyst 3.1 software (Roche Diagnostics, 
Mannheim). 
 
4.3.8 Antibodies 
The following antibodies were used for immunoprecipitation (IP) and immunoblot analysis 
(IB) (Table 4.5 and 4.6). 
primary antibodies use specification company 
mouse anti-phosphoTyr IB (1:10000) monoclonal, 4G10 UBI 
rabbit anti-EpoR IP (3 l) IB (1:10000) polyclonal, M-20 Santa Cruz 
mouse anti-SHIP1 IB (1:5000) monoclonal, P1C1 Santa Cruz 
rabbit anti-PI3 kinase p110 IP (5 l) IB (1:2000) monoclonal Upstate 
rabbit anti-PI3 kinase p110 IP (5 l) IB (1:2000) polyclonal, H-219 Santa Cruz 
rabbit anti-PI3 kinase p85 
N-SH2 domain 
IP (5 l) 
IB (1:10000) polyclonal, serum Upstate 
rabbit anti-Gab1 IP (5 µl) IB (1:2000) polyclonal Upstate 
rabbit anti-Gab2 IP (5 µl) IB (1:2000) polyclonal Upstate 
rabbit anti-Akt IB (10ul) IB (1:2000) polyclonal Cell signaling 
rabbit anti-Akt Ser473 IB (1:2000) monoclonal,193H12 Cell signaling 
rabbit anti- Akt Thr308 IB (1:2000) monoclonal, 244F9 Cell signaling 
rabbit anti-PDI IB (1:5000) polyclonal Sressgen 
rabbit anti-PTEN IB (1:2000) polyclonal Cell signaling 
rabbit anti-Grb2 IB (1:2000) polyclonal Cell signaling 
rabbit anti-Shc IB (1:2000) polyclonal Cell signaling 
mouse anti-GSK-3 IB (1:2000) monoclonal, 0011-A Santa Cruz 
rabbit anti-p GSK-3
(Ser21/9) IB (1:2000) polyclonal Cell signaling 
mouse anti-S6 IB (1:2000) monoclonal, 54D2 Cell signaling 
rabbit anti-pS6 (Ser240/244) IB (1:2000) polyclonal Cell signaling 
rabbit anti-pS6(Ser235/236) IB (1:2000) polyclonal Cell signaling 
rabbit anti-p44/p42 MAPK IB (1:2000) polyclonal Cell signaling 
rabbit anti-phospho-p44/p42 
MAPK (Thr202/Tyr204) IB (1:2000) polyclonal Cell signaling 
mouse anti-14-3-3  IP (10 l) IB (1:2000) monoclonal, H-8 Santa Cruz 
mouse anti-p21 IB (1:1000) monoclonal BD Pharmingen 
mouse anti-p27 IB (1:1000) monoclonal BD Pharmingen 
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Table 4.5. Primary antibodies. 
conjugates use specification company 
donkey anti-rabbit IgG HRP IB (1:10000) polyclonal GE Healthcare  
sheep anti-mouse IgG HRP IB (1:10000) polyclonal GE Healthcare  
Protein A HRP IB (1:10000) - GE Healthcare 
donkey anti-goat IgG HRP IB (1:10000) ployclonal Santa Cruz 
Table 4. 6. Secondary antibody conjugates used for immunoblot analysis. 
4.4 RNA analysis 
4.4.1 Extraction of total RNA 
Per time point total RNA from1.5 to 3 x 106 BaF3-EpoR and CFU-E cells was isolated using 
the RNeasy Mini Plus Kit (Qiagen). RNA was extracted according to the manufacturer’s 
instructions for suspension cells. To eliminate traces of DNA, on-column digests using the 
RNAse-free DNAse Set (Qiagen) were performed. RNA was stored at -80°C or directly used 
for quantification and reverse transcription. 
 
4.4.2 Quantification of RNA 
The concentration of total RNA samples was determined by measuring the absorbance of 
diluted 1:50 in TRIS buffer pH 7.4 at 260 nm (Ultrospec 3100 pro, GE Healthcare). 
 
4.4.3 Quantitative two-step RT-PCR 
To generate cDNA, 2 µg of total RNA was transcribed with the QuantiTect Reverse 
Transcription Kit (Qiagen) according to the manufacturer’s instructions (Table 4.7). 
Quantitative PCR (qPCR) was performed using a LightCycler 480 (Roche Diagnostics, 
Mannheim) in combination with the hydrolysis-based Universal ProbeLibrary (UPL) platform 
(Roche Diagnostics, Mannheim). For the detection and quantification of pre-rRNA, qPCR 
was performed using a LightCycler480 in combination with SYBR Green (Roche Diagnostics, 
Mannheim). In general, qPCR amplifications were performed in 96-well format in a 20 µl 
reaction volume containing 5 µl of 1:5 or 1:25 diluted template cDNA, 0.2 µM of forward and 
reverse primer, 0.2 µl of the appropriate UPL probe and 10 µl LightCycler 480 Probes Master 
solution (Roche Diagnostics, Mannheim) or with 10ul SYBR Green Master mix I according to 
the manufacturer’s manual. Primer pairs were generated using the automated UPL Assay 
Design Center (www.roche-applied-science.com) (Table 4.8). 
Crossing point (CP) values were calculated using the Second Derivative Maximum 
method of the LightCycler 480 Basic Software (Roche Diagnostics, Mannheim). PCR 
efficiency correction was performed for each PCR setup individually based on a dilution 
series of template cDNA. Relative concentrations were normalized using HPRT or RPL32 as 
reference genes. 
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PCR step Temperature Time 
initial denaturation 95°C 5 min 
50 cycles 
melting 95°C 10 s 
primer annealing 60°C 30 s 
DNA synthesis and 
data acquisition 72°C 1 s 
cooling 40°C 2 min 
Table 4.7. PCR program for quantitative PCR. 
Target gen Sequence 
name Left Right 
Foxo1_11 cttcaaggataagggcgaca gacagattgtggcgaattga 
Foxo3a_64  gctaagcaggcctcatctca ttccgtcagtttgagggtct 
Ccnd2_45 ctgtgcatttacaccgacaac cactaccagttcccactccag 
Ccng2_12 ccacgcgattgtattttgtc agctgcgcttcgagtttatc 
Cdkn1a_16 aacatctcagggccgaaa tgcgcttggagtgatagaaa 
Cdkn1b_62 gagcagtgtccagggatgag tctgttctgttggccctttt 
PTEN_102 gtggcggaacttgcaatc ctactttgatatcaccacacacagg 
SHIP1_76 cctctgtcgccaaagaagtt agcttccacctttcccagat 
Pim-1_93 cagtctacacggactttgatgg cgcagaccatgtcatagagc 
Junb_3 ccacggagggagagaaaatc agttggcagctgtgcgtaa 
Table 4.8 q RT-PCR primers. UPL probe numbers are given in the primer names. 
 
4.4.4 Microarray analysis 
Microarray analysis I: Epo stimulated or non-stimulated CFU-E cells (performed by Julie 
Bachman) (Figure  
Primary CFU-E cells were isolated from mice fetal livers (E13.5) and starved 1 h. Cells were 
resuspended in Panserin 401/ 50 µM beta-Mercaptoethanol and stimulated with 0.5 U/ml 
Epo (Jansen-Cilag). Stimulated samples were taken after 0, 1, 2, 3, 4, 5, 6, 7, 8, 14, 19, 24 h, 
while non-stimulated samples could only collected after 0, 1, 2, 3, 4, 5, 6, 8 h. 
Microarray analysis II: Epo promoted BaF3-EpoR cells survival and proliferation   
BaF3-EpoR cells were cultured overnight (22h) under pro-starvation condition, namely RPMI 
supplemented with 0.05U/ml Epo. On the next day, cells were diluted to 50 x 104 cells/ml with 
fresh pro-starvation medium and cultured for 3h. Then, cells were stimulated with 0.5U/ml 
Epo or remain unstimulated. After 0, 1, 2, 3, 4, 5, 6, 7, 8, 20, 24 h, stimulated and non-
stimulated samples were taken. 
Microarray analysis III: Epo stimulated PTEN-overexpressing or control BaF3-EpoR cells 
PTEN or empty vector as control transduced BaF3-EpoR cells were prepared as described 
above. After washing with serum free medium, BaF3-EpoR cells were starved for 5 h and 
resuspend at densities of 20 x 104 cells / ml in RPMI medium by supplementing with 0.5 U/ml 
Epo. Stimulated and non-stimulated samples were taken after 0, 1, 2, 3, 4, 5, 7, 18h. 
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Per time point total RNA from 2-4 x 106 CFU-E or BaF3-EpoR cells was isolated using the 
RNeasy Mini Plus Kit (Qiagen). RNA was extracted according to the manufacturer’s 
instructions for suspension cells. The quality of total RNA samples was assessed with the 
Bioanalyzer 2100 (Agilent) to ensure that 28S/18S rRNA ratios were in the range of 1.5 to 
2.0 and concentrations were comparable between samples. Mouse Genome 430 2.0 Arrays 
(Affymetrix) were applied (performed by Maria Saile, Mannheim). 
Raw microarray data were processed using the R environment (www.r-project.org) 
together with the Bioconductor toolbox (www.bioconductor.org). Normalization was 
performed using the variance stabilization algorithm (vsn) available in Bioconductor (Huber et 
al., 2002). Quality of the results has been assessed using made4, an R package for 
multivariate analysis of gene expression data (Culhane et al., 2005). Subsequent probe 
annotation was handled with the Bioconductor package annaffy. The logarithmic gene fold 
expression was calculated with respect to the gene expression at 0 hours. The gene 
expression kinetic from each experiment was ranked according to the absolute value of the 
combined mean and peak fold expression (performed by Jie Bao, Freiburg).   
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Figure 4.3 The procedures of microarray sample collection. 
 
4.5 Modeling Approaches 
4.5.1 Computational data processing  
Randomized quantitative immunoblotting data was processed using GelInspector software 
(Schilling et al., 2005a) to suppress correlated blotting errors. The addition of calibrators 
allowed for quality control and normalization of the raw data. The following calibrators were 
applied: GST-EpoR for pEpoR and tEpoR. PDI and -actin were applied as normalizer for 
signals from total cell lysate. For first estimates, cubic smoothing splines were determined 
(MATLAB csaps function with smoothness parameter 0.3) and used for criteria-mediated 
error reduction. 
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4.5.2 Scaling factors and error estimation  
Immunoblotting measurements typically yield relative concentrations, while the model is 
formulated in absolute concentrations. To define the absolute receptor phosphorylation level, 
it was assumed that the receptors on the CFU-E cell surface are maximally 75% 
phosphorylated (Figure 2.8 C, at 5 min stimulated with 10 U/ml Epo). In addition, a receptor 
phosphorylation level of 50% or 90% was also tested in silico, but this had no significant 
influence on the model behavior. To define the absolute amount of phosphorylated Akt, a 
quantitative protein array was applied that combines in-spot normalization and binding 
model-based calibration. The maximal phosphorylation degree of Akt was determined to be 
54% in CFU-E cells stimulated with 2.5 U/ml Epo. Based on such information, experimental 
data was transferred into absolute concentration in nM. 
As the quality of a mathematical model is determined by its deviation from the data 
relative to the measurement error, the variability of the data had to be estimated. All 
stimulation experiments were performed at least twice with reproducible results. To estimate 
the error of the immunoblot results, the standard deviations of experimental data were 
estimated with an error model, considering contribution of 10 % relative error and a 5 % 
absolute error. This error estimation confirms the approximately 20 % error of the 
immunoblotting technique determined in previous studies (Schilling et al., 2005a). To 
estimate the error of the proliferation data, the standard deviations of experimental data were 
estimated with 10 % relative error. 
  
4.5.3 Optimization of parameters  
Multi-experiment fitting was accomplished by the Matlab toolbox PottersWheel (Maiwald and 
Timmer, 2008). After rescaling the data from wild-type and overexpression experiments in 
two cell types, the four datasets were fitted simultaneously. Kinetic parameters starting from 
random initial values, which were uniformly distributed in a logarithmic space, were optimized 
by minimizing the sum of the squares of the muti-experiment data from the model simulation. 
In this process, we constrained the parameters in CFU-E and BaF3-EpoR cells to hold the 
same values. Local minima in the parameter space were avoided by repeating this process 
5000 times. For further analysis of the model we used the best 1% of 5000 optimized 
parameter sets. 
 
4.5.4 Statistical analysis 
The 2-values were calculated to determine the agreement between measured proliferation 
data and the integral of pAkt. The different integration times were examined.The 2-values 
were calculated separately for control cells and PTEN and SHIP1 overexpression in each cell 
type. The total 2-values constituted the sum of 2-values. The best time window with the 
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lowest total 2-value was identified at 12 min in CFU-E cells and 16 min in BaF3-EpoR cells. 
In CFU-E cells, the integral of pAkt failed to describe the reduced basal proliferation of 
SHIP1-overexpressing cells, resulting in much higher 2-values compared to control and 
PTEN overexpression. Therefore, the SHIP1 overexpression data was excluded for the total 
2 calcualtion in CFU-E cells.  
 
Figure 4.4 Determination of the agreement between measured proliferation data and the 
integral of pAkt. The different integration times were examined.The 2-values were calculated 
separately for control and PTEN and SHIP1 overexpression data in each cell type. The total 2-values 
constituted the sum of 2-values. 
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6 Appendix 
6.1 Observables and data sets 
CFU-E time course stimulated with 2.5U Epo      
# MCode drivingFunctions(1).name = 'CFUE-Epo';   
# MCode drivingFunctions(1).stimuli(1) = pwGetDrivingFunction('steps',[-60 0],[0 1]); 
Time-min  Stimulus 
pEpoR  pAkt   
blu/cell nM/cell blu/cell nM/cell  
0 1 0.41 0.02 5.28 24.50  
1 1 10.30 0.45 13.27 61.58  
5 1 35.60 1.56 36.63 170.02  
8 1 33.20 1.45 30.09 139.68  
10 1 27.60 1.21 47.40 220.00  
12 1 27.20 1.19 36.25 168.24  
14 1 25.40 1.11 29.90 138.78  
16 1 26.10 1.14 31.15 144.58  
18 1 21.10 0.92 42.59 197.69  
20 1 18.00 0.79 30.29 140.57  
25 1 16.90 0.74 35.48 164.67  
30 1 15.20 0.67 32.69 151.72  
35 1 12.00 0.53 31.25 145.03  
40 1 8.21 0.36 25.09 116.47  
45 1 8.94 0.39 24.90 115.58  
50 1 8.28 0.36 27.50 127.63  
55 1 7.03 0.31 18.94 87.91  
60 1 4.62 0.20 14.71 68.28  
Table 6. 1 1h time course of EpoR and Akt phosphorylation in CFU-E cells stimulated with 2.5U 
Epo.   
 
BaF3-EpoR time course stimulated with 5U Epo    
# MCode drivingFunctions(1).name = 'BaF3-Epo';   
# MCode drivingFunctions(1).stimuli(1) = pwGetDrivingFunction('steps',[-60 0],[0 1]); 
Time-min  Stimulus 
pEpoR  pAkt  
blu/cell nM/cell blu/cell nM/cell 
0 1 70.13 0.87 1.89 2.50 
1 1 89.29 1.11 1.48 1.95 
5 1 269.30 3.35 6.25 8.28 
8 1 288.02 3.59 16.57 21.95 
10 1 290.90 3.62 16.46 21.80 
12 1 316.83 3.95 16.29 21.58 
14 1 308.91 3.85 13.17 17.44 
16 1 324.03 4.03 10.31 13.66 
18 1 290.18 3.61 9.71 12.86 
20 1 340.59 4.24 8.67 11.48 
25 1 234.74 2.92 8.01 10.61 
30 1 265.70 3.31 6.20 8.21 
35 1 213.14 2.65 8.12 10.75 
40 1 207.38 2.58 6.25 8.28 
45 1 226.10 2.82 4.79 6.35 
50 1 186.50 2.32 3.94 5.22 
55 1 169.21 2.11 3.87 5.13 
60 1 131.77 1.64 4.25 5.63 
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Table 6. 2 1h time course of EpoR and Akt phosphorylation in BaF3-EpoR stimulated with 5U 
Epo.   
Dose response        
CFU-E receptor phosphorylation ( 20081020)     
tEpoR  
1000 
molecules/cell  Volum 399 4.16 nM      
 
10U (5min) 75% phosphorlyated 
:  3.12 nM     
        
Time-min 0.1 0.5 1.0 2.5 5.0 10.0 U/ml Epo 
0 0.05 0.05 0.05 0.05 0.05 0.05  
5 0.19 0.98 1.31 1.56 2.31 3.12  
10 0.25 0.93 1.60 1.41 2.53 2.04  
20 0.19 0.64 0.92 1.87 1.20 1.69  
60 0.14 0.30 0.30 0.27 0.34 0.40  
120 0.12 0.27 0.28 0.34 0.42 0.44  
        
BaF3-EpoR receptor phosphorylation ( 
20110215)     
Time-min 0.5 5 50 U/ml Epo    
0 0.53 0.53 0.53     
5 0.94 2.80 5.09     
10 0.91 3.60 5.96     
30 0.55 1.23 2.72     
60 0.26 1.24 2.53     
120 0.17 0.55 1.61     
180 0.17 0.31 0.94     
 Table 6. 3 Dose response of EpoR phosphorylation in CFU-E and BaF3-EpoR cells   
 
Dose response        
Akt phosphorylation (nM) in CFU-E cells (20081022)    
Time (min) 0.1 0.5 1 2.5 5 U/ml Epo  
0 4.29 4.29 4.29 4.29 4.29  
5 13.57 123.93 162.00 183.51 185.34  
10 49.92 202.82 223.90 220.00 237.17  
20 44.32 124.49 201.76 236.14 215.99  
60 26.21 70.72 87.71 54.41 74.59  
120 10.73 39.92 38.20 86.66 91.27  
       
Dose response       
Akt phosphorylation (nM) in BaF3-EpoR cells     
Time (min) 2.5 5 5 10 50 U/ml Epo  
0 3.37 3.37 3.91 3.91 3.37  
5 15.10 25.77 27.56 31.02 44.52  
10 19.50 20.87 22.73 30.20 38.07  
20 7.72 7.18 9.52 9.68 18.91  
60 10.21 5.64 5.86 8.53 16.18  
120 7.72 2.68 5.67 5.84 5.77  
180.0 8.65 2.83 5.72 5.80 7.28  
Table 6. 4 Dose response of Akt phosphorylation in CFU-E and BaF3-EpoR cells   
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CFU-E oe PTEN  x 12 fold      
# MCode drivingFunctions(1).name       = 'CFUE-Epo';   
# MCode drivingFunctions(1).stimuli(1) = pwGetDrivingFunction('steps',[-60 0],[0 1]); 
# xCol-Time-
min 
parCol-
Stimulus nM/cell    
0 1 4.93    
1.5 1 23.15    
5 1 73.21    
10 1 80.40    
15 1 58.27    
20 1 42.42    
30 1 33.64    
40 1 20.87    
50 1 12.77    
60 1 8.80    
      
CFU-E oe SHIP1  x 11 fold     
# MCode drivingFunctions(1).name       = 'CFUE-Epo';   
# MCode drivingFunctions(1).stimuli(1) = pwGetDrivingFunction('steps',[-60 0],[0 1]); 
# xCol-Time-
min 
parCol-
Stimulus nM/cell     
0 1 22.28    
1 1 55.27    
3 1 170.14    
5 1 148.12    
8 1 145.96    
10 1 162.80    
12 1 151.14    
16 1 149.41    
20 1 79.02    
30 1 101.48    
45 1 72.55    
60 1 28.28    
Table 6. 5 Effect of PTEN or SHIP1 overexpression on Akt phosphorylation in CFU-E cells 
BaF3-EpoR  oe PTEN x 3 fold    
 oe SHIP1 x 4 fold     
#Time-min Cells Blot  
pAkt nM 
21.8 
Middel 
Value 
Standard 
Deviation 
0 control 1 0.53 2.99 3.49 
0 control 2 5.46    
10 control 1 21.80 21.80 1.25 
10 control 2 23.05    
10 control 2 20.55    
30 control 1 11.54 12.09 2.34 
30 control 1 14.57    
30 control 2 13.14    
30 control 2 9.13    
60 control 1 6.08 6.42 0.91 
60 control 1 7.41    
60 control 2 5.33    
60 control 2 6.87    
0 oe PTEN 1 0.43 0.43    
10 oe PTEN 1 3.29 4.11 1.15 
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10 oe PTEN 1 4.92     
30 oe PTEN 1 1.37 1.79 0.59 
30 oe PTEN 1 2.20     
60 oe PTEN 1 0.51 0.73 0.30 
60 oe PTEN 1 0.94     
0 oe SHIP1  2 3.73 3.73    
10 oe SHIP1  2 13.02 12.03 1.40 
10 oe SHIP1  2 11.04     
30 oe SHIP1  2 5.39 6.05 0.94 
30 oe SHIP1  2 6.71     
60 oe SHIP1  2 5.05 4.72 0.46 
60 oe SHIP1  2 4.40     
Table 6. 6 Effect of PTEN or SHIP1 overexpression on Akt phosphorylation in BaF3-EpoR cells 
  
PTEN x 11 fold-overexpressing cells and control CFU-E cells stimulated with 
2.5 U/ml Epo   
20100927       
Time (min)  Cells  PTEN  pAkt pGSK3 pS6 pErk  
0 control 0.63 0.01 0.13 0.04 0.04 
10 control 2.39 1.00 1.00 0.32 1.00 
30 control 1.07 0.52 0.45 0.70 0.08 
60 control 1.19 0.38 0.27 0.85 0.07 
120 control 0.57 0.33 0.18 1.00 0.04 
150 control 0.93 0.25 0.24 1.00 0.06 
0 oe PTEN 8.65 0.00 0.06 0.01 0.04 
10 oe PTEN 11.51 0.31 0.34 0.12 0.85 
30 oe PTEN 10.70 0.09 0.08 0.12 0.07 
60 oe PTEN 13.71 0.04 0.05 0.10 0.04 
90 oe PTEN 15.05 0.02 0.04 0.11 0.03 
120 oe PTEN 11.40 0.02 0.05 0.26 0.05 
150 oe PTEN 12.70 0.01 0.05 0.20 0.03 
       
       
PTEN x 4.2 fold-overexpressing and control BaF3-EpoR cells stimulated with 
5U/ml Epo   
20100309       
Time (min)  Cells  PTEN  pAkt pGSK3 pS6 pErk  
0 control 0.806 0.06 0.23 0.06 0.01 
10 control 0.786 1.00 1.00 0.91 1.00 
30 control 1.539 0.62 0.54 1.00 0.67 
60 control 0.872 0.24 0.44 0.65 0.16 
120 control 1.195 0.20 0.19 0.09 0.10 
150 control 0.744 0.08 0.17 0.04 0.03 
180 control 1.059 0.06 0.21 0.08 0.02 
0 oe PTEN 4.840 0.09 0.16 0.04 0.01 
10 oe PTEN 3.417 0.49 1.00 0.48 0.91 
30 oe PTEN 4.363 0.13 0.47 0.64 0.50 
60 oe PTEN 5.876 0.14 0.56 0.51 0.27 
120 oe PTEN 2.956 0.12 0.30 0.13 0.07 
150 oe PTEN 3.206 0.07 0.19 0.06 0.03 
180 oe PTEN 4.633 0.10 0.19 0.09 0.02 
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Table 6. 7 Effect of PTEN on the phosphorylation patterns of GSK3 and mTOR in CFU-E and 
BaF3-EpoR cells. 
SHIP1x 10 fold-overexpressing and control CFU-E cells stimulated with 2.5 U/ml 
Epo  
20101108      
Time (min) SHIP1 pAkt pGSK3 pS6 Ser235/236 pErk 
0 1.76 0.02 0.12 0.19 0.05 
10 2.32 1.00 1.00 0.37 1.00 
30 1.03 0.19 0.28 0.82 0.08 
60 2.40 0.48 0.66 0.90 0.11 
90 0.97 0.25 0.35 1.00 0.04 
120 0.27 0.30 0.31 0.92 0.06 
150 0.40 0.16 0.30 0.89 0.11 
180 0.97 0.06 0.04 0.73 0.05 
0 6.36 0.02 0.08 0.21 0.07 
10 11.57 0.58 0.46 0.30 0.45 
30 8.45 0.29 0.18 0.51 0.14 
60 11.67 0.09 0.15 0.46 0.11 
90 4.55 0.04 0.14 0.52 0.06 
120 9.91 0.07 0.09 0.33 0.09 
150 10.05 0.05 0.13 0.70 0.10 
180 14.46 0.05 0.13 0.70 0.13 
      
SHIP1x 4 fold-overexpressing and control BaF3-EpoR cells stimulated with 5U/ml 
Epo  
20101108      
Time (min) SHIP1 pAkt pGSK3 pS6 Ser235/236 pErk 
0 1.26 0.06 0.30 0.10 0.03 
10 1.50 1.00 1.00 0.99 1.00 
30 0.58 0.38 0.22 0.74 0.27 
60 1.27 0.34 0.46 0.92 0.29 
90 0.74 0.14 0.19 0.41 0.08 
120 0.72 0.09 0.26 0.18 0.07 
0 3.22 0.09 0.37 0.11 0.03 
10 3.08 0.74 1.03 0.86 1.12 
30 3.78 0.34 0.36 1.00 0.31 
60 4.00 0.32 0.49 0.91 0.23 
120 3.71 0.14 0.47 0.49 0.18 
Table 6. 8 Effect of SHIP1 on the phosphorylation patterns of GSK3 and mTOR in CFU-E and 
BaF3-EpoR cells. 
Hill 
function BaF3-EpoR  20080811    Hill function
CFU-E 
20080805     
f=y0+a*x^b/(c^b+x^b) M2 PTEN  SHIP1  f=y0+a*x^b/(c^b+x^b) M2 PTEN  SHIP1
  a 1.00 0.67 0.89    a 0.92 0.36 0.56 
  b 1.62 1.90 1.57    b 1.10 1.10 1.08 
  c 0.69 0.90 0.56    c 0.27 0.60 0.45 
  y0 0.00 0.00 0.00    y0 0.08 0.02 0.01 
           
 Epo M2 PTEN SHIP1    Epo  PTEN SHIP1 M2 
 100 1.07 0.68 0.76   50 0.35 0.57 0.96 
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 100 0.88 0.60 0.86   50 0.41 0.62 0.93 
 100 0.89 0.62 0.82   10 0.34 0.57 1.06 
 100   0.57 0.87   10 0.34 0.57 0.87 
 50 0.94 0.68 0.88   5 0.35 0.48 1.10 
 50 0.97 0.73 0.80   5 0.38 0.50 1.06 
 50 1.01 0.69 0.87   1 0.22 0.42 0.90 
 50   0.66 0.92   1 0.26 0.43 0.63 
 10 1.06 0.63 0.90   0.5 0.18 0.32 0.68 
 10 0.99 0.76 0.86   0.5 0.19 0.32 0.75 
 10 1.05 0.63 0.94   0.1 0.06 0.10 0.32 
 10   0.67 0.95   0.1 0.07 0.10 0.30 
 5 0.94 0.68 0.85   0.05 0.04 0.05 0.21 
 5 0.99 0.65 0.95   0.05 0.05 0.05 0.20 
 5 1.11 0.72 0.96   0.01 0.03 0.03 0.10 
 5   0.67 0.91   0.01 0.02 0.03 0.10 
 1 0.54 0.27 0.45   0.005 0.03 0.02 0.10 
 1 0.57 0.35 0.65   0.005 0.02 0.02 0.09 
 1 0.68 0.46 0.53   0.001 0.01 0.02 0.09 
 1   0.33 0.65   0.001 0.02 0.02 0.07 
 0.5 0.40 0.17         
 0.5 0.34 0.19 0.44       
 0.5 0.52 0.21 0.45       
 0.5   0.18 0.52       
 0.1 0.01 0.01 0.01       
 0.1 0.01 0.01 0.01       
 0.1 0.02 0.01 0.02       
 0.1   0.01 0.03       
 0.05 0.01 0.01 0.01       
 0.05 0.01 0.01 0.01       
 0.05 0.02 0.01 0.01       
 0.05   0.01         
 0.01 0.01 0.01 0.01       
 0.01 0.01 0.01 0.01       
 0.01 0.01 0.01 0.01       
 0.01   0.01         
 0.005 0.01 0.00 0.01       
 0.005 0.01 0.00 0.01       
 0.005 0.01 0.01 0.01       
 0.001 0.01 0.01 0.01       
 0.001 0.01 0.00 0.01       
 0.001 0.01 0.00 0.01       
 0 0.01 0.00 0.01       
 0   0.00 0.01       
 0 0.01 0.01 0.01       
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Table 6. 9 Effect of PTEN and SHIP1 overexpression on cell proliferation (3H-Thymidine 
incorporation assay) in CFU-E and BaF3-EpoR cells 
6.2 Initial amount of molecules in the receptor and PI3K/Akt core models 
Parameter Symbol Value   Unit 
Concentrations or densities 
CFU-E cells 
Cytoplam volume   399 m3 
Cell surface area   372 m2 
EpoR  4.16 nM 
  2.7 molecules/m2 
EpoR phosphatase  41.5 nM 
Gab1  21.2 nM 
PI3K  12.45 nM 
PI(4,5)P2  1.0e4 nM 
SHIP1   15.4 nM 
PTEN   10.4 nM 
Akt  406.5 nM 
PDK1  41.5 nM 
 
BaF3-EpoR 
Cytoplam volume  1400 m3 
Cell surface area  729 m2
EpoR  18.64 nM 
  21.5 molecules/m2 
EpoR phosphatase  41.5 nM 
Gab2  35.6 nM 
PI3K  12.5 nM 
PI(4,5)P2  1.0e4 nM 
SHIP1   84.2 nM 
PTEN   107.3 nM 
Akt  509.94 nM 
PDK1  41.5 nM 
Table 6. 10 Initial amount of molecules in the receptor and PI3K/Akt core models. 
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6.3 Ordinary differential equations of receptor and core PI3K/Akt models 
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6.4 Estimated kinetic parameters 
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6.5 Q-PCR analysis of PTEN and SHIP1 mediated mRNA expression 
 
Figure 6.1 Epo regulated mRNA expressions of genes of interest in CFU-E cells. Starved CFU-E 
cells were stimulated with 0.5, 1 and 5 U/ml Epo or remained non-stimulated for 2h. mRNA levels of 
the indicated genes were analysed by quantitative RT-PCR. Relative concentrations were normalized 
with RPL32. Error bars represent standard deviations of three biological replicates. 
 
 
Figure 6.2 Q-PCR analysis of SHIP1 mediated mRNA expressions in CFU-E. CFU-E cells-
overexpressing SHIP1 (S) or control vector (C) were starved and stimulated with 1 U/ml Epo or 
remained non-stimulated for 2h. mRNA levels of the indicated genes were analysed by quantitative 
RT-PCR. Relative concentrations were normalized with RPL32 and the fold change was calculated 
with respect to the expression of control cells at 0h. Error bars represent standard deviations of two to 
three biological replicates. 
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Figure 6.3 Q-PCR analysis of PTEN and SHIP1 mediated mRNA expressions in BaF3-EpoR 
cells. BaF3-EpoR cells-overexpressing control vector (C), PTEN (P) or SHIP1 (S) were starved and 
stimulated with 1 U/ml Epo or remained non-stimulated for 2h. mRNA levels of the indicated genes 
were analysed by quantitative RT-PCR. Relative concentrations were normalized with HPRT and the 
fold change was calculated with respect to the expression of control cells at 0h. Error bars represent 
standard deviations of two to three biological replicates. 
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Figure 6.4 Q-PCR analysis of Epo-induced Pim-1 expression in CFU-E and BaF3-EpoR cells. 
Growth factor-withdraw (A) CFU-E cells and (B) BaF3-EpoR cells were stimulated for the indicated 
times with 1 U/ml Epo. mRNA levels of Pim-1 were analysed by quantitative RT-PCR. Relative 
concentrations were normalized with RPL32 in CFU-E cells and with HPRT in BaF3-EpoR cells. The 
fold change was calculated with respect to the expression of control cells at 0h. Error bars represent 
standard deviations of two technical replicates. 
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6.6 PI staining and TUNEL assay data 
 
Figure 6.5 Overexpression of PTEN affects the cell cycle distribution of CFU-E cells. The cell cycle 
distribution of the control (M) and PTEN-overexpressing (P) CFU-E cells was analyzed by PI staining and 
FACS. M00-1: control cells at 0 h; M1-1, M1-2, M1-3: biological triplicates of cells 10 h after stimulation 
with 1 U/ml Epo; P00: PTEN-overexpressing cells at 0h; P1-1, P1-2: biological duplicates of cells 10h 
after stimulation with 1U/ml Epo. M1: SubG1; M2: G0/G1; M3: S; M4: M/G2. 
Appendix  125 
Appendix  126 
 
 
 
Figure 6.6 Overexpression of PTEN affects the cell cycle distribution of BaF3-EpoR cells (I). The 
cell cycle distribution of control (M) and PTEN-overexpressing (P) BaF3-EpoR cells was analyzed by PI 
staining and FACS. Cells at 0h (00) and cells after 16h stimulation with different dose of Epo in the range 
from 0 to 5 U/ml were analyzed. M1+ M2: <2N; M3: G0/G1; M4: S; M5: M/G2. 
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Figure 6.7 Overexpression of PTEN affects the cell cycle distribution of BaF3-EpoR cells (II). The 
cell cycle distribution of control (M) and PTEN-overexpressing (P) BaF3-EpoR cells was analyzed by PI 
staining and FACS. Cells at 0h (00) and cells after 40h stimulation with different dose of Epo in the range 
from 0 to 5 U/ml were analyzed. M1+ M2: <2N; M3: G0/G1; M4: S; M5: M/G2. 
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Figure 6.8 Overexpression of PTEN affects the apoptosis of CFU-E cells. The apoptosis of control 
(M) and PTEN-overexpressing (P) CFU-E cells was analyzed by TUNEL assay and FACS. Cells after 
10h treatment with or without 1U/ml Epo were analyzed. 
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Figure 6.9 Overexpression of PTEN affects the apoptosis of BaF3-EpoR cells. The apoptosis of 
control (M2) and PTEN-overexpressing (PTEN) as well as SHIP1-overexpressing (SHIP1) CFU-E cells 
was analyzed by TUNEL assay and FACS. Control Cells after 24h treatment with different dose of Epo in 
the range from 0 to 1 U/ml Epo were analyzed. PTEN and SHIP1-overexpressing cells after 24h 
treatment with 1U/ml Epo were analyzed.  
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6.7 Other appendix data 
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Figure 6.10 Comparison of stoichiometries and Epo-induced activation dynamics of signaling 
components in CFU-E and BaF3-EpoR cells. Growth factor-depleted CFU-E cells (2x107 cells/ml) 
and BaF3-EpoR cells (4x107 cells/ml) were stimulated for the indicated times with 2.5 or 5 U/ml Epo, 
respectively. (A) TCL (20 l) were loaded and analyzed by immunoblotting. (B)The ratio of total and 
phosphorylated signaling components between CFU-E and BaF3-EpoR cells were depicted as bar 
charts with standard deviation. 
 
Figure 6.11 Epo-induced activation and association pattern of Gab insoforms in CFU-E and 
BaF3-EpoR cells. Growth factor-depleted CFU-E cells (2x107 cells/ml) and BaF3-EpoR cells (4x107 
cells/ml) were stimulated for the indicated times with 2.5 or 5 U/ml Epo, respectively. The lysates were 
immunoprecipitated (IP) with the indicated antibodies and the immunoprecipitates were subjected to 
immunoblotting (IB) in (A) CFU-E and (B) BaF3-EpoR cells. 
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6.8 Abbreviations 
4E-BP1             Eukaryotic translation initiation factor 4E (eIF4E) binding protein 1  
7-AAD 7-aminoactinomycin D 
Akt                       thymoma viral proto-oncogene 
BFU-E burst forming unit-erythroid 
bp base pairs 
BSA bovine serum albumin 
Ccnd1                 cyclin D1 
Ccnd2                 cyclin D2 
Ccnd3                 cyclin D3 
Ccng2                 cyclin G2 
CD cluster of differentiation 
cDNA complementary DNA 
CFU-E colony forming unit-erythroid 
CFU-GEMM colony forming unit-granulocytes, erythrocytes, monocytes, macrophages 
CIS cytokine-inducible SH2 domain-containing protein 
d days postconception 
DMEM Dulbecco’s modified eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide triphosphate 
Dox doxycycline 
DTT dithiothreitol 
E. coli Escherichia coli 
ECL enhanced chemiluminescence 
EDTA ethylenediaminetetraacetic acid 
EGFR epidermal growth factor receptor 
EGFP enhanced green fluorescent protein 
Epo erythropoietin 
EpoR erythropoietin receptor 
ER endoplasmic reticulum 
FACS fluorescence activated cell sorter 
FCS fetal calf serum 
FLC fetal liver cells 
Foxo1                  forkhead box O1 
Foxo3                  forkhead box O3 
g g force 
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G418 geneticin 
Gab Grb2-associated binder 
G-CSF granulocyte colony-stimulating factor 
GFP green fluorescent protein 
GHR growth hormone receptor 
Grb growth factor receptor-bound protein  
GSK 3                 glycogen synthase kinase 3 
h hours 
HA hemagglutinin 
HBS hepes buffered saline 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HIF hypoxia-inducible transcription factor 
HPRT                  hypoxanthine guanine phosphoribosyl transferase 
HRP horseradish peroxidase 
HSC hematopoietic stem cell 
IB immunoblot 
Ig immunglobulin 
IL interleukin 
IMDM Isocove’s modified Dulbecco’s medium 
IP immunoprecipitation 
JAK Janus kinase 
kDa kilodalton 
LB Luria Bertani broth 
M molarity 
MAPK mitogen-activated protein kinase 
min minutes 
ml milliliter 
mTOR                 mammalian target of rapamycin 
µl microliter 
neo neomycin resistance gene 
nm nanometer 
o/n over night 
ODE ordinary differential equations 
p21                      Cdkn1a cyclin-dependent kinase inhibitor 1A 
p27kip1                  Cdkn1b cyclin-dependent kinase inhibitor 1B 
p85                      phosphatidylinositol 3-kinase 85 kDa regulatory subunit 
p110                    phosphatidylinositol 3-kinase 110 kDa catalytic subunit   
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PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDGFR platelet-derived growth factor receptor 
PDK1                  3-phosphoinositide-dependent protein kinase 1 
PE phycoerythrin 
Pfu Pyrococcus furiosus 
PI3K phosphatidylinositol 3-kinase 
PKB protein kinase B 
PKC protein kinase C 
PtdIns(3,4)P2      Phosphatidylinositol (3,4)-bisphosphate 
PtdIns(3,4,5)P3   Phosphatidylinositol (3,4,5)-trisphosphate 
PtdIns(4,5)P2      Phosphatidylinositol (3,4)-bisphosphate 
PTEN                  phosphatase and tensin homolog 
puro puromycin 
rhEpo recombinant human erythropoietin 
rpm rounds per minute 
RPL                     ribosomal protein L32 
RT room temperature 
SBP streptavidin-binding peptide 
SCF stem cell factor 
SDS sodium dodecyl sulfate 
SH Src homology 
SHIP1                  Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 
SHP SH2 domain-containing protein tyrosine phosphatase 
S6K1                    Ribosomal protein S6 kinase beta-1 
S6                        Ribosomal protein S6 
SOCS suppressor of cytokine signaling 
Sos son of sevenless 
STAT signal transducer and activator of transcription 
strep streptavidin 
TAE  Tris-acetate-EDTA 
Taq Thermus aquaticus 
TB Terrific broth 
TBS Tris buffered saline 
TBST Tris buffered saline with Tween-20 
TE Tris-EDTA 
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Tet tetracycline 
TfR transferrin receptor 
TM transmembrane 
TPO thrombopoietin 
Tris Tris(hydroxymethyl)-aminomethane 
U unit of enzyme activity 
WEHI Walter and Eliza Hall Institute 
w/v weight per volum
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